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Abstract
Patients with acute myeloid leukaemia (AML) frequently relapse after chemotherapy-
induced remission from their disease and effectivly become resistant to treatment. Cells
from these patients may demonstrate the ability to grow autonomously in culture and
express high levels of bcl-2 protein which confers resistance to chemotherapy-induced
apoptosis and a poorer disease prognosis. Bcl-2 protein levels were therefore
quantified in normal and AML cells. Autologous bone-marrow and peripheral-blood
progenitor cell transplantation offer a treatment option but may be contaminated by
tumour cells which contribute to disease relapse. Strategies have therefore been
devised to purge tumour cells from the harvest to improve chances of patient recovery.
One treatment option which may bypass resistance to chemotherapy-induced
programmed-cell death mechanisms uses a class of drugs called antisense. These
drugs have been shown to inhibit the translation of specific DNA sequences in vitro
but have had limited clinical efficacy due to poor cellular uptake and targetting. Bcl-2
therefore offers a cellular target for antisense-mediated inhibition in AML to improve
the efficacy of chemotherapy and patient survival. I have therefore studied the
mechanisms of cellular uptake of antisense into cells of normal and leukaemic
phenotype and its effectiveness at the induction of apoptosis in these cells. Antisense
was found to be preferentially associated with monocytes, neutrophils and eosinophils
with lower levels associated with lymphocytes and KGl-a (AML) cells. This uptake
was found to be associated with expression of the adhesion molecule Mac-1 (CD1 lb-
CD18). However antisense appeared to be sequestered into cytoplasmic vesicles and
was predominantly functionally ineffective at reducing bcl-2 protein levels or in the
induction of apoptosis. Antisense effects were also studied in the presence and absence
of apoptotic stimuli from Cycloheximide, Actinomycin D or Cytosine arabinoside.
There were no potentiating effects of bcl-2 antisense with either Cycloheximide or
Actinomycin D at inducing apoptosis ofAML cells. However there was a synergistic
effect of antisense bcl-2 in the presence of Cytosine arabinoside, an agent used in the
clinical treatment ofAML. It was not clear whether effects of antisense could be
attributed to true antisense-mediated or non-specific polyanionic effects mediated
through integrin binding. Therefore antisense bcl-2 does not appear to be an effective
therapy on its own for the generic treatment of AML but may function as a second-line
adjunct therapy in resistant or relapsed cases ofAML which fail to respond to
conventional chemotherapy. AML cells expressing CD1 lb are associated with a poorer
disease prognosis, are more likely to have elevated bcl-2 levels and resistance to
therapy. It is these cells which are most likely to show a synergistic tumouricidal effect
of bcl-2 antisense and Cytosine arabinoside. The role of antisense as a general agent
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Leukaemias are essentially tumours arising from blood cells. These leukaemic cells
accumulate in the bone-marrow which eventually results in bone-marrow failure. The
abnormal cells eventually spill out into the peripheral blood, causing an elevated white
cell count. The consequences of bone marrow failure are anaemia (low red cell count),
neutropenia (low neutrophil count resulting in inability to fight infections),
thrombocytopenia (loss of platelets causing clotting disorders). In acute leukaemias,
there may also be involvement of other organs (eg. spleen, liver, lymph nodes, CNS).
Classification of leukaemias:
Leukaemias are divided into acute or chronic forms.
When patients with acute leukaemia present they have by definition more than 50%
blasts in their bone-marrow. The disease can be further classified on the basis of the
primary cell type involved into acute myeloid leukaemia (AML) or acute lymphoblastic
leukaemia (ALL). AML can be further sub-divided according to the French-American-
British (FAB) system which assigns a classification number (MO to M7) depending on
the degree of cellular maturity.
When the total number of leukaemic blasts approaches 1012 the patient becomes ill
from severe bone-marrow failure. Involvement of other organs may however not occur
until the leukaemic cell population reaches 50% total blood cells or more.
Chemotherapy is used to induce a clinical remission where there are less than 5% blast
cells present in the bone marrow. Disease relapse may only be confirmed by
morphology using microscopy when the blast cells comprise more than 5% of all cells.
At this level (5%) approximately 108 leukaemic cells may still be present in the patient,
however, providing other haematological parameters have returned to normal values
this state corresponds to disease remission. Patients are said to relapse if more than this
number of leukaemic cells are present following induction of complete remission with
chemotherapy. Using sensitive cytogenetic, molecular biological or immunological
techniques disease may still be detected at levels less than 5% although the blood and
marrow appear histologically normal (Seivers et.al. 1995). It is likely that this minimal
residual disease (MRD) contributes to the frequent disease relapse seen in AML.
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Origins
Ultimately the causes of leukaemia are not known although the acute leukaemias
probably arise from selective proliferation of a single abnormal stem or progenitor cell
which is able to form clonal daughter cells. In AML there is limited differentiation of
the leukaemic blasts, but the cells are capable of further proliferation which causes the
rapid replacement of the normal haemopoietic cells of the bone-marrow by leukaemic
blasts. AML probably arises from a pluripotent stem cell or more mature myeloid
progenitor. These myeloid progenitor cells are capable of differentiating into cells of
the erythroid (red blood cells), granulocytic-monocytic (neutrophils, monocytes,
eosinophils, basophils), and megakaryocytic (platelet) lineages. Lymphoid progenitors
give rise to T and B cells. Typically AML blasts can be discriminated from ALL blasts
by their expression of the cell surface proteins CD 13 and CD33, do not express
nuclear terminal deoxy-nucleotidyl transferase (TdT) and have T cell receptor genes in
the germline configuration.
Patients treated with drugs for a primary (often so-called solid tumour eg. lung or
breast cancer) cancermay develop leukaemia intitiated by the chemotherapy used to
treat the primary disease, this is referred to as secondary AML. Of all the leukaemias,
the acute leukaemias comprise more than 50%. AML may arise in any age group but is
the most common form of (70-80%) adult acute leukaemias. Of childhood leukaemias
only a minor fraction (10-15%) are AML with ALL being the most common form.
Therapy
For anaemic leukaemia patients with severe bone-marrow failure red blood-cell
transfusions are given. Also since haemorrhage is an important early cause of death in
many leukaemias regular platelet transfusions are given to correct the
thrombocytopenia or during initial induction chemotherapy. This is a particular
problem with patients with acute promyelocytic leukaemia (APML) who develop a
severe disseminated intravascular coagulation (DIC) who may also be treated with
fresh-frozen plasma. The severe reduction in neutrophils results in a reduced ability to
fight infection. This may be treated with effective prophylactic use of antibiotics and
growth-factors to stimulate production of neutrophilic cells.
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Chemotherapy:
The primary aim of chemotherapy is to induce clinical remission (defined as less than
5% blast cells in the bone marrow) then to eliminate any remaining leukaemic cells by
several additional consolidation courses of chemotherapy. Cyclical combinations of
two, three or four drugs are given with treatment-free intervals to allow recovery of the
marrow. Approximately 60-70% of adults with AML will attain complete remission
after induction therapy, however remission rates in adults are inversely related to age.
The primary target for most cytotoxic drugs used in leukaemia chemotherapy are
highly replicative cells. There are therefore non-specific effects on other highly
replicative systems such as the gut, skin and hair follicles all of which contain
regenerating compartments and are also able to recover following therapy. Cytotoxic
combinations of three or more drugs are used to increase cytotoxic effects, overcome
the potential for development of drug resistance and thus improve the likelihood of
achieving remission
Induction therapy in AML normally consists of a combination of cytosine arabinoside,
an anthracycline (daunorubicin) and either 6-thioguanine or etoposide. All AML sub¬
types (FAB M0-M7) are normally treated with similar drug combinations except for
APML (M3) patients who receive all-trans retinoic acid in addition to chemotherapy to
obtain remission. Two or three consolidation courses of intensive chemotherapy are
usually given post-remission with similar drugs (Stone et.al.1993).
However remissions are not achieved in 10-20% ofAML patients even following two
courses of induction therapy. These high risk patients are normally selected for bone-
marrow or peripheral-blood stem-cell transplants. In patients over 60 years of age such
aggressive treatment is not normally an option because of the increased mortality so
treatment options tend to be more limited (Hoffbrand et.al. 1993).
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Transplantation:
Transplantation of bone-marrow may be an option in patients under 45 years old with
AML in first remission using HLA-matched bone-marrow from a donor (allogeneic
bone-marrow transplantation (BMT). It may also be considered in patients who are in
early stages of disease relapse or are in their second or subsequent remissions. Bone-
marrow transplantation allows the functional recovery of the haematopoietic and
immune systems following the myelo-ablative therapy used to kill the remaining
leukaemic blasts.
There may be a beneficial side effect of this treatment if T cells from the donor marrow
recognise the leukaemic patient cells as foreign and initiate a rejection reaction (graft-
versus-host disease GVHD). This type of response may also result in a reduced risk of
relapse by also rejecting the leukaemic blast cells in a graft-versus leukaemia (GVL)
reaction. Bone-marrow donations from an identical twin (syngeneic marrow) or from
the patient themselves (autologous marrow) carry little risk of this potentially fatal
GVHD but also no potential for the beneficial (and potentially curative GVL). These
types of transplant are normally carried out in first remission or after relapse and re-
induction therapy (second remission). There is however the potential to transplant
tumour cells with an autologous transplant which may require purging of the leukaemic
blasts. Recently there has been a move to utilise stem cells (cells required to recover the
haematopoietic system) which have been collected from peripheral blood rather than
bone-marrow. These are refered to as peripheral blood progenitor cell transplants
(PBPCT) and have been associated with a quicker recovery of normal blood function
parameters and lower side effects than bone-marrow transplantation. This type of
therapy is also cheaper and involves less morbidity and mortality to the patient as well.
The prognosis for remission induction and survival is determined by prognostic
indicators such as immunophenotype, possession of certain cytogenetic abnormalities
or growth characteristics of blast cells. Patients who are considered a good risk are
given chemotherapy only; standard risk patients are treated with chemotherapy, and
may be recommended for transplant; patients who are deemed poor risk are given
transplant if a good donor is available, otherwise intensive chemotherapy is given.
Patients with secondary AML tend not to respond to standard treatment and because of
the toxic effects on the marrow from treatment of the initial disease most patients are
unable to have an autologous stem cell transplant, however if they are otherwise
suitable they may be eligible for allogeneic bone-marrow. Overall the chances of
obtaining an initial remission with chemotherapy are between 50 and 80% dependent
on age. Long-term survival is dependent on whether the patient is in a good, standard
or poor risk category. Good risk patients have a 5 year survival of about 60%; for
patients with standard risk disease it is much harder to predict the likely outcome
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without a transplant (Hunter et.al.1993). Patients with poor risk disease have an
extremely low chance oflong-term survival without a successful bone-marrow or stem
cell transplant.
Therefore in this thesis an alternative treatment option for patients in standard or poor
risk categories was sought. The potential efficacy of one of the new promising
molecular therapies was studied to look for an enhancement of tumour cell killing. This
"antisense" therapy specifically targets bcl-2, a protein associated with the prolonged
survival of many types of tumour cell including leukaemic cells. This drug can be
administered on its own or in combination with standard chemotherapeutic regimens
and should enhance their effectiveness at killing leukaemic cells.
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Origins of Acute Myeloid Leukaemia (AML)
Many forms ofAML are associated with specific chromosomal abnormalities including
translocations where one part of a chromosome becomes aberrantly linked to part of
another chromosome resulting in the production of disregulated protein expression or
the formation of a novel fusion gene-product. Gene inversions, duplications or
deletions may similarly occur. This has often lead to the functional characterisation of
normal proteins involved in cell proliferation or differentiation.
Oncogenesis
Exposure of bone-marrow to ionising radiation can cause leukaemia through induction
of chromosomal breaks, recombinations or point mutation activation of oncogenes,
translocations and gene rearrangements may also frequently occur in leukaemias and
lymphomas. For example gene rearrangements of the immunoglobulin (Ig) gene or T
cell receptor (TCR) give rise to fusion genes. Translocations may also occur in other
types of leukaemia and lymphomas eg. the Philadelphia translocation t(9; 22) in CML
involving abl tyrosine-kinase; the t(15;17) translocation, involving the retinoic acid
receptor, is associated with acute promyelocytic leukaemia (APML-M3) ; or the
t(14;18) translocation, involving bcl-2 which is found in approx 85% of follicular
lymphomas. Evidence that activated oncogenes are involved in leukaemogenesis is
however somewhat indirect, though it has been possible to reproduce some leukaemic
phenotypes in mice with putative oncogenes introduced into the germ-line. There is an
increased risk of leukaemia associated with some hereditary diseases, particularly
Down's syndrome (trisomy 21- where acute leukaemia especially ALL, may have an
increased frequency). There is also an increased risk if family members have
leukaekmia with a greater risk greater in identical twins. Existing haematological
disease such as myeloproliferative diseases may also predispose to AML. Treatment of
these conditions with chemotherapeutic drugs may also induce leukaemic progression
through damage of oncogene DNA. This progresssion of leukaemic stem or early
progenitor cells may also be associated with development of new chromosomal
abnormalities.
Haematopoietic cells require growth-factors for survival and proliferation and changes
in the function of receptors for these molecules are associated with leukaemia
progression, though do not initiate the disease (Lang et.al.1990). Growth-factor
receptors may have serine-threonine or tyrosine-kinase activity which induces
phosphorylation of other signal transduction proteins including the receptor itself.
Growth-factor receptors either directly, or more often through second-messenger
signalling cascades, activate genes through transcription factors which bind DNA
promoter sites and regulate the transcription of genes. The proteins coded for by these
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genes often control the proliferation and differentiation of cells and are normally strictly
regulated in a spatial and temporal fashion. Functional disregulation or deletion of
these genes is thought to play an important role in leukaemic progression. Loss or
functional inactivation of tumour suppressor genes such as p53 or retinoblastoma have
also been described in CML in blast transformation, AML and MDS. Alteration of one
allele may have a dominant effect if the mutated protein overrides the normal function
of the protein (Sherr, 1996). For example tumour suppressor proteins such as p53 and
the retinoblastoma protein act as control mechanisms which regulate the cell cycle and
alterations in these proteins have fundamental effects on cell cycle progression in AML
(Russell et.al.1995). Similarly gains of all or parts of chromosomes may result in
amplification of genes and are common in the leukaemias and myelodysplasias and
commonly include extra copies of chromosomes 8, 12, 19, 21 and losses affecting
chromosomes 5, 6, 7, 11, 20 and Y (Hoffbrand et.al.1993).
There are also an important family of proteins whose role appears to be in the
prevention of cell death in response to a number of potentially life-threatening stimuli.
Cells deprived of growth factors or damaged cells may undergo a genetically
programmed cell death known as apoptosis. The oncogene BCL-2 codes for a protein
which inhibits cell death by apoptosis and elevated levels of bcl-2 protein are requently
found in leukaemias and other tumours and contribute to resistance to chemotherapy
(Hickman et.al. 1994). The mechanism by which bcl-2 protein levels are regulated is at




The AML FAB subtypes are associated with different morphology and cytochemical
staining and in many cases characteristic chromosomal changes and expression of
surface proteins. Antibodies are helpful in the differentiation of ALL from AML and in
the diagnosis ofAML M6 or M7. The treatment and prognosis of each of the
classifications are basically similar but there are some clinical differences as well as
differences in treatment. However a study of 448 AML patients in first complete
remission showed better disease free survival (DFS) with AML FAB 1, 2, 3 than M4
or 5. Sub-groups of AML patients also have poor prognosis; AML secondary to
therapy; AML preceded by myelodysplastic syndrome; chromosomal abnormalities eg.
deletions involving chromosomes 5, 7, trisomy 8, Philadelphia positive AML, or a
white cell count greater than 100 xl09 per litre (Geller, 1993).
In most cases clinical features and morphology can discriminate a diagnosis of AML
from ALL. In ALL the blasts show no differentiation (with the exception of B-ALL)
whereas in AML some evidence of limited differentiation to granulocytes or monocytes
is usually seen. When the blasts are un-differentiated special tests are required to
confirm the diagnosis and to classify and sub-divide the leukaemia. Cytochemistry eg.
for myeloperoxidase may help to show granule development or non-specific esterases
(NSE) for monocytic differentiation in AML. Immunological markers can also be used
to distinguish AML from ALL, myeloid leukaemic cells are usually CD13+, CD33+
and TdT-. Occasionally a hybrid acute leukaemia can arise in which blast cells show
features of both AML and ALL. These features may be on the same cell (bi-
phenotypic) or on separate populations (bi-lineage). They include inappropriate
expression of immunological markers eg. TdT+ AML or CD13+ ALL or inappropriate
gene rearrangements and treatment is usually given on the basis of the dominant cell
type.
AML accounts for 77% of the acute leukaemias (in adults 89%, in children 19%).
These are broken down as follows Ml - 18%, M2 - 28%, M3 - 8%, M4 - 27%, M5 -
10%, M6 - 4%, M7 - 5% (Walker et.al.1994). Briefly AML Ml, M2, and M3 show
predominantly granulocytic differentiation and differ in the extent and nature of
granulocytic maturation; M4 shows both granulocytic and monocytic differentiation;
M5 has a predominantly monocytic differentiation and M6 predominantly
erythroblastic differentiation; M7 is associated with leukaemic megakaryocytes.
The diagnosis of minimally differentiated leukaemia (MO) is made if myeloperoxidase
8
markers and megakaryocyte markers.
In myeloblasts leukaemia without maturation (Ml) blasts show evidence of
granulocytic differentiation with more than 3% of the blasts myeloperoxidase positive,
maturation beyond this stage is not apparent (Knapp et.al. 1994).
In patients with myeloblasts leukaemia with maturation (M2) blasts can be
distinguished from Ml by cells maturating to, or beyond, the promyelocyte stage
(myelocytes, metamyelocytes, and mature granulocytes may be found in varying
proportions). The leukemic cells often have prominent nucleoli with varying amounts
of cytoplasm, usually with many azurophilic granules. A specific chromosomal
translocation (8;21) is frequently associated with this morphology. AML M2 has more
than 30% myeloblasts with greater than 3% MPO+ with greater than 10% maturing
granulocytes and less than 20% monocytic cells.
The t( 15; 17) translocation is associated with acute promyelocytic leukaemia (APML-
M3) which involves translocation of the retinoic acid receptor. The majority of cells are
abnormal promyelocytes, with a characteristic pattern of heavy granulation. A severe
coagulation disorder - disseminated intravascular coagulation (DIC) is almost
invariably associated with M3 AML sub-type. A small number of patients with APML
have a version of this leukaemia known as M3 variant (M3V).
Myelomonocytic leukaemia (M4) cells have both granulocytic and monocytic
differentiation in the bone-marrow and peripheral blood. M4 resembles M2 except that
the proportion of promonocytes and monocytes exceeds 20% of the white blood cells.
M4E variant has a variable (usually < 10%) number of abnormal eosinophils present.
Most cases are associated with changes in chromosome 16 [inv(16)j and have a good
prognosis.
Poorly differentiated monoblastic leukaemia (M5) is characterized by large blasts with
several nucleoli. The large cytoplasm is basophilic and often pseudopodia are present.
Monoblasts, promonocytes, and monocytes are found; with more monocytes in the
peripheral blood than the bone-marrow, in which the predominant cell is the
promonocyte. Infiltration of other tissues are associated with this phenotype
particularly of the skin and gums, are common in patients this morphologic subtype.
Erythroleukaemia (M6) involving is characterised by an excess of erthyhroblasts. The
blast cell count (excluding erythroblasts) exceeds 30% of nucleated cells in the bone-
marrow though the percentage of myeloblasts and promyelocytes with erythropoietic
changes can be variable.
9
M7 (mcgakaryoblastic) leukaemia is often aeeompamed by fibrosis of the bone-
marrow. Blasts ean either resemble immature megakaryocytes or be undifferentiated
resembling lymphoblasts. The diagnosis can be confirmed by ultrastruetural
demonstration of platelet peroxidase or detection of platelet antigens CD41 or CD61
(Hirsch-Ginsberg et.al.1993).
Cytogenetics
Certain chromosome changes are typical of different AML sub-types and can be useful
in the diagnosis and monitoring of residual disease (MRD) dunng and following
therapy. Chromosome changes may carry a prognostic significance in AML, with the
most frequent changes being trisomy 8 or monosomy 7 (Lowenberg et.al.1993). In
children or young adults there are more balanced translocations, however in secondary
AML or elderly patients there are usually numerical and unbalanced changes. The
t(8;21) translocation, involving the AML-1 and ETO gene fusion, is the most common,
found in 10% AML associated with M2. A complete remission (CR) rate of 80% and
disease-free survival (DFS) of 67% is associated with this form of the disease. The
t(3;21) translocation also involves the AML-1 gene and the EVI-1 gene; M2 with
t(8;21) which involves the AML-1 gene (which has an ATP binding domain). The
t(15;17) is associated with most cases in APML and results in severe coagulation
disorder but is otherwise associated with a better prognosis (Grimwade et.al. 1997).
APML t( 15; 17) results in a fusion gene between PML (zinc finger protein) with the
retinoic acid receptor. The inv(16) chromosomal inversion accounts for 16% of
cytogenetic abnormalities in AML and is mainly associated with the M4E variant but
also M2 and M4, 5, MDS and CML in blast crisis. Deletions of chromosome 5q are
associated with therapy-related AML/MDS (secondary disease) and confers a poorer
prognosis. The receptors for growth-factor receptors IL-3, 4, 5, 9, GM-CSF, CSF-1
receptor, CD 14, EGR-1 (zinc finger transcription factor), IRF-1 (interferon response
factor) are all found on 5q31.(De Greef et.al.1996). Other less common changes seen
are trisomy 4 in M2 or M4 (also trisomy 8 or 22), also t(8;16), inv(16) in M4; trisomy
8 is also seen in M5 as is t(8;16) (Walker et.al. 1994).
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Immunological classification.
Widespread application of flow cytometry using fluorescent-tagged monoclonal
antibodies has allowed routine immunological classification of acute leukaemias. For
example antibodies to myeloperoxidase, CD33 and CD 13 identify virtually all myeloid
leukaemias.
Immunologic markers on normal haematopoietic cells normally forms a lineage-
































(Figure 1) (Freedman et.al. 1993)
In AML many of these antigens are also expressed but either in the incorrect sequence
or with co-expression of lymphoid markers. There is unfortunately no single marker to
identify the leukaemias. There does not appear to be direct correlation between
immunophenotype and prognosis though some individual markers are associated with
a good or poor response rates.
Multi-parameter flow cytomety (which utilises 3 or more colours in combination with
light scatter characteristics) has found, for example TdT and CD7 co-expression with
the normal myeloid markers CD 13 and CD33. No normal tissues have been found to
express these markers, however this is limited to only 25% AML patients (Campana
et.al. 1995; Campana, 1993). Terstappen et.al. 1992 have described patterns of
expression of normal cell-surface antigens in AML, expression of non-myeloid
antigens, asynchronous expression of myeloid antigens or expression on immature
cells, overexpression of myeloid antigens, absence of myeloid antigens in AML.
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Under the FAB system the presence of more than 3% myeloperoxidase (MPO) positive
blasts confirms a diagnosis of AML. Using monoclonal antibodies on permeabilised
cells it is possible to detect MPO in the majority ofAML samples and CD34 positive
cells. APML (M3) and the majority of CD 14 positive AML (monocytic) do not
however express the CD34 marker. CD 13 and CD 14 are markers associated with a
low complete remission rate, but a favourable outcome is associated in patients with
CD 15 associated with M5 and M4. CD34 is associated with MO and Ml and M5a but
not M3 orM5b (Campos et.al. 1989).
The majority of AML express stem cell factor CD117 (ckit receptor) on early blasts,
though some are CD34-, CD117-. CD15 (a later myeloid antigen) is associated with
favourable outcome though it can be lacking on M3 promyelocytes (Knapp
et.al. 1994). CD4 is found on up to 75% adult AML, CD7 is expressed in 10% AML
(Hirsch-Ginsberg et.al. 1993). The CD34 marker is expressed on up to 70% AML
patients and is normally found on haematopoietic progenitors, high endothelial venules
(HEV), vascular endothelium and some fibroblasts and may play a role in progenitor
cell adhesion to bone-marrow stroma (Steen et.al. 1996).
MO accounts for 5-10% of all AML cases. MO AML patient blasts are 70-80% CD13,
and CD33 positive there is also consistent expression of CD34 and HLA-DR and
antibody-detected myelo-peroxidase (MPO) (Castoldi et.al.1996). These cells are
normally CD7 and TdT negative. No chromosomal abnormalities are specific for this
type of leukaemia, however -7/7q-, +13. -5/5q- may be present. M0 can be diagnosed
with certainty using antibodies to myeloid associated antigens CD 13, 14, 15, 33, 34,
and HLA-DR. AML M0 have a poor prognosis if positive for CD34, CD7, HLA-DR
and TdT. M0 are normally found to be negative for CD22, 3, 13, 19, 10, 37, 2, 33,
14, 61 and glycophorin A
Ml can be positive for CD1 lb, however CD14 and 15 are usually negative.
Ml and M2 can express CD34, 33, 13, HLA-DR and 20% patients express CD 14.
CD 15 is associated with M2 though karyotyping gives the definitive diagnosis.
APML M3 has strong MPO+ cells and non-specific esterases (NSE) and is associated
with the t( 15; 17) karyotype. M3 are CD34 and HLA-DR negative as are 20% ofMl
and M2 and 10% ofM4 and M5). The presence ofNK cell / myeloid markers in acute
leukaemia may appear to be M3 by morphology, but do not demonstrate any detectable
PML-RAR fusion transcripts (De Greef et.al. 1996).
M4 myelomonocytic AML cells are MPO+, non-specific esterase (NSE) positive and
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M4 myelomonocytic AML cells are MPO+, non-specific esterase (NSE) positive and
more than 20% cells are pro-monocytes. The (inv 16) M4 variant has an increased level
of eosinophils. M4 and M5 can express CD13, 33, 11c, 15, 14, 36, lib, possibly
cytoplasmic lysozyme, CD4, 7,19, or the NK markers CD 16 or 56.
M5 AML (monocytic leukaemia) has diffuse NSE positivity with less than 3% MPO
positive cells.
M6 AML (erythroleukaemia) has similar morphology toMl, 2, or 4 blasts but with the
presence of dysplastic erythroid precursors. M6 can express glycophorin A, CD71
(transferrin receptor), and may also express CD36, CD7, 15, HLA-DR.
CD41, 42, 61 antigens are predominantly found on AML M6 and 7.
M7 are known to express CD61 (platelet glycoprotein Ilia), von Willebrand antigen,
CD41 (Freedman et.al.1993).
Generally speaking patients with a worse complete remission rate and survival include
CD 13, CD33, CD 14 , CD1 lb, HLA-DR, CD34, CD9, MDR and bcl-2 whilst only
CD15 indicates a better complete remission and survival (Sanz et.al.1996).
Therapy
Treatment for AML is normally in two distinct phases:
a) induction therapy used to achieve disease remission and
b) consolidation therapy to prevent further disease relapse.
Consolidation therapy appears to be most effective when given either immediately after
remission or can be delayed for several months.
Induction therapy usually produces marrow aplasia and together with the leukaemia-
induced bone-marrow failure patients therefore require support including red cell and
platelet transfusions as well as treatment for infections. Colony-stimulating factors eg.
granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony
stimulating factor (GM-CSF) are currently used to increase the number and activation
state of neutrophils. These growth-factors are normally administered following
induction therapy resulting in a shorter neutropenic period and reduced incidence of
infection. Drugs such as cytosine arabinoside are proliferation (S-phase) specific and
as such affect replicating cells, however some leukaemic cells have a long dividing
time and may escape chemotherapy. Growth-factor mobilisation of non-proliferating
leukaemic pogenitors into cycle may augment S-phase specific drugs (Schiller, 1991).
Studies have noted that simultaneous addition of cytosine arabinoside (AraC) and GM-
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CSF resulted in greater cell death (Stone et.al.1993). Mobilisation of stem or
progenitor cells with G-CSF or GM-CSF may also lead to proliferation of leukaemic
clones and cause disease relapse. Growth-factors may also induce differentiation eg. in
the treatment ofAPML retinoic acid is routinely used to induce terminal differentiation
followed by cell death, M-CSF has also been used to induce terminal differentiation in
leukaemic blasts (Bernstein, 1993).
Unfortunately the majority of AML patients respond only transiently to therapy and
ultimately die of their disease. Following induction therapy using anthracycline
(daunorubicin) and cytosine arabinoside (AraC) 70-80% AML patients achieve
complete remission but many subsequently relapse and die resulting in a poor (20-
60%) 5-year survival rate (Schiller, 1991). Treatment options for these relapsed or
refractory patients include chemotherapy (high dose cytosine arabinoside, idarubicin,
etoposide), autologous or allogeneic bone-marrow or peripheral blood progenitor
transplant, or combined chemotherapy plus growth-factors. High dose cytosine
arabinoside is associated with 40% complete remission in patients with relapsed,
refractory or secondary AML (Stone et.al.1993). Most AML patients in first remission
are treated with AraC consolidation therapy alone, or followed by allogeneic or
autologous bone-marrow or peripheral blood progenitor cell transplantation or
autologous peripheral blood stem cell transplantation. Allogeneic BMT allows the
potential for a curative graft-versus-leukaemia effect, however post-transplant survival
is similar to survival following remission induction chemotherapy due to transplant-
associated mortality. Allogeneic transplantation however remains the only potential for
a cure after disease relapse. The efficacy of using autologous transplantation following
purging is currently being studied.
Drug resistance
Leukaemic cells often develop resistance to chemotherapy following treatment,
probably due to the selective expansion of cells with an underlying resistance
mechanism eg. presence of the multi-drug resistance protein (MDR-1) (Sonneveld,
1996). Resistant cells express high levels of p-glycoprotein (MDR-1) which is an
ATP-dependent drug efflux pump. MDR can however be blocked by cyclosporin A or
verapamil. MDR-1 is frequently found in cases of de novo AML (19-75% of untreated
cases). Patients with refractory or relapsed AML express MDR-1 (which can be
detected by flow cytometry) more frequently . Drugs which block MDR result in a
higher intracellular concentration of cytotoxic drugs, though this may also affect
normal CD34 positive progenitors which normally express p-glycoprotein.
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Other mechanisms of drug inactivation include glutathione-S-transferases which
inactivate drugs by the addition of GSH. For cytotoxic effects cytosinc arabinoside
requres to be phosphorylated to Ara-CTP which then competes with dCTP for
incorporation into DNA by polymerases. After incorporation into DNA Ara-CTP acts
as a chain terminator (Sonneveld, 1996). Resistance to retinoic acid (ATRA) can
develop through a lowering of plasma levels of ATRA through a cytochrome p450-
mediated mechanism. Treatment with 9-cis retinoic acid however is able to overcome
this plasma clearance (Fenaux et.al.1996).
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Minimal and Residual Disease (MRD)
Following induction of disease remission with chemotherapy patients may have less
than 5% blasts (detected by light microscopy) together with recovery of normal
hematopoietic parameters. Approximately 75% ofAML patients achieve this type of
remission though the majority subsequently relapse, it is unfortunately difficult to
predict who will relapse. Patients in clinical remission with 5% tumour cells represents
a tumour burden of between 108-101° leukaemic cells and this "minimal residual
disease" (MRD) is not detectable by conventional means (Stone et.al. 1993). More
sensitive methods for detection ofMRD include cytogenetics, FISH, colony growth,
PCR and multi-parameter flow cytometry.
Cytogenetics is able to detect the presence of 1 tumour cell in 10 normal cells,
fluorescence in situ hybridisation (FISH) detects 1 cell in 10-100. Southern blotting
using labelled DNA probes can detect 1 tumour cell in 100-1000 normal cells, flow
cytometric antibody detection 1 cell in 40,000 (Dwenger et.al. 1996). Detection of
chromosomal translocations are the most useful method formonitoring AML since
they are tumour-specific markers detectable by the polymerase chain reaction (PCR).
Positive PCR results does not always mean imminent relapse as the patient can be in
complete remission (CR), however increasing PCR positivity may prelude a imminent
relapse. Monitoring MRD in AML does not seem to be relevant for changing clinical
treatment. Contrastingly APML (M3) with t(15;17) positivity is associated with
relapse. Presumably these resistant MRD cells are non-dividing or slow-cycling cells
since most chemotherapy acts upon cells in S-phase. Leukaemic cells in the bone-
marrow may however not show the nuclear proliferation antigen. Other strategies such
as the use of growth-factors to mobilise cells into cycle may be effective eg. CML
progenitors can be induced to differentiate into CML dendritic cells (using, TNF-a, IL-
4, GM-CSF) which are able elicit an anti-CML tumour response (Dwenger
et.al. 1996).
Molecular Techniques
Conventional cytogenetic karyotypic analyses detect only residual dividing leukaemic
cells in metaphase. Fluorescent in situ hybridisation (FISH) techniques can be used to
detect numerical chromosomal changes of cells in interphase. Translocated or mutated
oncogenes may be detected by polymerase chain reaction (PCR) to look for tumour-
specific gene markers. These molecular tests using PCR may offer a sensitivity of
detection of one tumour cell in 105 normal cells. This however must be interpreted
with caution because of the potential for changes in genotype. Clonal evolution may
arise so a negative result may be misleading during disease progression and there may
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also be patchy distribution of MRD within marrow or blood. For example
disappearance of bcr-abl transcripts in B-ALL after BMT may subsequently reappear
with disease relapse (Nizet et.al.1991). PCR can be used to detect chromosomal
translocations in AML eg. t(15;17); t(8;21); inv(16); t(9;22), t(6;9) or RT-PCR to
detect APML M3 (Campana et.al.1995; Langlands et.al.1993).
Patients with APML are treated with ATRA to induce differentiation of the leukaemic
clone and results in remission. Molecular techniques always detect residual disease in
these patients, RT-PCR offers the most rapid diagnosis and all patients positive at the
end of therapy subsequently relapsed. The t(8;21) translocation, associated with 20%
ofM2 AML cases, causes a fusion gene to be formed between AML-1 and ETO genes.
RT-PCR again offers the most rapid diagnosis. The inv(16) mutation is associated
with acute myelomonocytic leukaemia with excess of eosinophils. A fusion gene
consisting of CBF0 (core binding factor beta) and MYH-II (myosin heavy chain) again
can be detected by molecular techniques using RT-PCR for diagnosis. The t(6;9)
translocation seen infrequently in AML can also be detected by RT-PCR of the fusion
gene of DEK and CAN (Morgan, 1994).
Southern blots only detect 1-5% abnormal cells in a population of normal cells. PCR
using the T cell receptor gene rearrangements detects one clonal cell in 103 normal
polyclonal cells. However the sensitivity can be increased using allele specific primers
to detect one clonal cell in KF-IO6 normal cells. Patients maintaining CR showed a
decline in PCR detectable abnormal cells, but maintained steady levels or even rose
when patients relapsed (Nizet et.al.1991). T cell gene rearrangements are present in
10-40% of AML cases. PCR sensitivity using T cell receptor (TCR) delta gene or
t(14;18), or IgH gives a sensitivity of one tumour cell in 104-105 normal cells
(Langlands et.al. 1992). Again using allele (patient) specific primers PCR can detect
point mutations in N and K-ras or p53 found in 25-30% AML patients (Russell
et.al. 1995).
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Flow cytometry in MRD
There is unfortunatley no single immunologic marker which is suitable for detection or
classification of AML. Normal phenotypic markers are expressed and it may only be
the combination of markers or their relative levels which distinguish the leukaemic
from normal cells (Figure 1). Immunologic markers detected by flow cytometry
allow one cell in 104 to be detected. For example flow cytometry using a combination
of immunological markers to detect "leukaemia-specific" combinations of antigens eg.
TdT-t- myeloid cells are present in 75% cases ofAML (Campana et.al. 1995). Single
immunologic markers are therefore not appropriate for MRD detection. Two, three or
even four colour analysis help identify lineage infidelity (eg. lymphoid antigens on
myeloid blasts), asynchronous antigen expression (Table 1). For example, 40-70%
AML patients have antigen expression which allow 104 tumour cells detection by
immunophenotyping (Castoldi et.al. 1996).
CD 1 3/33 lib 15 14/36 GlycA 41/6 1 OR TdT i 34 9
FAB
MO + | - +/- - - - + + +
M 1 + + /- +
M 2 + + /- -
M 3 + - +/- - ! -
M 4 + + /- + + + i +/- -
M 5 + + /- +/- i + i - - I + +/-
M 6 + /- + /- + + - +/- -
M 7 + /- - + + + + /- ! +
(Table 1) Possible combinations of cell surface marker expression in AML.
Four patterns of aberrant expression of normal cell surface proteins:
a) expression of non-myeloid antigens eg CD2, CD5, CD7 on myeloid blasts.
b) asynchronous expression of myeloid antigens eg. co-expression of CD34 and CD 15
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or CD 16.
c) over-expression of myeloid antigens eg. increased CD34 and CD 14 expression on
neutrophils.
d) absence of myeloid antigens eg. lack of CD33 expression or co-expression of
CDllb and CD15 (Terstappen et.al.1992).
45-70% of AML patients express CD34 (Nimgaonkar et.al.1996; Brito-Babapulle
et.al.1990) though AML Ml, 2, 3 do not show any differences in CD34 epitope
expression, though normal hematopoietic CD34 positive cells express class III
epitopes rather than class I or II (Steen et.al.1996).
Studies using markers for solid tumours have confirmed the presence of tumour cells
in peripheral blood, bone-marrow and apheresis products (Volpi et.al.1994; Brenner
et.al.1993). Using anti-cytokeratin and an anti-CD45 antibody to detect breast cancer
cells it was found that tumour content (per CD45+ mononuclear cell) was greater in
bone-marrow than peripheral blood or apheresis products. Cytokeratin however only
reacts with approximately 80% breast cancer cells. This detection method allows the
discovery of 1 tumour cell in 200,000 mononuclear cells (Clarkson, 1993). The
sensitivity of the methodology can be increased by using 4-colour immuno¬
fluorescence in combination with immuno-magnetic cell-sorting where it is possible to
detect a theoretical one tumour cell in 107 normal cells. Cytokeratin-19 is however also
found in normal individuals without breast cancer (using nested PCR) (Pantel, 1996).
Colony assays in MRD
Clonogenic assays have indicated that the growth ofAML blasts are derived from
leukaemic progenitors (Clarkson et.al.1970; McCulloch, 1983). Some leukaemic
progenitors have the capacity for self-renewal (Buick et.al. 1979) however with
restricted differentiation potential (Castoldi et.al. 1996).
The first culture assays for leukaemic blast cells were modifications of existing culture
methods for normal haematopoietic progenitors (Senn et.al. 1967; Pike et.al.1970).
These assays used an agar bi-layer system with a feeder layer of normal leucocytes to
provide colony-stimulating factors known to be essential for the proliferation of the
normal cells (Robinson et.al.1971). For detection of AML standard haematopoietic
colony assays were relatively inefficient with poor yield, clusters (<40 cells) rather
than colonies (>40 cells) tended to form and cells from only 30% of patients formed
proper colonies (Spitzer et.al. 1976). Growth of leukaemic blasts was found to be
predominantly growth-factor dependent and used methyl-cellulose for the mechanical
support for the colonies, and conditioned medium from cell lines as the source of
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colony-stimulating factors (Buick et.al.1977). Colonies were found to be present in
81% of patients in remission and patients with relapse therefore it was not felt to be a
reliable indicator of relapse although the sensitivity of these colonies to 4-hydro-
peroxycyclophophamide (4-HC) was (Campana et.al.1995). There is also the problem
that some AML blasts with the potential to cause clinical relapse may fail to grow in
culture systems (Seivers et.al.1995).
Colony assays are able to detect between 0.01 to 1% of colony forming cells. Up to
70% of AML blasts have been shown to exhibit partial or total autonomous growth in
in vitro blast cell colony assays. There was a correlation between the ability of AML
blasts to produce GM-CSF and IL-lp and the capability to grow autonomously in vitro
(Bradbury et.al.1997; Reilly et.al. 1989a). Blasts with the highest levels of GM-CSF
were able to grow autonomously. AML blasts have been shown to produce GM-CSF,
G-CSF, IL-1, IL-6, and TNF-«.
IL-1 and GM-CSF have been shown to act in an autocrine fashion, with IL-1
regulating levels of GM-CSF secretion which in turn causes blast cells to proliferate.
Four patterns of colony formation were described and related to disease prognosis.
Group 1 patients - showed no growth in culture: group 2 patients grew only in the
presence of exogenously added colony-stimulating factoirs; group 3 patients were
partially autonomous but showed enhanced growth upon addition of growth factors
and finally group 4 patients who exhibited fully autonomous growth (Reilly
et.al. 1989a). Of a study of 114 patients with AML 37 were low proliferators, 39
intermediate and 38 showed a high proliferative potential. A 36% 3 year survival was
associated with low proliferation rates (68% CR rate and 49% DFS); a 3% 3 year
survival with high proliferation rates (39% CR rate and 11% DFS). AML M4 and M5
were shown to have a greater proliferative capacity than Ml and M2. There was no
correlation of proliferation with age, sex, white blood cell (WBC) count or percentage




Myeloablative chemotherapy followed by allogeneic bone-marrow is considered
curative for AML. This procedure can be considered for patients in first remission post
chemotherapy. However only 10-20% patients will be eligible to receive allogeneic
transplants because of age or lack of an available donor. Autologous transplants may
also be considered but may harbour tumour (Hammert et.al. 1997). Peripheral blood
progenitor-cell (PBPC) transplants may be the only option when there is a hypocellular
marrow (caused by prior therapy) or tumour involvement in the marrow, or lack of
donors (Sharp et.al. 1992). Combination chemotherapy can induce a remission on up
to 80% AML, however more than 50% relapse, whilst salvage therapy may re-induce a
second CR of 4 months. Autologous BMT (ABMT) for AML in first remission gives a
DFS of 34-57%. Relapse is the major cause of failure of ABMT.
A series of elegant studies have shown the potential for transplanting tumour cells
within autologous bone-marrow or PBPC grafts to contribute to disease recurrence.
The St Jude's group (Rill et.al. 1994; Brenner et.al. 1993) labelled a portion of the graft
with a neomycin resistance gene and showed that in 3 out of 4 relapse cases some of
the patients' cells contained the marker. AML, CML, ALL, lymphoma, muliple
myeloma and breast cancer, neuroblastoma have all been studied with gene marking
and transplanted cells shown to contribute to disease relapse. For example the
neomycin resistance gene was expressed found in CD34+, CD56+ leukaemic AMLs
after relapse, markers which both were expressed on the original tumour. In normal
transduced cells levels of the gene expression were greatest in myeloid >T cells > B
cells (Heslop et.al. 1995; Rill et.al. 1994). The neomycin resistance gene was detected
either by PCR on sorted blast cells or on resistant colonies grown on G418 (neomycin
analogue) (Brenner et.al. 1993).
The clinical value of purging has not been established by clinical trials (due to a lack of
trials) though several studies suggest a contribution to relapse from non-purged grafts.
However 20-70% breast cancer patients undergoing high dose chemotherapy have
been shown to have tumour cells in otherwise histologically normal bone-marrow
(Kvalheim et.al. 1996).
CD34+ cells selected by immunomagnetic beads gives a 2-4 log reduction of tumour
cells. Using 2 cycles of depletion gives up to 6 log reduction of tumour cells with 30-
40% bone-marrow progenitor loss. Immunobeads can give a 5 log reduction,
complement lysis 1-2 log reduction, immunotoxins 1 log reduction. Leukapheresis
products frequently contain 2-4 x 1010 nucleated cells. CD34 immunomagnetic
enrichment in breast cancer however only gives 2-4 log reduction of tumour (Kvalheim
et.al. 1996). Nevertheless CD34 positive cell selection is not possible in AML since up
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to 70% of AML cases will express CD34 (Nimgaonkar et.al. 1996; Brito-Babapulle
et.al. 1990). It is possible however to get up to a 7 log reduction of AML blast cells and
1-4 log reduction in CD 15 positive cells without loss of progenitors using a
combination of CD34 selection and CD 15 depletion. More than 95% AMLs expressed
CD15 following neuraminidase treatment to reveal the epitopes and 45-70% AML
express CD34 (Nimgaonkar et.al.1996). Using immunobeads it is possible to see a
sensitivity of 2 cells in 107 mononuclear cells by selecting cells with greater than 3
beads per cell (Pantel et.al. 1996).
Crypreservation has been shown to provide an element of tumour cell purging in AML
though the reasons for this are unclear (Allied et.al. 1991) but may be related to blast
cell differentiation caused by the cryopreservative DMSO.
It is may be however that complete tumour ablation may not be required, simply
reducing the numbers to a manageable level may be enough. Patients with ALL who
have less than 105 tumour cells have remained in remission (Dwenger et.al. 1996).
Animal studies have shown that a 3-4 log reduction in tumour burden can result in a
curative transplant (Hammert et.al. 1997). Whether this represents a manageable level
for establishment of an anti-tumour response is unclear.
Stem cells and Haematopoiesis
Pluripotent stem cells are capable of self-renewal and respond to haematopoietic
growth-factors by increasing the production of required lineages. Pluripotent stem cells
resemble lymphocytes in terms of their size and granularity they are also wholly
contained within the CD34+, Lin-,SCF+ cell compartment (Sutherland et.al. 1994). A
more mature common progenitor cell appears to give rise to a number of cell lineages
including the erythroid, granulocytic, monocytic and megkaryocytic whilst another
gives rise to cells of the lymphoid lineage (Figure 2). The earliest myeloid
progenitor, called the CFU-GEMM (colony forming unit granulocyte-erythroid-
monoctye-megakaryocyte), and lymphoid progenitors form in the bone-marrow which
















Monocytes Neutrophils Eosinophils Basophils Lymphocytes
(Figure 2)
This figure demonstrates the normal hierarchical development of cells in the bone
marrow and their subsequent maturation to functional haematopoietic cells.
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The stem cells comprise only a very small percentage (less than 0.1%) of nucleated
cells in the bone-marrow. Historically the CFU-GM has been the standard by which
stem cells for clinical transplantation were enumerated. On average a patient required 7-
10 leukaphereses to obtain enough CFU-GM per kg to ensure engraftment following
peripheral blood progenitor cell (PBPC) transplantation (more than 3 x 105 CFU-GM
per kg). Recently recombinant growth factors G-CSF or GM-CSF plus chemotherapy
has been used to mobilise up to 2-300 more progenitors than normally circulate in
peripheral blood and allows more sucessful engraftment (Shea et.al. 1992).
Transplantation
Chemotherapy is the main form of treatment in leukaemia and in some cases
radiotherapy may also be used. Unfortunately both anti-cancer drugs and radiotherapy
also cause severe damage to normal cells in the bone-marrow. Spacing out the
treatment over several months minimises the damage and allows recovery of normal
marrow function. The most common reason for transplantation is to treat a leukaemia
which has either not responded to therapy or has relapsed following initial therapy.
Allogeneic bone-marrow transplants may be useful in high-risk groups eg.
chemoresistant AML. Allogeneic BMT are age-restricted (to less than 55 years) and
compatibility of the HLA-donor. There may be as high as 50% relapse rate following
allogeneic BM or PBPC transplants but the potential for for a graft-versus-leukaemia
(GVL) effect makes it the treatment of choice. T cell depletion increases the relapse rate
but decreases the GVHD and GVL reaction (Schiller, 1991).
Autologous Transplant
Some patients may be able to use their own autologous marrow or peripheral blood
stem cells. This can be used for patients with CML, AML, lymphoma and myeloma
and solid tumours including breast and testicular cancer. Autologous transplants may
be offered to a large proportion of patients who are harvested in complete remission.
There is a low risk of GVHD but no potential for a GVL and there is always the
possibility of transplanting tumour, although various purging strategies have been
tried, including 4-hydroperoxycyclophosphamide (4-HC) or immunologic purging
(Rubin et.al. 1994). Autologous marrow is harvested in complete remission at a time of
minimal residual disease and then purged to remove tumour cells by pharmacologic or
immunologic methods. However 4-HC is non-specific and also affects normal
hemopoietic precursors.
It is possible to get a 1-2 log purging using antibody but there may be 106-109 tumour
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cells in a complete remission marrow leaving 104-107 tumour cells. Purging may either
destroy normal marrow function or provide incomplete tumour cell depletion and is
therefore not ideal.
Sources of Stem Cells
Stem cells can be obtained from bone-marrow, the peripheral circulation or from the
umbilical cord blood. Until recently bone-marrow had been the only source of stem
cells for transplantation. Marrow can be frozen and stored for months or even years.
This is often done for patients with chronic myeloid leukaemia or lymphomas. Storing
marrow taken during remission may offer a therapeutic option if the leukaemia should
return and may also reduce the tumour cell contamination (Allieri et.al.1991).
There are normally very small numbers of stem cells circulating in the blood known as
peripheral blood progenitor cells (PBPC). Normally there are insufficient numbers of
these to harvest from the blood though it is possible to recruit progenitor cells from the
bone-marrow into the peripheral blood by using growth-factors on their own or in
combination with a small dose of chemotherapy. GM-CSF has been shown to increase
the numbers of CFU-GM in peripheral blood 60 fold following chemotherapy
(Socinski et.al.1988). Patients who receive peripheral blood progenitor cell transplants
spend a shorter time in hospital and have fewer complications because their neutrophil
and platelet counts return to normal more rapidly. Autologous stem cells have the
potential for contamination with tumour cells which may contribute to disease relapse.
It may be possible to remove, or to reduce the numbers of leukaemia cells by purging
techniques using antibodies to isolate stem cells then return them to the patient. A
similar approach is to use antibodies against the leukaemia cells to deplete them from
the marrow. Both methods can be used on the same harvest.
The ideal donor is an identical twin because tissue types will be identical to the patient.
A transplant between identical twins is called a syngeneic transplant. There are no
problems with rejection or GVHD though the relapse rate is higher than with allogeneic
grafts. The next most suitable donor is a matched sibling. The remainder of patients
require a matched-unrelated donor (MUD). This however requires close tissue-type
cross-matching and requires continual immunosuppression. The closeness of a match
needed for a good result depends on which of the human leucocyte antigens (HLA) are
mismatched.
Leukaemic patients who are considered good risk are not normally given a transplant
as treatment can be more dangerous than beneficial. Autologous and allogeneic
transplants can both be used for the treatment of acute leukaemia even though the
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but benefit from being free of leukaemia cells which could be re-infused at the time of
transplant, and may also exert a GVL which is potentially curative.
AML patients with a good risk category of disease have an excellent chance of doing
well on standard chemotherapy and are not candidates for a transplant. Patients with
poor risk disease are unlikely to achieve long-term remission with drugs alone and are
more likely to be transplanted. Patients with standard risk disease fall into patient-by-
patient care (Buchner, 1993).
Growth-factors
Haematopoietic growth-factors are glycoprotein hormones which regulate
differentiation and proliferation of progenitor cells and the function of mature blood
cells. Recently recombinant haematopoietic growth-factors have been used to reduce
the complications associated with chemotherapy and transplantation. For example G-
CSF is used to stimulate the production of normal granulocytes and monocytes after
transplant which also helps reduce infections. There is an significant increase in the
number of CFU-GM in the peripheral blood of patients with Hodgkin's disease in
bone-marrow following treatment with GM-CSF (Haas et.al.1992). Peripheral blood
stem progenitor cell transplants take about two weeks for blood counts to improve to
acceptable levels. It takes longer (up to two years) for full function to recover,
especially bone-marrow.
Growth-factor function in haematopoiesis
Bone-marrow cells grown in semi-solid medium eg. agar ormethyl-cellulose with
purified growth-factors form distinctive colonies. Colonies grown in G-CSF form
neutrophils and precursors; those grown in M-CSF form macrophages; those in IL-3
form many different lineages; colonies grown in GM-CSF form neutrophils,
macrophages, eosinophils and other cells.
Granulocyte colony-stimulating factor (G-CSF) has a 2.0 kilobase (kb) mRNA
transcript which yields an 18-22 kiloDalton (kDa) protein produced by monocyte and
fibroblasts. Granulocyte-monocyte colony-stimulating factor (GM-CSF) has a 1.0
mRNA yielding a 14-35kDa protein synthesised by T cells, fibroblasts and endothelial
cells. Interleukin 3 (IL-3) is a 14-28kDa protein produced from a l.Okb mRNA
transcript by T cells. Monocyte colony-stimulating factor (M-CSF) has a 4.0
mRNAproducing a 35-45kDa protein produced by monocytes. There is also a 1.8
mRNA M-CSF transcript producing 18-26kDa produced by fibroblasts and endothelial
cells. All these CSF are effective at picomolar concentrations in vitro and probably less
in vivo. IL-3 and GM-CSF activities overlap and are both produced by T cells though
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in vivo. IL-3 and GM-CSF activities overlap and are both produced by T cells though
there is little sequence homology. IL-3 is more active on the earliest progenitors and
also able to cause increased platelet, granulocyte and monocyte production. Few
normal cells express detectable mRNA for G-CSF, IL-3, GM-CSF except when
activated. GM-CSF has different amounts of glycosylation with different biologic
activity (heavily glycosylated forms have least activity). GM-CSF acts on earlier
progenitors than G-CSF (Clark, 1987).
Clinical administration of G or GM-CSF to patients with myelosuppression causes a
rapid recovery and elevation of neutrophil count and primes these cells for bactericidal
action and also the production of cytokines by mature neutrophils, monocytes and
eosinophils. Two or more factors probably act synergistically in a coordinated fashion
to initiate the signal to divide or differentiate. Also one growth-factor may affect the
production of its own receptor or that of another growth factor. For example IL-1 has a
variety of effects mainly related to inflammation. Stem cell factor (c-kit) acts on
pluripotent stem cells and early myeloid and lymphoid progenitors. IL-1 and IL-6
enhance the effects of SCF, IL-3 and GM-CSF on survival and differentiation of early
progenitors. EPO, G-CSF, M-CSF, and IL-5 act on later cells which are more
committed to one cell lineage, IL-6 also has a role in megakaryocyte formation. Cloned
bone-marrow stromal-cell lines constitutively produce only IL-6, M-CSF and require
induction by IL-1 to produce GM-CSF and G-CSF. Bacterial infection causes a rapid
production of M-CSF, G-CSF, IL-5, 6 and a small rise in GM-CSF within 3-6 hours,
there is no detectable IL-3 found however (Nicola, 1989).
Growth-factor effects are mediated through specific receptors on target cells. Many
growth-factor receptors belong to a structurally similar receptor family (IL-2 to 6, GM-
CSF, G-CSF, Erythropoietin). Ligand binding causes receptor dimerisation initiating a
series of phosphorylation events, though there is no direct tyrosine kinase activity. A
smaller group of growth-factors (IL-1, M-CSF, SCF) belong to the immunoglobulin
super-family which do have intracellular tyrosine kinase activity. Receptor activation
may cause changes in second-messenger molecules including cAMP, cGMP, diacyl-
glycerol and inositol tri- and tetra-phosphate (IP3 and IP4), phosphatidyl-inositol
triphosphate and calcium ions. These compounds phosphorylate other proteins
involved in signal transduction which may bind together via SH (src homology)
domains causing a phosphorylation cascade. The products of RAF (a serine-tyrosine
kinase) and MAPK (mitogen activated kinase) transmit signals from cytoplasm to
nucleus which activate transcription factors by phosphorylation. Proteins called cyclins
are caused to bind to protein kinases in the cdc2 family to form a complex involved in




Significantly G-CSF given to patients with relapse or refractory leukaemia significantly
reduces neutropenia (Byrne et.al. 1997). A longer complete remission was found in
patients with a high S-phase index presumably growth factors were increasing the
proportion of blast cells in cycle. However patients treated with GM-CSF during and
after chemotherapy did worse than patients given chemotherapy alone (Buchner,
1993).This may be due to growth-factor-induced blast cell proliferation. Blast cells
from different patients obviously may express receptors for combinations different
growth-factors and therefore respond to their presence by proliferation or
differentiation depending on their relative maturity. Growth-factors also affect the
survival and function of normal mature cells with a common mechanism of apoptosis
inhibition.
Apoptosis is a genetically-programmed cell suicide pathway which appears to be a
default process for cells deprived of positive survival stimuli from growth factors.
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Apoptosis
As indicated in the previous section most cells depend on growth-factor support for
proliferation and survival. In many cases removal of growth-factors results in the cells
entering into a period of quiescence known as GO (Cory, 1995). If this period is
extensive then cells undergo a programmed cell death called apoptosis (Kerr .et.al
1972). Most known chemotherapeutic agents thus far studied also induce apoptosis in
target cells, usually through a mechanism which senses the DNA damage caused by
these agents. Induction of apoptosis is not limited to highly proliferative cells
(Hickman et.al. 1994).
Apoptosis is an irreversible cellular process whereby target cells are actively removed
from tissues by phagocytic cells following growth factor removal, or detection of
cellular damage. It is associated with obvious cellular shrinkage, nuclear condensation
and membrane blebbing. In many diseased and normal tissues (eg. during immune
function or organ development) cells are actively removed from the surrounding matrix
without provoking an inflammatory response
Apoptosis is the loss of cell volume associated with cytoskeletal breakdown resulting
in blebbing of the plasma membrane (Wyllie et.al.1984). A variety of active
intracellular signalling processes occur, including loss of water, endonuclease
activation causing (DNA cleavage at inter-nucleosomal sites (Wyllie, 1980) and
fixation of the cell membrane through tissue transglutaminase activation (Piacientini
et.al. 1991). DNA cleavage however can be partial or even absent when apoptosis
occurs (Cohen et.al. 1992; Falcieri et.al. 1993).
Programmed cell death however and apoptosis may occur through distinct pathways
and (PCD) does not necessarily involve inter-nucleosomal DNA fragmentation. Some
cells may use both methods, for example TNF-a-induced death of lymphocytes may
occur either via apoptotic or non-apoptotic pathways (Cohen, 1993) depending on the
culture conditions. Therefore techniques dependent on DNA cleavage eg. agarose gel
electrophoresis or in situ end-labelling of fragmented DNA, may fail to detect these
cells (Sgone et.al. 1998; Gorczyka et.al. 1993).
Apoptotic cells round up and lose contact with neighbours, there is loss of cell volume
(due to secretion of water and ions) causing an increase in density. Membrane blebbing
occurs before loss of membrane integrity but probably after nuclearmargination and
condensation and fragmentation. Nuclear changes in apoptosis can occur without
oligonucleosome production (Bellamy et.al. 1995).
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A number of extracellular agents eg. TNF-a, Fas, chemotherapeutic agents cause
activation of sphingomyelinases and release ceramide (from membrane
sphingomyelin). Ceramide activates a serine-threonine phosphatase and regulates ICE
proteases and the retinoblastoma protein and stress-activated protein kinases. Ceramide
levels increase in response to 1, 25-dihydroxy vitamin D3, TNF-a, endotoxin, IFN-v,
IL-1, Fas, CD28, dexamethasone, retinoic acid, progesterone, ionising radiation,
chemotherapy heat and nerve growth factor (NGF). Serum withdrawal in leukaemic
cells can result in a 15 fold increase in ceramide. The membrane permeable ceramide
analogues C2 or C6 may induce apoptosis, senescence, cycle arrest or terminal cell
differentiation. Cell cycle arrest induced by ceramide results in dephosphorylation of
retinoblastoma protein. Actinomycin D causes ceramide increases by a p53 dependent
mechanism. Accumulated ceramide activates CAPP (ceramide activated protein
phosphatase) which may result in either retinoblastoma protein activation and cycle
arrest or YAMA activation leading to apoptosis ( Hanuun. et al 1996).
Downstream effects ofTNF-a or Fas, Ara C, vincristine, ionising radiation cause an
increase in ceramide an effect which can be inhibited by bcl-2 overexpression. In some
cell lines however ceramide may protect from apoptosis. Ceramides will induce HL-60
differentiation. CAPP activates protein kinase C through phosphorylation. Ceramide is
produced by a sphingomyelinase which may mediate the effects of Ara C, TNF-a or
Fas. Ceramide and diacyl glycerol (DAG) do not function solely as signal transduction
agents (Hannun, 1996).
Role of bcl-2 in prevention of apoptosis
Myeloid cells have viability factors which suppress apoptosis and are required
throughout the differentiation process. The colony stimulating factors (CSF) and IL-3
function as growth-factors, however IL-1 and IL-6 can also function as viability
factors without inducing growth, as can PMA or bcl-2. Viability and growth are
separately regulated processes. Homeostasis in normal tissue is a balance of cellular
proliferation and removal via cell death.
Bcl-2 was characterised from B cell lymphomas with the t( 14; 18) translocation.where
the abnormally regulated protein was shown to cause reduced apoptosis (Zutter
et.al. 1991; Korsmeyer, 1992). There is a recently characterised family of molecules,
structurally related to bcl-2, whose major role appears to be in the maintenance of
cellular homeostasis. This bcl-2 family of proteins shares structural homology features
known as Bcl-2 homology regions (BH). Cellular death or viability is partly mediated
by competitive hetero and homo-dimerisation between pairs of antagonists or agonists.
Family members share the bcl-2 homology regions BH-1,2, 3 or 4 and it appears to
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be the ratio of anti-apoptotic to pro-apoptotic members eg. bcl-2 to bax which
determines apoptosis (Figure 3).
(Figure 3)
(Yang et.al.1996)
Hetero- and homodimerisation require the BH-1 and BH-2 regions (Sedlak
et.al. 1995). For example BH4 regions are conserved among anti-apoptotic bcl-2
homologues. Bcl-2 is located on the inner mitochondrial membrane and nuclear pores
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lines. Cells remain in GO until IL-3 is administered (Hockenbery et.al.1990). In the
presenee of DNA damage bel-2 transfeetcd cells were able to survive (Hickman
et.al. 1994). Similarly 67% of lymphoma cells underwent apoptosis when treated with
5-fluorodeoxyuridine for 24 hours as compared with 8% of cells with a bcl-2
expressing vector (Fisher et.al. 1993a). Bcl-2 transfection into cortical thymocytes
protects them from radiation, glucocorticoids and anti CD3 antibody induced
apoptosis. Overexpression of bcl-2, bcl-xl suppress apoptosis in the absence of
growth-factors whereas overexpression of bad, bax, bik override signals from growth-
factor receptors and induce apoptosis. Apoptosis suppressor members prevent
apoptosis when heterodimerised but are incapable of protecting from apoptosis when
heterodimerised with an inducer molecule (Cory, 1995; Kroemer, 1997).
The normal sequence of signalling events may be growth-factor or cytokine binding its
receptor causing the activation of phosphoinositide 3-kinase which in turn releases
inositol phosphates. These in turn activate Akt (a serine-threonine kinase) and PDK1
which induces phosphorylation of bad-bcl-xl which causes a dissociation of bad from
bcl-xl. Bad in turn is sequestered by 14-3-3 (a phosphoserine binding protein) and bcl-
xl is able to prevent apoptosis via cytochrome c inhibition (Franke et.al. 1997) Levels
of bcl-2 or bcl-xl may be regulated by growth-factors which thus maintains cellular
viability. Upon growth-factor removal bad is de-phosphorylated, dissociates from 14-
3-3 and heterodimerises with bcl-xl. Homo-dimerised bcl-2 or bcl-xl bind to ced 4
homlogues, then bind the inactive form of cysteine proteases. When homodimer
binding to ced-4 is disrupted the cysteine proteases become activated ie. normally bcl-2
or bcl-xl homodimers sequester ced-4 and apoptosis is prevented. Heterodimerisation
of bcl-xl with bax, bak or bik causes ced-4 release and apoptosis induction. Bad (a
pro-apoptotic member) is normally sequestered by 14-3-3 in the cytosol as the
phosphorylated (bad) form (Franke et.al. 1997).
Not only absolute protein levels (Hu et.al. 1996) but post-translational modifications of
these proteins may alter functional activity through phosphorylation at serine residues
eg. bcl-2 function is lost when phosphorylated (Kroemer, 1997). Disruption of the
mitochondrial membrane potential (via apoptotic signals), and therefore permeability
transition (PT) pores, causes uncoupling of the respiratory chain, cessation of ATP
synthesis, depletion of reduced glutathione (GSH) and nicotinamide-adenine-
dinucleotide (phosphate) NAD(P) stores, superoxide production, calcium efflux from
the mitochondria and protein leakage. Release of cyochrome c and apoptosis inducing
factor (AIF) induce proteolytic activation of caspase (cysteine protease-CPP32) and
cause apoptosis. Activation of CPP32 is dependent on the release of cytochrome c
from mitochondria (which is normally blocked by bcl-2). Bcl-2 does not affectAIF
formation or the effects of cytochrome c (or AIF) on isolated nuclei, again
demonstrating the requirement for bcl-2 location on mitochondrial membranes.
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Permeability transition inhibitors eg. N-methyl-val-4-cyclosporin A are able to inhibit
apoptosis. Bcl-2 and bcl-xl are relatively poor inhibitors of Fas, TNF-a andTRADD
(TNF-a receptor associated death domain) death effectors. Inactivation of bcl-2 can be
achieved by agents acting on microtubules (eg. taxol and colchicin) through
hyperphosphorylation during the G2-M phase of the cell cycle (Kroemer, 1997).
Clinical role of bcl-2 in AML
In patients with AML levels of bcl-2 appear to be correlated to disease prognosis, with
patients having high levels of bcl-2 showing a poorer response to chemotherapy
(Campos et.al. 1993). 82 samples of de novo AML were measured for bcl-2 content
and it was found that a mean of 23% were bcl-2 positive. The percentage bcl-2 positive
cells was higher in M4 and M5 sub-types and those with highest blast cell counts. Bcl-
2 levels also were correlated with CD34 expression. High levels of bcl-2 were
associated with poor complete remission and shorter survival. The percentage bcl-2
positive cells were highest in monoblastic M4 and M5 and lowest in M3 promyelocyte
AML. AML MO-15% positive; Ml-25%; M2-14%; M3-8%; M4-35%; M5-29%; M6-
35%. KGl-a (an AML cell line) were 97% bcl-2 positive and HL-60 (an APML cell
line) 85% positive but with an intensity lower than KGl-a (Delia et.al. 1992). In
normal bone-marrow bcl-2 was found in mature myeloid cells up to the promyelocyte
and erythroblast stages. These authors suggested that high bcl-2 levels in AML was a
consequence of the absence of differentiation, rather than deregulated expression
(Campos et.al. 1993).
Autocrine growth ofAML blasts in culture is related to a poor complete remission rate
(Lowenberg et al). Autonomously growing AML cells in culture have been shown to
have an autocrine GM-CSF-induced up-regulation of bcl-2 (neutralised by anti-GM-
CSF antibodies). In patients with non- or partial autonomous growth bcl-2 levels were
up regulated by exogenous GM-CSF (Nunez et.al. 1994). CD34 positive AML cells
were found to express higher levels of bcl-2 than CD34 negative AML blasts. Anti
GM-CSF antibodies were able to down-regulate bcl-2, leading to an increased
sensitivity to cytotoxic drugs (Bradbury et.al. 1997). G-CSF, used to ameliorate
chemotherapy-induced myelosuppression in AML, may also enhance proliferation of
those tumour cells with the G-CSF receptor. Recombinant human G-CSF is known to
enhance the survival of leukaemic AML cells in response to adriamycin and etoposide
treatment probably through a bcl-2 mediated mechanism (Kondo et.al. 1994).
Some AML cell lines can be induced to differentiate even if they are independent of
exogenous growth-factors for growth notably the promyelocytic leukaemia cell line
HL-60. Differentiated HL-60 cells have much reduced bcl-2 levels but even before
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HL-60. Differentiated HL-60 cells have much reduced bcl-2 levels but even before
terminal differentiation these cells re-acquire normal requirements for growth-factors,
which if removed causes cells to undergo apoptosis. PMA treatment was able to rescue
these cells from apoptosis but was inhibited by amiloride (a Na-H+ antiporter
inhibitor) (Sachs et.al. 1993). Bcl-2 down regulation in these cells is not sufficient for
induction of differentiation. Bcl-2 mRNA down regulation was seen only in the
parental cell and not in an adriamycin-resistant form even though both forms were able
to differentiate (Blagosklonny et.al. 1996).
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Antisense
The pivotal role of bcl-2 in the survival of AML blasts, association with poorer
survival and in the development of tumour resistance to chemotherapy therefore makes
it a central target for drug therapy in AML and other cancers (Campos et.al. 1994;
Kitada et.al. 1994). A novel form of molecular therapy has attracted the attention of
many researchers and drug companies (Zamecnik et.al. 1978, 1986). This inhibitory
therapy uses drugs called called antisense DNA and molecules can be designed with
exquisite specificity for known protein targets in disease. By designing a synthetic
DNA molecule complementary to the mRNA sequence of a known protein, levels of
expression of that protein may be selectively modulated. This has important
implications in the design of novel therapeutics since drug development times are
reduced with the potential for increased drug specificity and reduced side effects.
Antisense DNA molecules can be targetted to several RNA sites important in the
synthesis and assembly of proteins: the AUG site to prevent the translation complex
assembly: the 5' cap region to prevent ribosome assembly: the protein coding region to
prevent the translation process: or other RNA areas to prevent mRNA transport from
the nucleus to cytoplasm (Warzocha et.al. 1997). RNAse-H-mediated digestion of
RNA has been found to be the predominant mechanism of antisense action in down-









Antisense molecules may prevent the production of proteins by steric hindrance
preventing translation, or RNAse H-mediated digestion of the RNA-cDNA
heteroduplex.
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Many recent reports have suggested good in vitro efficacy with selective mRNA
targetting and effective down-regulation of target protein function eg. the bcr-abl
fusion protein in CML (Chasty et.al.1996), gpl20 in HIV (Lisziewicz et.al.1994)
using antisense molecules, however large scale clinical trials have been largely
unsuccessful with limited effectiveness, and potentially serious side effects. Side
effects largely mimic the actions of polyanionic molecules, and as such may affect
blood clotting factors (elongation of APTT) (Webb et.al. 1997) complement activity
and heparin-binding proteins eg. fibrinogen. An antisense phosphorothioate to HIV
has been shown to cause mild thrombocytopenia, elevated serum transaminase levels
and elongated activated partial thromboplastin times (APTT) with a dose of 2.5mg/kg
(Plenat, 1996).
Uptake of Antisense
Cellular studies on uptake of antisense molecules have shown that at 4°C 90% of the
antisense associated with cells is localised on the cytoplasmic membrane. However at
37°C the intracellular concentration rises to a plateau after 1-2 hours in serum-free
medium. Antisense oligodeoxynucleotides were taken up in a sequence independent
manner and were inhibited by plasmid DNA or yeast transfer RNA (Neckers, 1993).
This uptake appeared to be a receptor-mediated phenomenon with many authors
describing a potential 80kDa cell surface antisense-receptor.
Labelled ligand-receptor complexes internalised by endocytosis display a punctate
intracellular fluorescence consistent with patterns of cellular antisense uptake by
microscopy (Clarenc et.al. 1993). Antisense binding has been described as having a
single dissociation constant in the low nanomolar range, with most cells expressing
20-100,000 binding sites per cell. Nuclear, membrane and cytoplasmic staining
patterns have also been described. Studies using microinjection of fluorescent-tagged
oligodeoxynucleotides have demonstrated a rapid localisation of antisense to nuclear
structures which was not dependent on ATP or temperature (Leonetti et.al. 1991)
Recent reports have suggested that CD1 lb is a potential mechanism by which antisense
phosphorothioates can be internalised into cells (Benimetskaya et al). Soluble
fibrinogen, but not an GRGDSP peptide, was able to inhibit binding of a 15mer
antisense to HL-60 cells by up to 40%. Synthetic heparin analogues were also able to
inhibit antisense binding to both the aM and |32 subunits of Mac-1. Both aM and p2
subunits are believed to contain heparin binding sites and a metal ion-dependent
adhesion site (MIDAS) which bind Ca2+ and Mg2+. Phosphodiester antisense Mac-1
binding was shown to be Ca2+ or Mg2+ dependent whereas phosphorothioate (where
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an acidic oxygen is replaced with sulphur) was not.
Mac-1 is a member of the leucocyte integnn family and has been shown to bind ICAM-
1, fibrinogen, C3bi, factor X, heparin. The (32 integrins share the non-covalently
associated p chain CD 18 and differ only in their alpha sub-unit: LFA-1 = CD1 la-
CD18: Mac-1 = CD1 lb-CD18: pl50,95 = CD1 lc-CD18. Alpha subunits share a
conserved 200 amino acid I (inserted) domain which contains a heparin-binding site
and three tandem divalent-cation binding repeats (MIDAS or EF-hand domains).
Antibodies to the EF region however had no effect on phosphorothioate binding.
Because of its pivotal role in the maintenance of cellular homeostasis and elevated
levels in poor prognosis AML makes bcl-2 bt an ideal target for antisense therapy. The
effectiveness of 4ug/ml of cytosine arabinoside has been shown to be more effective in
the presence of antisense to bcl-2. The highest intracellular antisense phosphorothioate
content was achieved at 4-5 days which accounts for the delay in its effectiveness
(Campos et.al. 1994). A 16mer antisense phosphorothioate to IL-1(3 converting enzyme
(ICE) at 10-75uM inhibited proliferation of peripheral blood and bone-marrow
leukaemic cells and inhibited CFU-L formation. IL-1 has been shown to be important
in initiating paracrine and autocrine growth ofAML blasts (Stosic-Grujicic et.al. 1995).
Antisense bcl-2 has also been shown to down-regulate lymphoma growth in SCID
mouse model (Cotter et.al. 1994) and in human lymphoma (Webb et.al. 1997). Wilms
tumour gene product (WT) may also be a therapeutic target for antisense therapy in
AML since it too is associated with a poor prognosis (Olsson et.al.1996) and was
found to be expressed in all of 96 patients with AML or CML. There were no effects
ofWT antisense on normal CFU-GM but leukaemic colonies were inhibited. A WT
cDNA driven by a CMV promoter abrogated antisense efects as determined by How
cytometry (Yamagami et.al. 1996).
U937 cells (a leukaemic cell line with monocyte-macrophage characterises) treated
with c-myc antisense by electroporation caused rapid cell death (presumably through
an antisense effect). The treatment appeared to have little effect on murine
hematopoietic cells. Electroporation causes transient membrane pore formation, and
with optimisation 100% transfection and suppression of c-myc and decreased cell
viability can be achieved (Bergan). U937 cells have low levels of bcl-2 but when
transfected with a vector containing bcl-2 they increased their resistance to cytosine
arabinoside by 3 logs (Suresh et.al.1996).
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Aims & Objectives
This thesis has set out to detemine bcl-2 levels, monitor the delivery dynamics and
effectiveness of antisense uptake in AML and normal blood cells in an attempt to
obtaining either an effective purging protocol which could be used to remove tumour
cells from bone-marrow and apheresis products, or to provide a more effective therapy
for the treatment of refractive and resistant AML.
Growth patterns of AML blast growth in vitro have been shown by others to be related
to bcl-2 protein levels and subsequent disease prognosis. These parameters were
therefore characterised. Values for bcl-2 protein expression in normal versus AML
cells were obtained.
In an attempt to reduce the leukaemic cells' resistance to chemotherapy (mediated
through bcl-2) an antisense directed to bcl-2 protein was used to either effect leukaemic
cell cytotoxicity directly or to increase their sensitivity to standard chemotherapy.
Antisense uptake into normal and leukaemic cells was characterised and the
mechanisms of internalisation sought with a view to improving the selectivity of drug
action towards tumour cells. The functional effectiveness of antisense was monitored








Permeabilisation buffer (for bcl-2 measurement)
70% Methanol in PBS (1 litre)
PBS-Azide-BSA (PAB) buffer (1 litre)
1% Bovine serum albumin (BSA) lOg
0.1% NaN3 (Sodium azide) lg
PBS to 1 litre
FACS Row™ Becton Dickinson (Sheath fluid) (20 litres)
Cell preparation for flow cytometry (FACS) analysis:
Cells were harvested and adjusted to 106 cells/ml, washed twice (200g, 5 minutes) and
resuspend in 1ml PBS. An appropriate amount of titrated labelled antibody was added
and incubated for 20 minutes on ice in the dark (to avoid photo-bleaching and to reduce
non-specific reactions). Cells were then washed twice with PBS as before. If required
a permeabilisation step for cytoplasmic antigen (bcl-2) detection was carried out after
staining for surface antigens as above (Aiello et.al.1992). Cells were resuspend in 1ml
of 70% methanol-PBS and incubated for 20 minutes at 4°C (Sartor et.al. 1994; Jung
et.al.1997). Cells were then washed twice and resuspend in 1ml PBS. Where
required, non-specific antibody binding to Fey receptors was blocked by incubating the
cells with 10(4.1 non-immune, non-labelled isotype control for 20 minutes at 4°C. Cells
were then washed with PBS and stained with the labelled antibody for 20 minutes at
4°C, then washed as usual in PBS. Finally the cells were resuspend in 300(41 PBS for
immediate FACS analysis (or in PAB if there was any delay prior to staining).
39
Flow cytometry (FACS) analysis
To ensure reliable performance and repeatibality between data FACS calibration was
performed on a regular basis usiing Calibrite™ beads (Becton Dickinson #95-0002)
according to the manufacturers protocol.
CellQuest™ software (Beckton Dickinson, Oxford UK) was loaded and connected to
the cytometer; appropriate instrument settings for each cell type set; the required
number of events (eg.routinely 20-30,000 cell "events" or 50,000 for rare cells such as
CD34+ cells); acquisition plot set on forward-scatter (size) versus side-scatter
(granularity); parameter description set to the fluorescent antibody label then data
acquired.
Data analysis
A bivariate analysis plot of forward versus side scatter was initially used to determine
the size and granularity of the cells under study. A plot of the required parameters was
then prepared, for example CD34 expression versus side scatter gave the best
visualisation of stem cells (low granularity and high CD34 expression). It was then
necessary to gate the population of interest and subsequently plot a third, or fourth
parameter for example bcl-2 levels on a histogram plot of CD34 positive cells (CD34
versus SSC). Histograms were compared by Kolmogorov-Smirnov statistics where a
value of p<0.05 was considered significant.
CD34 positive cell determination in AML and normal peripheral blood
and bone marrow
A mononuclear cell preparation (106 cells/ml) of blood or bone-marrow was stained
with lOfil CD34-PE monoclonal antibody (HPCA-2, Beckton-Dickinson, Oxford,
UK). CD 34+ cells were identified on the basis of low side scatter and CD34
positivity. This is a simplified version of the recently adopted ISHAGE protocol,
namely : firstly a histogram of CD45+ve (gate Rl).was identified, secondly a
histogram of CD34+ve (gate R2) cells was identified. A CD45 versus side scatter dot
plot (identified blasts with low side scatter low CD45 (gate R3) and finally a FSC
versus SSC plot confirmed these cells were contained within the lymphoid and blast
region (Sutherland et.al.1994).
40
Quantitation of antibody binding
The Quantum Simply Cellular™ (Sigma, UK) kit was used for antibody quantitation.
It eontained a mixture of microbeads coated with five differing capacities for antibody
binding. The fluorescence signal from the peak channel was used to construct a
calibration curve from which unknown values were determined (Figure 9b). Cells
under study and 50|d of microbeads (approximately 105 beads) were dispensed into a
test tube and labelled with enough test antibody to ensure saturation. Beads and cells
were prepared in the same manner and processed for flow cytometry as indicated
above and the flow-cytometer aligned for optimal detection of cells and beads. The
microbeads were analysed by gating on the singlet population and the peak fluorescent
channel determined for each bead population. A regression line was plotted between
the standard points of antibody-binding capacity (ABC) versus peak fluorescence
channel (linear scale-channel numbers) and unknown values extrapolated from the
equation of the regression line (Figure 9b).
Stable cell labelling
PKH2-GFL stable green fluorescent cell linker was used to monitor the sensitivity of
How cytometric detection of tumour cells populations in culture in the MRD
experiments. PKH2 is an aliphatic fluorescent chromophore for labeling membrane
lipid. It has an excitation wavelength of 488nm and emission wavelength of 504nm,
propidium iodide has an emission wavelength of 570nm (Horan et.al.1990).
Fluorescent red blood cells intensity remained relatively constant over 60 days using
10-5M PKH-3 (Slezak et.al. 1989; Traycoff et.al. 1995).
Firstly a single cell suspension (2 x 107 cells per stain) was prepared and cells washed
once in IMDM (without serum) at 200g for 5 minutes at 25°C. The supernatant was
aspirated and cells resuspend in diluent A. The dye was prepared in diluent A at two
times final concentration in a polypropylene tube. Cells were then added to the dye and
mixed immediately and incubated for 5 minutes at room temperature. The reaction was
quenched with 2ml foetal calf serum (FCS) and incubated for 1 minute. Two volumes
of complete medium were added and cells washed three times, cells resuspend in an
appropriate volume of medium and the analysis completed. Varying cell and dye
concentrations were required to optimise staining conditions for each cell population.
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Cell culture reagents
Red blood cell lysis
20 ml samples of anti-coagulated blood (IOO4I preservative-free heparin) were lysed in
a hypotonic solution using 4-10 volumes of ammonium chloride red cell lysis buffer.
Leucocytes were sedimented at 200g and the haemolysed supernatant aspirated. The
lysis and centrifugation step was repeated if neccessary until a clear solution was
obtained. The supernatant was again aspirated and discarded and the resulting cell
pellet resuspend in 1ml of medium and cell viability counted using trypan blue.
Red blood cell (RBC) lysis buffer (1 litre)
Ammonium chloride (NH4CI): 8.26g
Potassium bicarbonate (KH2CO3): 1-OOg
Na2 EDTA: 0.0037g
This solution was filter-sterilised with a 0.24m filter and renewed within one month.
Tissue culture medium (500ml)
10% foetal-calf serum (FCS heat-inactivated for 30mins at 60°C) 50ml
1% Penicillin (50U/ml)-Streptomycin (50fig/ml) solution 5ml
1% L-Glutamine solution 5ml
IMDM (Iscove's Minimal Dulbecco's Medium) 500ml
Trypsin-EDTA for harvesting adherent cell lines 0.25%
Hanks Balanced Salts Solution (HBSS)
Trypan blue (0.2%) cellular viablity stain:
Cellular viability methods and reagents
0.2% Trypan blue in PBS was used for routine determination of cellular viability;
viable cells exclude the stain, whereas dead (or permeabilised) can not, therefore stain
blue. Briefly IO4I cells were mixed with 90[d trypan blue and IO4I of the mixture
counted immediately. The cell count per ml was given as the number of viable cells in
one large hemacytometer square x 105.
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Propidium iodide (PI) solution (0.25%) was used for determination of ecllular viability
by ilow cytometry. Viable cells exclude the stain, whereas dead (or permeabilised)
cells take up the stain into their nuclei whereupon the quantum yield of the propidium
iodide (PI) fluorescence increases and the cells emit a bright fluorescence. A 0.025%
stock solution used at 40|d per ml of cells.
Fluorescein-diacetate (FDA) solution was also used for determination of cellular
viability. Viable cells contain non-specific esterases which cleave fluorescein-diacetate
into free tluorescein (being highly charged, cannot diffuse across intact membranes)
therefore intact cells fluoresce brightly with a green fluorescence, dead (or
permeabilised) cells however, allow the stain to diffuse out of the cell and do not
fluoresce. A stock solution of 5mg/ml was made in acetone, aliquoted and stored at -
20°C in the dark. A working solution of 10ul stock solution was dissolved in 1ml of
PBS. 5jil of this was then added to 50[il cell of suspension (106 cells/ml), mixed and
left for 15 minutes at room temperature. The cell sample was centrifuged at 200g, the
supernatant discarded and cell pellet resuspended in PBS and analysed for viability.
Mononuclear cell (MNC) preparation
Freshly harvested, anti-coagulated (lOOOU/ml PumpHep preservative-free heparin,
Leo Laboratories, Bucks, UK- 100 id per 20ml) blood or bone-marrow samples were
processed using aseptic conditions (laminar-flow cabinet). An equal volume of sterile
Hanks Balanced Salt Solution (HBSS Sigma, UK) was added and the diluted sample
layered carefully onto Lymphoprep™ solution in a conical tissue-culture centrifuge
tube. The sample was then centrifuged at 700g for 15 minutes to pellet the
erythrocytes. Mononuclear cells (comprising monocytes and lymphocytes) were
carefully removed from the interface and washed twice with 20ml HBSS by
centrifuging at 200g for 5 minutes at 4°C. The mononuclear cell pellet was
resuspended in 1ml HBSS and cellular viability assessed using trypan blue as
described above prior to further processing.
Culture of cell lines
Cryopreserved cell pellets were rapidly thawed in the 37°C water bath. The cells were
then tranferred to 1ml thawing mixture and incubated for 1 minute. lOmls of IMDM
was then added and the mixture incubated a futher 10 minutes. Cells were then washed
twice and resuspended in IMDM, and cellular viability assesed using trypan blue.
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KGl-a cells (Koeffler et.al. 1978) were cultured as a suspension in IMDM (containing
20% FCS, 2mM L-glutamine, and penicillin (0.5U/ml) + streptomycin solution
(0.5jig/ml) and maintained at a density of between 105-106 cells per ml. Medium was
renewed every 3-4 days and the cells sub-cultured following removal of dead cells by
layering over Lymphoprep™ and collecting viable cells at the interface. Cells were then
plated out in fresh medium at 105 cells per ml and cultured at 37°C, 5% C02.
Immunophenotyping of KG1-a cells was performed using appropriate acute leukaemia
monoclonal antibody panels by Mrs Anita Ford (Haematology Department Western
General Flospital, Edinburgh). Cells were found to be positive for CD34 (98%), HLA-
DR (1%), CD7 (93%), CD15 (74%), CD33 (1%), CD13 (98%), CD45 (100% ) and
negative for CD19, 10, 20, 5, 4 and 3.
HL-60 and other cell lines were grown in IMDM with 10% FCS and the medium
renewed every 3-4 days.
Blast cell colony (BCCA) assays
5637-conditioned medium (5637-CM) was used as a source of colony stimulating
factors for the blast cell colony assay (BCCA) (Gabrilove et al). A cryopreserved cell
pellet (107 cells) was rapidly thawed from liquid nitrogen storage in a 37°C water bath.
The thawing mixture comprised 20ml FCS, 2ml heparin (1000 IU/ml), 2ml DNAse
(20,000 IU/ml), 2ml MgSC>4 (0.15M). Thawed cells were added to 20ml of HBSS
and washed twice at 200g for 5 minutes, 4°C. The cell pellet was resuspended in 10ml
of pre-warmed complete medium (IMDM with 10% FCS) then added to a 25cm2
tissue-culture flask and transferred to a 37°C humidified CO2 incubator (5%) until cells
were confluent, replacing the medium every 3-4 days. When the cells were confluent,
the medium was discarded and the cells washed twice with HBSS. For further sub¬
culture cells were trypsinised with 2ml of 0.25% trypsin-EDTA for 10 minutes at 31°C
to remove adherent cells. The trypsin was inactivated with 5ml FCS. The cells were
collected and washed in HBSS, resuspended in complete medium and split into two or
more culture flasks for further culture. For preparation of conditioned medium (CM)
fresh medium was applied to confluent cells and left for 5-7 days to allow growth-
factor production. The medium was then aspirated, centrifuged at 200g to pellet debris,
the supernatant was then filter-sterilised through a 0.2nm filter and batches pooled as a
source of growth factors (IL-1, IL-3, GM-CSF (Gabrilove et.al.1986) for use in the
blast cell colony assay.
44
Methyl-cellulose preparation for blast cell colony (BCCA) assays
3.2g Methyl-cellulose (Sigma) were autoclaved in a 200ml glass bottle, 100ml distilled
water with a magnetic stirrer were autoclaved in a separate bottle. Powdered IMDM
culture medium (Gibco, Paisley UK) was added to 500ml distilled H2O to which had
been added 3.0g NaHC03 to give a 2 x IMDM stock solution which was sterilised
using a 0.2|xm filter. The sterile methyl-cellulose was added to the sterile hot water,
mixing regularly. When the solution was completely mixed it was transferred to the
microwave for 10 minutes at the lowest power setting and allowed to simmer. When
cooled to hand temperature, 100ml of pre-warmed 2 x IMDM stock was added to give
a final mixture of 1.6% methyl-cellulose in IMDM. The mixture was then transferred to
the cold room (4°C), with constant stirring to allow the mixture to gel. When cool, the
mixture was aliquoted, centrifuged at 2000g for 10 minutes to remove debris and
stored at -20°C until required.
For blast cell colony assay patient samples (peripheral blood or bone marrow) were T
cell depleted with an excess of anti-CD2 Dynabeads (Dynal, Norway #111.01) to
remove a potential source of growth factors. Samples were grown in the presence or
absence of 5637-conditioned medium (5637-CM), and in the presence or absence of
serum to look for leukaemic blast colony formation. 2.5 x 106 mononuclear cells were
isolated from blood or bone-marrow as described above. Briefly anti-CD2 Dynabeads
were added at an optimal bead-to-target ratio and incubated at 4°C on a tilting and
rotating shaker for 30 minutes. After the incubation a 5-fold excess of IMDM was
added and the tube placed in the magnetic particle concentrator (Dynal, MP-1) for 2-3
minutes to collect the rosetted cells and unbound beads. Depleted supernatant was
transferred to a second tube, centrifuged at 200g for 5 minutes, and the cells
resuspended in 300fd IMDM at a concentration of 2 x 106 cells/ml.
450ul aliquots of the following were prepared in a sterile tube:
A) For serum-containing cultures.
10,000^1 of 1.6% methyl cellulose in IMDM; 2000^1 of foetal calf serum; 200jxl
penicillin (50U/ml stock) + streptomycin solution (50^g/ml stock) solution; 200jd L-
Glutamine (2mM stock solution): 2000^1 of growth factor (if required, otherwise
2(XX)ul IMDM); 3600|d IMDM. 50[d cells (2 x 106 cells/ml) were added to each 450fd
mixture.
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B) For serum-free cultures
10,000^1 of 1.6% methyl cellulose in IMDM; 200^1 penicillin (50U/ml stock) +
streptomycin solution (50[ig/ml stock) solution; 200ul L-Glutamine (2mM stock
solution): 2000^,1 of growth factor (if required, otherwise 2000[il QBSF-51); 5600^1
IMDM. 50fil cells at 2 x 106 cells/ml was added to each 450ul mixture.
Suspensions were prepared in sterile tubes, mixed thoroughly and allowed to stand for
5 minutes to allow bubbles to rise. A row of irrigation wells (100^.1 HBSS) was placed
around the wells of a 96-well flat-bottomed tissue-culture plate to prevent colonies
drying out. The cell suspensions were then plated out in triplicate on 96-well plates in
lOOjxl aliquots (20,000 cells per well) and incubated for 7 days. The number of
colonies containing more than 20 cells (approximately) was counted at three, five and
seven days after initiation of culture. The Autostimulatory Index (ASI) was determined
as folows
number of colonies per 2x1Q4 cells in NCM
number of colonies per 2x104 cells in 5637-CM
Group 1 fail to grow at all have an ASI of zero.
Group 2 grow only in the presence of growth factors have an ASI of less than 0.1.
Group 3 show autonomous growth but are further stimulated by growth factors have
an ASI of between 0.1 and 0.8.
Group 4 show autonomous growth which cannot be further stimulated and have an
ASI greater than 0.8 (Reilly et.al. 1989a)
MACS™ immuno-magnetic enrichment of CD34+ cells
This method was essentially adopted from the the CD34 positive isolation kit protocol
(Miltenyi code # 467-01). Briefly mononuclear cells were prepared as described above
from bone marrow or peripheral-blood stem-cell harvests using an anti-coagulated
sample (preservative-free heparin., Leo Laboratories, Bucks, UK). The washed cell
pellet was re-suspended in 300^1 HBSS per 108 cells and 100[d of reagent A1 (IgGi)
and 100(d of Reagent A2 (anti-CD34 QBEND-10-biotin) added per 108 cells, mixed
gently and incubated for 15 minutes at 4<>C. The cells were then washed in 5ml HBSS,
the supernatant completetly removed and cells resuspend in 400^1 HBSS. 100ul of
reagent B (magnetised Streptavidin) was added, the sample mixed gently and incubated
for 15 minutes at4oC. Cells were washed in HBSS and resuspend in 400|d of sterile,
de-gassed PAB. The cells were then added to a pre-filled mini-MACS™ column (type
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MS without flow-restrictor) and CD34 negative cells allowed to flow through and the
column washed with 4 volumes of PAB. The column was then removed from the
magnet, 1ml PAB added and CD34 positive cells eluted using the plunger; this step
was repeated, if required to increase recovery, with a fresh column and 500[d PAB for
further enrichment. To monitor the enrichment process a sample of the cells was




Most antisense oligo-deoxynucleotides (oligos) were used at a working concentration
of 5-15nM as the phosphorothioate derivative since this is more resistant to nuclease
digestion. Labelled oligos were labelled in situ during synthesis at the 5' end with
FAM (Fluorescein Addition Monomer). Upon receipt oligos were dissolved in distilled
water, filter sterilised with a 0.2um filter, aliquoted and stored at -20°C until required.
Bcl-2 antisense sequence (5 ' TCTCCCAGCGTGCGCCAT ); scattered (nonsense)
sequence (5 ' TGCACTCACGCTCGGCCT ) were obtained from Oswell DNA,
Southampton, UK).
Control antisense phosphorothioate (5' CTCTCGCACCCATCTCTCTCCTTCT) in
Biotinylated and FAM-labelled forms were obtained from Hybridon Ltd, Cambridge,
Mass, USA).
Streptolysin O reversible cell permeabilisation
Streptolysin O (Sigma, UK) was used for the reversible permeabilisation of viable cell
membranes to allow uptake ofmacromolecules, specifically antisense oligo-
deoxynucleotides (Spiller et.al. 1995). A range of enzyme concentrations and
incubation times were studied to monitor the most appopriate conditions for reversible
permeabilisation. Streptolysin O permeabilisation buffer was 137mM NaCl, lOOmM
PIPES, 5.6mM Glucose, 2.7mM KC1, 2.7mM EGTA, l.OmM NaATP, 0.1% BSA.
Briefly cells for permeabilisation were isolated, washed and resuspend in
premeabilisation buffer. An appropriate concentration of antisense was added to the
mixture and cells incubated in the presence of an optimal concentration of Streptolysin
O for 5-15 minutes at 37°C. After incubation cells were washed in complete medium
and membranes allowed to reseal for 2 hours. Cells were then washed again and
harvested, ready for subsequent analysis.
Liposomal transfection
A solution of antisense was made in serum-free medium (QBSF-51). A solution of
Lipofectin™ was also made up in serum-free medium (QBSF-51) and incubated for 10
minutes at room temperature. The two solutions were mixed together for 15 minutes at
37°C prior to addition to cells to allow micelle formation. Cells were incubated in the
presence of the liposomal-antisense mixture for 4 hours at37°C, 5% CCA. Cells were
then washed twice in serum-free medium, surface stained with fluorescent antibody
when required, and analysed.
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Apoptosis detection
Annexin V was used as a marker for early-stage apoptosis. Prior to nuclear
condensation and fragmentation cells undergo changes in membrane structure,
exposing internal phosphatidylserine residues on the surface (Fadok et.al.1992). This
was detected by the calcium-dependent molecule Annexin V which avidly binds
phosphatidylserine residues. Annexin V was obtained as the FITC conjugate from
Biowhittaker Inc (Bender Med Systems, UK). Annexin buffer was made as follows;
lOmM HEPES, 150mM NaCl, 5.0mM KC1, 1.8mM CaCl2> l.OmM MgCL. Cells
were harvested, washed twice and resuspended in annexin buffer. lOjxl Annexin V-
FITC (2.5^g) was added per 106 cells and 20^1 propidium iodide stock added
immediately prior to assay in order to determine viability. Live healthy cells were
Annexin-V negative, PI negative; dead (necrotic and late apoptotic) cells were
Annexin-V positive, PI positive; early apoptotic cells were Annexin-V positive, PI
negative.
A range of reagents with differing mechanisms of action were chosen to induce
apoptosis. Di-butyryl cyclic-adenosine mono-phosphate (cAMP ImM). Cycloheximide
(CHX 5CVM) This molecule prevents de novo synthesis of protein molecules by
interfering with the message translation step. Actinomycin D (Act D 4|xM). This drug
binds double stranded nuclear DNA, intercalates into the groove and prevents DNA
replication and de novo mRNA synthesis. Cytosine Arabinoside (AraC 1 fiM. This
drug is incorporated into nuclear DNA in place of deoxyribocytosine and prevents
elongation and causes strand breaks. All of the above stock solutions were made up in
IMDM and filter-sterilised with a 0.2^m filter.
Annexin + Antibody staining
Fluorescent surface antibody staining was carried out as indicated above. 106 cells
were then washed twice and resuspended in 1ml in annexin buffer. 10^1 Annexin V-
FITC was added and incubated for 10 minutes in the dark at 4°C. Cells were then
washed twice and resuspended in annexin buffer prior to analysis.
Annexin + PI (pemeabilised)
Annexin surface staining was performed as described. Cells were then resupended in
lml of 70% methanol in annexin buffer and permeabilised for 20 minutes at 4°C. Cells
were then washed twice in annexin buffer and 30^1 propidium iodide solution added
and incubated for 60 minutes at 4°C. Cells were analysed by FACS without washing.
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Antibody + DNA staining
Cells were stained for surface or cytoplasmic markers as described above. Cells were
then resupended in 1ml of 70% methanol in PBS and permeabilised for 20 minutes at
4°C. Cells were then washed twice in PBS and 30ul propidium iodide solution added
and incubated for 60 minutes at 4°C. Cells were analysed without washing.
Cell morphology
Morphology was assesed on May-Grunwald Giemsa stained cytospins of 105 cells
using the automated staining equipment in the Haematology department of the Royal
Infirmary, Edinburgh
MTT dye cell proliferation assay
The tetrazolium salt MTT (Sigma #M-5655) was used as an index of cell proliferation
on supension cultures. Briefly a single cell suspension was added to a 96 well culture
plate. Cells were plated out at differing densities in order to determine the most suitable
for analysis. Once selected, this density of cells was used for the remainder of the
experiment. The agent of interest was added to cells at the optimal density and 10[d of
MTT stock added for the final 4 hours (minimum) in order for dye conversion (to an
insoluble blue formazan dye) to take place. After incubation the cells were harvested by
adding 100fJ of a pre-warmed iso-propanol-HCl (0.3M) mixture to lyse the cells and
solubilise the dye. Optical density was measured at 570nm and the result extrapolated
from a standard curve (generated with known cell densities). The tetrazolium salt
(MTT) is reduced to an insoluble formazan, the optical density of which is related to
cell density extrapolated from a standard curve.
Fluorescence microscopy
Following staining with fluorescent markers, and analysis by flow cytometry, cells
were prepared for microscopy. 50^1 cells were added to a well on a microscope slide
and analysed under water-immersion lenses at x400-1000 magnification. For
preparation of 35mm slides 30 second exposures for fluorescent cells and 10 second
exposures for transmitted light were taken on Ektachrome 400ASA slide film.
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Confocal microscopy
Samples were incubated with antisense as described above, surface stained with
fluorescent antibody and 0. lftm optical sections analysed under ultraviolet (UV)
illumination with a confocal microscope (Zeiss). Digital images (PICS) were saved to
disk or printed.
Fluorescence quenching agents
In order to deteremine membrane versus cytoplasmic fluorescence a variety of
quenching agents were tested.
0.2% Trypan blue solution 0.2g/100ml (Sigma 34078) (van Amersfoot et.al. 1994).
0.2% Crystal violet solution 0.2g/100ml (Sigma 34024) (van Amersfoot et.al. 1994).
1% Tannic Acid solution lg/lOOml (Sigma T-0125) (Giaimis et.al.1994).
Fluorimetry was performed on a Perkin-Elmer fluorimeter. With reference to a PBS
blank the fluorescence of solutions of antisense was determined in the presence and
absence of the quenching agents indicated above.
Polyacrylamide gel electrophoresis (PAGE)
Native and denaturing polyacrylamide gel electrophoesis (PAGE) was used to reveal
the presence of potential secondary structure formation in the antisense molecules.
18% polyacrylamide gels were prepared as follows:
0.3ml distilled water; 4.5ml acrylamide stock; 4.5ml bis-acrylamide stock; 0.5ml Tris
Acetate EDTA (TAE buffer) (x20); 100nl Ammonium persulphate; 10|xl (TEMED).
For denaturing gels 7M uea (4.2g) was also included in the mixture.
Gels were run at lOOVolts, 20milli-Amps until the dye front was three-quarters down
the gel. DNA bands were revealed with addition of 25|d ethidium bromide solution to
the gel following removal from the apparatus. The gel was de-stained in distilled water
prior to photography.
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Antisense conjugation to poly-carboxylate beads
A 5'-NH2-linked oligodeoxynucleotide in the sense orientation was conjugated to
polcarboxylate microspheres using the EDC reagent (Peirce, UK). 5'-labelled
complementary antisense was added in excess and allowed to hybridise to the linked
sense DNA on the beads. Versions of the complementary sequence were allowed to
hybridise independently a) 5'-FAM-labelled antisense; b) 5'-Biotinylated antisense.
Molar equivalences for each of the antisense were thus determined by hybridising to a




Annexin assay development for apoptosis quantitation
Defects in apoptosis signalling mechanisms are believed to be an important factor in the
development of cancer (Ashwell et.al.1994). Apoptosis has been found to be an
important mechanism in the action of many chemotherapeutic drugs (Kaufmann, 1996)
and in the depletion of CD4 positive cells in HIV (Laurent-Crawford et.al. 1998).
Therefore the use of a simple, rapid and reliable method of evaluating the rate of
apoptosis may allow clinicians to monitor anti-cancer treatment in a dynamic fashion
and help assess novel therapeutic strategies. In vitro detection and quantification of
apoptosis may therefore be useful in the prediction of the sensitivity of tumours to
chemotherapy prior to initiation of treatment.
Many different types of anticancer drugs with disparate intracellular targets have been
shown to induce apoptosis in susceptible cells (Hickman et.al. 1994). There was
therefore a requirement for a rapid method of identification and quantitation of the
degree of apoptotis in cell populations. Obvious histologic findings include shrinkage,
nuclear condensation and fragmentation, with membrane blebbing, however this gives
limited information regarding cellular phenotype. Similarly it is often difficult to
quantify apoptotic cells within dynamic tissues, since these cells are rapidly removed
by phagocytes although apoptotic cells may remain recognisable within tissue for 4-9
hours (Arends et.al.1991). There was therefore a need for development of an assay
which could be readily quantified which also allowed detection of early stages of
apoptosis before cells were removed from tissues.
Several established flow cytometric methods have been used to quantify populations of
apoptotic cells. Most have hitherto depended on changes in staining patterns seen using
DNA-binding dyes. These depend on disturbances in membrane permeability or on the
presence ofmodified chromatin found in necrotic or apoptotic cells altering the spectral
characteristics of these dyes (Nicoletti et.al.1991).
Quantitative and qualitative changes in apoptotic cells have been assesed by measuring
the DNA hypodiploidy of cells (Figure 5). This labelling may be carried out on
whole cells, but more commonly utilises propidium iodide (PI) staining on isolated
nucleii (Telford et.al.1992) to measure the DNA fluorescence histograms of lysed cells
(Nicoletti et.al. 1991). This hypodiploid fluorescence histogram of DNA content is
easy to discriminate from normal cellular DNA content, however this technique
depends wholly on DNA fragmentation which is not always present in apoptosis or
programmed cell death. This hypodiploid (sub-Gl or AO peak) is due to an increased
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(Figure 5). How cytometric histogram of propidium iodide stained cells revealing the
different stages of the cell cycle and apoptotic cell (sub-GO) regions.
This method also allows determination of cells populations within different phases of
the cell cycle (Dive et.al.1998) and measurement of numbers of apoptotic, dead and
live cells. Apoptosis can be seen to be selective to cells within particular phases of the
cell cycle eg. S phase in myelogenous leukaemias (Del Bino et.al.1991) and GO phase
in thymocytes (Bruno et.al.1992).
Membrane permeability to DNA binding dyes is often combined with chromatin
changes and differential binding of DNA intercalating dyes to measure apoptosis. Low
permeability dyes such as propidium iodide, or 7-amino-actinomycin D (7-AAD)
discriminate cells with intact membranes and are normally combined with a second dye
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eg. Hoechst 33342 which enters ail cells and differentially stains the DNA of cells with
intact nuclei (viable) and of cells with an altered chromatin conformation (apoptotic and
necrotic cells (Dive et.al. 1998; Ormerod et.al. 1992; Ormerod et.al. 1993; Schmid
et.al. 1994). Cell membrane permeability however, only gauges the integrity of nuclear
and plasma membranes to DNA binding dyes such as ethidium bromide (EtBr) (Lyons
et.al. 1992), propidium iodide (PI) (Mower et.al. 1994), 7-amino-actinomycin D
(Schmid et.al.1992).
Apoptotic cells have been shown to have a high degree of DNA breaks or nicks
(Meyaard et.al. 1992) which can be detected by the TUNEL (TdT-mediated dUTP
nick-end labelling) technique (Sgone et.al. 1998) and in situ nick-translation assay
which exploit the presence of fragmented or nicked DNA within the apoptoic nucleus.
This provides a substrate for the addition of labelled nucleotide by terminal transferase
(TUNEL) or DNA polymerase (nick-translation). These only detect intermediate and
late stages of apoptosis strand breaks prior to DNA fragmentation but again is not
specific for apoptosis.
Other methods of distinguishing apoptosis from necrosis include characterisation of
intracellular changes using fluorescent probes. These include monitoring swelling and
lysis of the cell following mitochondrial damage using Rhodamine-123 retention in
apoptosis whereas in necrosis it is not retained. Similarly uptake of the fluorescent
stain acridine orange depends on an active ATP-dependent lysosomal proton pump
which also is preserved in apoptotic but not in necrotic cells. Typically the cell
membrane is permeable to the uncharged form of the dye, but once inside the cells the
dye becomes protonated and becomes entrapped and fluoresces red.
There are also intracellular and membrane changes associated with apoptosis (Mower
et.al. 1994). Apoptotic cells have a low DNA and protein content which is reflected in
changes in light scatter: PI positive, Hoechst 33342 positive cells have a reduced
forward scatter (size) and slightly increased side scatter (granularity) by flow
cytometry. Apoptotic cells may also be isolated by density gradients. These cells also
typically show reduced a DNA fluorescence (Telford et.al. 1991).
In parallel with these observations the apoptotic membranes express markers such as
the thrombospondin receptor and undergo spatial transformation such that inner
surface and associated phospholipid moieties become externalised (Fadok et.al. 1992).
Phosphatidylserine, a negatively charged membrane phospholipid, is thought to be one
ofmany potential signals for signalling the removal of apoptotic cells by phagocytes
and can be readily detected by avid binding to Annexin V (Andree et.al. 1990). The
Annexin V protein is a 320 amino-acid, 36kDa protein which is readliy conjugated to
fluorochromes allowing rapid identification of apoptotic cells in combination with
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immuno-phenotyping (Koopman ct.al. 1994, Vermes et. al.1995).
Considerable effort was spent in establishing this reliable and sensitive assay for the
detection of small numbers of apoptotic cells. Therefore agents known to effect
apoptosis were used in vitro to monitor changes in phosphatidyl-serine expression in a
dynamic fashion. This would then enable monitoring of the effectiveness of antisense
bcl-2 therapy at inducing apoptosis in acute myeloid leukaemia cells. If antisense
effects were found on leukaemic cells it was proposed to use this assay to compare the
relative effectiveness of different treatment strategies.
Normal peripheral blood mononuclear cells (PBMNC) were used as a control mixed
cell population. Cells from AML patients and continuosly growing cell lines KGl-a
(acute myeloid leukaemia) and SUDHL-6 (B cell lymphoma) were prepared in a
similar manner. Cells were then resuspended in complete medium (IMDM with 10%
FCS) at 2 x 106 cells perml and incubated with either 50uM cycloheximide (CHX to
inhibits novo protein synthesis through nbosomal peptidyl transferase inhibition) or
4uM actinomycin D (ActD intercalates DNA and inhibits de novo RNA transcription
but not protein synthesis from existing RNA) to induce apoptosis. Cytocentrifuge
preparations of 105 cells were stained by May-Grunwald Giemsa staining and
apoptosis was confirmed by evidence of cellular shrinkage and nuclear condensation
(Figure 6).
Aliquots of cells were extracted at 24 hour intervals and examined by histology for
evidence of apoptosis. Similarly cells were washed and stained with l^g/ml human
recombinant Annexin V-FTTC (BioWhittaker, Berks, UK) in Annexin buffer (lOmM
HEPES, 150mM NaCl, 5mM KC1, ImM MgCl, 2mM CaCl) to detect phosphatidyl-
serine. Propidium iodide staining (Sigma, UK) was used at (5CVg/ml) as evidence of
membrane disruption. Cells were analysed by standard flow-cytometric techniques
using a FACScan and CellQuest™ software (Becton Dickinson, Oxford, UK) data is
presented as bivariate dot plots of Annexin and PI expression. Cells were also studied
under standard ultraviolet (UV) fluorescence microscopy for evidence ofmembrane-
bound Annexin V-FITC and for propidium iodide staining of nuclear material.
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(Figwe • 6). -Top: Normalmorplologyof KG 1-acells
Bottom: Cells tre^ed-witL 4pM-Actiiiomy?iii D for 24 -hours*
sluowin^-feaJiires of apoptosis. May-^3ruiiwali Giemsa-(x200)
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Freshly isolated cells typically had normal morphology and light scattering
characteristics (Figure 6a) and showed very little (<20%) positivity for Annexin V.
Propidium iodide and trypan blue staining both indicated greater than 95% viability.
However, of cells treated with cytotoxic agents, those incubated with actinomycin D
showed features most typical of apoptosis. Cells had a characteristic reduced volume
and condensed nucleii (Figure.6b).
Early changes in light scattering described a separate sub-population of cells formed
with low forward scatter (FSC) and elevated side scatter (SSC) with a simultaneous
increase in the Annexin V positive population. At 24 hours viability remained greater
than 85% indicating membrane integrity (Figure 7) remained although by this stage
levels of Annexin V-FITC staining had become markedly elevated on most cells
(>85%). As treatment progressed beyond 48 hours cell membranes became disrupted
and were no longer able to exclude propidium iodide and in many cases there was
distinct loss of normal nuclear architecture (Figure 8). At this stage Annexin V and
propidium iodide staining became intense making it difficult to differentiate between
necrotic and apoptotic cells. However necrotic cells typically swell rapidly and burst,
leaking contents into the surrounding milieu provoking the release of pro-
inflammatiory mediators and are therefore rapidly engulfed by phagocytic cells. It
should be noted however that late stage apoptotic cells may undergo a secondary
necrosis possibly as a mechanism to recruit further phagocytic cells to the site.
Quantitation of apoptosis by many other existing methods can be time consuming and
highly inefficient since few lend themselves to both high throughput and semi-
automation whilst providing enough detailed information regarding cellular phenotype,
morphology and apoptotic status. Furthermore many depend on lysed or fixed cell
populations which similarly reduces the amount of information which can be collected
about this dynamic process. For example separation of high from low molecular
weight DNA (Wyllie, 1980; Wyllie et.al.1980) using centrifugation and
electrophoresis are both time-consuming and depend on lysed cells and presence of
DNA fragmentation. Changes in cell morphology eg. chromatin condensation using
electron microscopy (EM), phase contrast microscopy (Wyllie et.al. 1984) or
fluorescence microscopy using DNA binding dyes (Cohen et.al.1992) tend to use
fixed, isolated, non-viable cells. Fluorescent histograms demonstrating reduced
apoptotic DNA similarly correspond well to classical definitions of apoptotic cells.
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Murine B lymphocytes have three distinct stages of apoptosis only the later stages of
which can be detected using existing methodology: Stage 1. early apoptosis is
associated with decreased cell size and altered plasma membrane organisation; Stage 2.
intermediate stage involves DNA cleavage; Stage 3. permeabilisastion of the plasma
membrane. Alterations in apoptotic cell fluorescence correlates with reductions in cell
size (FSC) (Mangan et.al.1991; Dive et.al.1998; Ormerod et.al.1993). Stage 2
apoptosis has been detected using combinations of fluorescent DNA binding dyes. 7-
AAD alone as a marker for apoptosis measures changes in size in combination with
fluorescence which correlates well with other techniques (Philpott et.al. 1996). 7-AAD
may also be used in conjunction with immuno-phenotyping by flow cytometry and
requires far fewer cells per assay.
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(Figure 7). Bi-variate flow cytometric dot plots and histograms showing the increase
in Annexin-V positivity as KGl-a cells become spontaneously apoptotic.
Membranes lose integrity and become permeable to vital stains such as propidium
iodide.
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(Figure 8). Top apoptotic cells stained "with Annexin V-FITC
and propidium iodide at 24hours. Cells at 43 horns demonstrating
progressive loss of membrane integrity and nuclear architecture
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Apoptotic cells also undergo a variety of membrane changes including expression of
thrombospondin binding sites (Pytela et.al.1985), loss of sialic acid residues (Savill
et.al. 1993) and exposure of phosphatidyl serine (Fadok et.al. 1992) resulting from a
loss of normal membrane assymetry (Mower et.al. 1994). This is an important
mechanism in the recognition and removal of apoptotic cells by macrophages (Fadok
et.al. 1992). Annexin V has been shown to bind negatively charged phospholipids
(Andree et.al. 1990) in a calcium-dependent fashion. Apoptotic cells become Annexin
V positive after condensation of the nucleus occurs but before the membrane becomes
permeable to vital stains. Early light-scatter changes described a separate sub-
population of cells formed with low FSC and high SSC which identifies the increase in
cell density cauised by water loss, with a simultaneous increase in Annexin V +ve
population. At later time points both single Annexin +ve and Annexin / PI +ve cells
were found and by later stages all cells are double positive. All cells with positive
nuclear condensation were also found to be Annexin positive, whereas none of the
euchromatic nucleus were Annexin positive . Occasionally a cell with only DNA
condensation at the periphery of the nucleus (chromatin margination) was found.
These cells represent the early stages of apoptosis and stain only weakly for Annexin.
Annexin staining thus coincided with the appearance of nuclear condensation in
apoptotic cells.
DNA fragmentation into oligosomal bands has been shown to be present only in sorted
Annexin V staining cells. At later time points however, oligosomal band intensity
decreased, possibly due to further DNA degradation, whereas the level of Annexin
staining in cells with condensed a nucleus increased. Morphologically evident
apoptosis however, is not always followed by DNA fragmentation (Cohen et.al. 1992;
Falcieri et.al. 1993) though inter-nucleosomal cleavage by endonucleases is often used
to detect apoptosis.
In this thesis apoptotic cells were stained with Annexin V-FITC followed by
membrane permeabilisation and PI staining of DNA content. This revealed that the two
stains identified similar populations, albeit with Annexin V describing a higher
percentage apoptotic cells because of the membrane changes preceding DNA changes.
In conclusion phosphatidyl serine expression, and hence Annexin V-FITC positivity,
correlates well with many of the standard observations of apoptosis determination eg.
TUNEL, Hoechst 33342-EtBr staining and provides a sensitive and reliable detection
system. The combination of reversible high affinity binding (approx 10'iOM) and a
potentially large number of phosphatidyl serine sites (approximately 106) on the
surface of apoptotic cells allows a sensitive process of identifying apoptotic cells. Early
stage apoptotic cells may be readily identified and isolated on the basis of their
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phosphatidyl serine expression and may be collected for further studies using flow or
immunomagnetic sorting. Early apoptotic cells may be differentiated from late
apoptotic and necrotic cells on the basis of their light scatter and Annexin-propidium
iodide staining patterns. In conjunction with fluorescent antibodies to cell-surface
markers Annexin V-FITC may be used to identify sub-populations of cells undergoing
apoptosis in a dynamic system. This may have important considerations in clinical
applications where the effects of cytotoxic agents on discrete sub-populations of cells
such as tumours within a larger population of heterogeneous cells must be considered.
This Annexin V-FITC staining method was therefore routinely used to quantify
apoptotic cell populations and in the determination of the functional effectiveness of the
antisense therapy at killing leukaemic cells. Propidium iodide staining of DNA content
was used to identify stages in the cell cycle which were sensitive to drug and as an
independent confirmation of apoptosis.
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BcI-2 expression
Normal blood and bone marrow
To determine whether patients with AML had elevated levels of bcl-2 protein
expression a sensitive technique was required for quantitation. It was felt that
densitometric scans ofWestern blots would not provide the sensitivity required nor the
ability to discriminate sub-populations of cells within heterogeneous mixtures such as
bone marrow or peripheral blood. Therefore a quantitative flow-cytometric assay was
developed using immunophenotyping followed by cell permeabilisation and staining
with anti-bcl-2 monoclonal antibody (Clone-124 DAKO Ltd,UK). The assay uses a
measurement known as the mean equivalent of soluble fluorochrome (MESF) which is
used to construct a calibration of fluorescence intensity.
MESF is the relative channel number (RCN) for log amplifiers (RCN = peak channel
number x l()nd where nd = neutral density of filter normally has a value of zero)
(Macey, 1994).
The Quantum Simply Cellular Kit (Sigma, UK) uses a panel of five beads; one blank
and four standards. These beads are coated with a fixed and absolute binding capacity
for mouse antibodies and are used to construct a calibration curve for the antibody-
binding capacity (ABC) versus fluorescence signal intensity in channel numbers
(Figure 9a). Thus given a relative fluorescence intensity the ABC (or MESF) can be
given and is independent of the instrumentation the data is acquired on and the
software used to analyse it. Data from different laboratories can thus be directly
compared. In this study this was done for bcl-2, CD34, IgG antisera







SPECIFICITY OF BCL-2 ANTIBODY
10000
mL unlabelled bcl-2 antibody
-a KGl-a CELLS y = -92.752LOG(x) + 318.039 2 r= 0.981
SUDHL-6 CELLS -508.349LOG(x) + 1371.597 2 r= 0.937
(Figure 9c). Demonstrating the specificity of bcl-2 staining in cells following
permeabilisation.
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The specificity of the bcl-2 antibody (clone 124 DAKO, UK) was confirmed using a
competition experiment. Increasing amounts of unlabelled antibody were co-incubated
with the FITC labelled bcl-2 antibody and added to a fixed amount (106 cells) of either
KGl-a (myeloid leukaemia cells) known to express high levels of bcl-2 or SUDH1-6
cells with a t( 14; 18) translocation, thus with deregulated elevated bcl-2 levels. It can be
seen from the plot that there is direct competition between the labelled and unlabelled
antisera demonstrating specificity of staining (Figure 9c).
Lymphocytes have been shown to express intense bcl-2 staining, monocytes were
weaker and neutrophils essentially bcl-2 negative (Iwai et.al. 1994). Resting peripheral
blood lymphocytes (PBL) expressed both bcl-2 protein and message, whereas
lymphoblasts in mitogen-stimulated cultures lost bcl-2 protein and became apoptotic
despite expressing high levels of bcl-2 mRNA. This may be the result of post-
transcriptional regulation of the bcl-2 gene or post-translational modification of the
protein (Akagi et.al. 1994). More than 80% normal T and B cells were found to be bcl-
2 positive withT and B cells having similar levels (Aiello et.al. 1992). Differences in
absolute levels between different studies may be related to the cellular processing
method. Bcl-2 protein was detected in fresh PBL but levels decreased on storage
overnight (Reed et.al. 1992). It then underwent a marked increase upon stimulation of
cells by mitogens and lectins and cytokines. Similarly bcl-2 was found to be present in
freshly harvested blood but not in buffy coats independent of the anticoagulant used
for collection.
Results found in this thesis therefore compare favourably with those found by other
authors both in normal and malignant cell types and values fall into the expected
ranges. All samples were processed for bcl-2 expression on fresh samples within 2
hours of harvesting where possible. 70% methanol in PBS was used as the fixative
and permeabilisation agent since it had been shown that methanol or ethanol (70% in
PBS) both gave similar levels of fluorescence intensity (Steck et.al. 1995). The
methanol fixation method was selected because it allowed the simultaneous
determination of cell cycle phases (Slezak et.al. 1989) with bcl-2 and
immunophenotype determination.
Peripheral blood T and B cells were found to express similar amounts of bcl-2 protein
(29-37 x 103 MESF per cell), bone marrow monocyte precursors had lower amounts
(21 x 103 MESF) while peripheral blood monocytes had lower levels again (15 x 103
MESF) (Porwit-McDonald et.al. 1995). These levels are somewhat lower than levels
found in this thesis and the patterns are different although CD3 and CD 19+
lymphocytes were also found to have equal levels. In these volunteers normal
peripheral blood samples CD3+ T lymphocytes and CD19+ B lymphocytes were
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found to have similar values (n= 9 CD3+ 79,074 +/- 29,608 MESF; CD 19+ 72,691
+/- 20,428 MESF), monocytes had similar levels but with a greater range 118,632 +/-
42,867 MESF (Figure 10). The reason for this discrepancy is unclear but may be
related to processing. Reed (1992) found that storage of cells for extended periods
resulted in a reduction in bcl-2 levels and this may occur in different cell types at
different rates.
Bone marrow CD34 positive blasts and myeloblasts have have twice the levels of
lymphocytes 51 x 103 MESF. CD34+, CD 10+ lymphoblasts have low levels of bcl-2
(8-10 x 103 MESF) and CD34-CD10+ lymphoblasts have even less <5 x 103 MESF
(Porwit-McDonald et.al.1995). In this study CD34+ cells from normal bone marrow
or peripheral blood stem-cell donors had comparable levels (73,822 +/- 32,498 MESF)
to lymphocytes (Figure 10).
AML cells
Other authors have noted an association between bcl-2 expression and response to
chemotherapy and found that patients with more than 20% bcl-2 positive blasts related
to a 29% complete remission (CR) rate whereas less than 20% bcl-2 positive blasts
equated to 85% complete remission (Ganser et.al.1994). Bcl-2 expression was found
to be highest in the monocytic M4 and M5 AML patients and was correlated to CD34
expression. High levels of bcl-2 protein in undifferentiated cells may lead to prolonged
lifespan. Bcl-2 levels decrease in AML with granulocytic and monocytic differentiation
with AML Ml and M2 expressing significantly higher levels than M3 orM4 or 5.
Small undifferentiated blasts which were HLA-class II dim have higher bcl-2 levels than
large differentiated blasts which were class II bright. AML Ml were found to have 40%
bcl-2 positive blasts, M2-50%, M3-22%, M4-19%, M5-15% with an overall average
of 25 x 103 MESF for all groups ofAML (Porwit-McDonald et.al. 1995).
Similarly of 82 newly diagnosed AML samples bcl-2 content was measured and found
that a mean of 23% were positive. The percentage bcl-2 positive blasts was found to be
higher in M4 and M5 sub-types and those with highest blast cell counts. Bcl-2
expression was correlated with CD34 expression and high levels associated with poor
complete remission and shorter survival. KGl-a cells (an undifferentiated AML M0
AML cell line) were 97% bcl-2 positive and HL-60 (promyelocytic leukaemia cell line)
cells 85% positive though their intensity was lower than KGl-a (Delia et.al. 1992).
Bcl-2 percentage positive cells were highest in monoblastic M4 and M5 and lowest in
M3 promyelocytic AML. Another study found thatM0 were 15% bcl-2 positive, Ml-
25%, M2-14%, M3-8%, M4-35%, M5-29%, M6-35%. Normal normal foetal bone-
marrow has the highest levels but bcl-2 was found in mature myeloid cells up to the
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promyelocyte and erythroblast stages. Differentiated HL-60 had a much reduced bcl-2
levels and it was suggested a high bcl-2 expression in AML is a consequence of the
absence of differentiation, rather than deregulated expression (Campos et.al.1993)
As a group the AML leukaemie blasts cell bcl-2 MESF in this thesis was 56,208 +/-
6879 MESF n=55 a level which was similar to normal CD34+ cells and lymphocytes
(Figure 10). However there were individual patients within the group with a higher
bcl-2 content. It was not possible to further identify the disease classification of these
AML patients or their subsequent disease progress as the clinical information was not
made available. The highest levels of bcl-2 were found in the hematologic cell lines.
Those with the t( 14;18) translocation having the highest levels (SUDHL-6 cells
1,594,338 MESF). This is not surprising since these cells have deregulated bcl-2
levels with this type of translocation. Other haematologic cells similarly have elevated
levels of bcl-2 protein, the mechanism by which this arises is not clear, though may be
related to altered growth factor expression. KGl-a (AML cell line) had 178,620
MESF, HL-60 (promyelocytic leukaemia) cells had a MESF of 78,837, Raji (Burkitts
lymphoma) 642,571 MESF, Jurkat (T cell lymphoma) 1,677,585 MESF. These levels
were found to be higher than those associated with carcinoma cell lines MGH-U-
30,620 MESF and EJ-25,040 MESF, CF-PAK-64,305 MESF, though in one cell line
SD (104,662 MESF) the levels were similar to KGl-a levels (Figure 1 0). Predictably
in KGl-a cells and in blast cells from AML patients associated with light scatter
characteristic of apoptotic cells showed a marked reduction in bcl-2 levels such that a
bi-phasic population of bcl-2 expression was often seen (Figure 30). Healthy cells
had approximately an order of magnitude more bcl-2 protein than apoptotic cells. Thus
apoptotic cells could now be identified either by their bcl-2 expression, Annexin V
positivity, light scatter characteristics or DNA histogram depending on which was
more approriate for the experiment. This feature has similarly been observed by other













(Figure 10). Levels of bcl-2 protein expression in differing cell types as assesed by
flow cytometry. MESF was determined from the calibration curve constructed using
the Quantum Simply Cellular™ calibration kit (Figure 9b).
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Colony formation as a determinant of Residual Disease
The sensitivity of deteetion of tumour cells is greatest with the polymerase chain
reaction (PCR) and multiparameter flow cytometry with levels of sensitivity-
approaching one tumour cell in 104 (flow cytometry), or 105 (PCR) normal cells with
a realistic separation at a level of 10-4-10-5 cells by PCR (Campana et.al. 1995; Negnn
et.al.1991).
In this thesis the theoretical limits of tumour cell detection by flow cytometry were
determined using the stable lipophilic membrane dye PKH-2. Following optimisation
of staining conditions this green fluorescent dye is incorporated into cell membranes
where it remains stable for up to 10 days (Horan et.al. 1990). Serial log dilutions of
labelled KGl-a cells stained with ly.M PKH-2 were seeded into buffy coat cells.
30,000 cells were counted by flow cytometry and and the number of positive cells
recorded. A plot of expected versus recovered positive cells confirmed that the
expected sensitivity of flow-cytometric detection of tumour cells is is approximately
one cell in 104 (Figure 1 la).
PCR and immunocytochemical detection of tumour cells however do not detect tumour
viability or clonogenicity. Cell culture allows approximately a 2 log increase in the
number of cells representing 7-8 cell divisions (28=256). Culture systems must
however provide appropriate ligands and growth factors to ensure appropriate selective
conditions for tumour cell survival and growth (Sharp et.al. 1992; Sharp et.al. 1995;
Sharp et.al. 1996). Growth patterns of AML cells in semi-solid culture systems have
been classified by into four growth patterns and the models related to disease
prognosis (Reilly et.al. 1989a; Lowenberg et.al. 1993). They defined a parameter
known as the autostimulatory index (ASI) to classify four patterns of cell growth. ASI
is colony growth in the absence of conditioned medium (CM) divided by the number
of colonies grown in conditioned medium from the bladder cancer cell line 5637. This
cell line has been shown to secrete growth factors (IL-1, IL-3, IL-6, GM-CSF) which
promote leukaemic colony growth in vitro (Gabrilove et.al. 1986).
Patients with AML blasts defined as group 1 do not grow under any of the conditions;
group 2 patient blast cells are colony-stimulating factor (CSF)-dependent and have an
ASI of less than 0.1; group 3 AML patients have partially autonomous growth and
have an ASI of between 0.1-0.8. Blast cell growth in these patients can be further
stimulated by addition of exogenous growth factors; group 4 patients exhibit fully
autonomous gowth and are not stimulated further by growth-factor addition and have
an ASI greater than 0.8.
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(Figure 11a). Demonstrating the levels of sensitivity of detection of rare cells by
flow cytometry. KGl-a cells labelled with PKH-2 were seeded into buffy coats and
the number of positive cells detected versus the expected count was plotted.
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Blast-cell conditioned-medium from autonomous growing blasts has been shown to
enhance normal CFU-GM formation. Similarly conditioned medium from cultured
AML patient blast cells stimulated the growth of other AML blasts except those from
patients in group 4, the conditioned medium from which showed no autostimulatory
activity on other cells. This growth promoting activity is though to be due to release of
GM-CSF (regulated by IL-lp) acting in an autocrine and paracrine fashion on the blast
cells to promote cell proliferation. Anti-GM-CSF antibody however failed to inhibit
group 4 blasts autonomous growth even though they did secrete GM-CSF therefore
this growth factor was thought to act in a direct intracellular signalling manner. Group
3 cells can be made to grow autonomously if the cell density is increased (Reilly
et.al. 1989a).
Autonomous growth of AML blast cells in vitro is also associated with higher bcl-2
levels. Antibodies to GM-CSF were able to down regulate bcl-2 levels, and
exogenously added GM-CSF in dependent cells, caused an increase in bcl-2 protein
expression. 78-90% of CD34+Lin- cells expressed bcl-2, however very early
haemopoietic cells (CD34+, Lin-, 38+) were bcl-2 negative but expressed bcl-xl.
CD34+ normal bone marrow had greater than 75 x 103 MESF bcl-2. Whilst CD34+
normal bone marrow cells express bcl-2; CD34 positive AML cells express higher
levels of bcl-2 than CD34 negative AML cells. Bradbury found that CD34+ AML
MESF expressed 43.6 +/- 3.3 xlO3 MESF bcl-2; CD34- AML expressed 31.7 +/- 3.7
x 103 MESF bcl-2. CD34+ blasts had 65-107 x 103 MESF bcl-2 whereas CD34-
blasts from the same patient were 33-82 xlO3 MESF bcl-2. AML blasts express 11.1-
99.9 x 103 MESF bcl-2. Growth factor dependent cells (groups 2 and 3) were 19.3+/-
2.4 x 103 MESF bcl-2 (rising to 27.9+/- 4.4 x 103 upon addition of GM-CSF); CSF-
independent cells had a higher level 40.9+/- 3.6 x 103 MESF bcl-2. No detectable
increase in apoptosis was seen with the addition of an anti-GM-CSF antibody even
though there was a reduction in bcl-2 expression (51.4+/- 8.9 decreasing to 38.5+/-
7.4 x 103 MESF bcl-2 upon antibody addition). The presence of high levels of bcl-2
may therefore maintain cell viability in the absence of growth factors (Bradbury
et.al. 1997).
Bcl-2 levels in KGl-a cells and other cell types studied in this thesis (lymphoma and
AML patients, SUDHL-6 cells, Raji) appeared to be related to stages in the cell cycle.
Simultaneous measurement of DNA and bcl-2 content showed that larger blast-like
cells appeared to be in the G2-S-M phases of the cell cycle and expressed elevated (2-
fold) levels of bcl-2 over cell in the Go-Gi regions. Other authors have however found
no association between bcl-2 content and cell cycle status.
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In order to determine the detection limits of the colony assay a control system was
established. Serial log dilutions ofKGl-a (acute myeloid leukaemia) eells were seeded
into 0.8% methylcellulose BCCA. The number of colonies were counted at both 5 and
16 days to see if sensitivity could be increased by allowing a greater number of cell
divisions. The sensitivity was found to be similar in both cases with a cell dilution of 2
x 1CK cells per ml being an approximate cutoff, beyond which there was no colony
formation (Figure 1 lb). This approximates to a maximum of one leukaemic colony
forming cell per 200 KGl-a cells seeded.
A maximum of 1 cell in 1-200 is able to form a colony, again stressing the unique
value of the CFU assay at detecting only replicating cells (Lotem et.al. 1993). Though
these cells may appear positive by flow cytometry or PCR they may in fact not
contribute to disease relapse. Therefore even with the exquisite sensitivity of these
approaches the true leukaemia-initiating cell may not be detected. Further isolation and
characterisation of these leukaemic colony-initiating cells should lead to more
information on the cellular defect(s) which precipitate the leukaemic process. Only then
will effective strategies be designed and able to target most effectively these cells rather
than the more differentiated highly replicative progeny. Recent studies on the SCID
mouse acute myeloid leukaemia-initiating cells have suggested these cells expressed
CD34 will be discussed in more detail elsewhere in this thesis (Terpstra et.al. 1996;
Terpstra et.al. 1997; Bonnet et.al. 1997).
However an attempt to purify these cells a CD34+ immunomagnetic (MACS™) cell
isolation was undertaken. Here CD34+ KGl-a cells were seeded into buffy coats at
serial log dilutions and CD34+ cells isolated. However it was found that only a tenfold
increase in the number of selected CD34+KGl-a cells could be achieved and not the
106-107 fold increase as suggested by the manufacturers literature. These selected
CD34+ cells were found to have a reduced CD38 expression and lower granularity
indicating a less mature phenotype but studies to confirm that these cells were
leukaemic CFU-initiating cells were not performed as there were insufficient funds
available to repeat the experiment.
Similarly KGl-a cells were labelled with the stable membrane dye PKH-2 and seeded
in serial log dilutions into Jurkat cells with the cells harvested at 24 hour intervals. It
was expected that as leukaemic cells divided they should express a two-fold reduction
in the PKH-2 dye content with a concomitant doubling of cell numbers.
It was felt that in combination with CD34+ antibody staining, this dye should identify
the colony-initiating cells. It was expected that the more proliferative, more mature
cells would lose their CD34 positivity, increase in granularity and reduce their PKH-2
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content. Leukaemic colony-initiating cells were expected to maintain their CD34
positivity, low granularity and retain a high PKH-2 content. As expected there was a
reduction in PKH-2 content in KGl-a cells as they divided but unexpectedly the Jurkat
cell line seemed to increase in positivity. It was felt that these cells were phagocytosing
labelled KGl-a cells either because of some marker expression (eg. KGl-a cells are
known to express Fas and Fas ligand -Dr H Roddie personal communication)
following labelling or due to an limited anti-leukaemic effect. In any event the
experiment was abandoned.
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(Figure 111). Top: Low power magnification (xl25) of colony formation from a patie
with AML. Colonies with greater than 20 cells were counted at 7 days.
Bottom: High power magnification (x300) demonstrating the clonality of these cells.
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SENSITIVITY OF BLAST CELL COLONY ASSAY
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(Figure 11c). This graph demonstrates the levels of detection of leukaemic colony-
forming cells in methyl-cellulose. The limit appears to be one colony formed at 2000 to
20,000 cells per ml depending on the length of incubation.
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Other authors have suggested that cell-cell contact is required for autonomous AML
blast growth. AML blasts were cultured in flat-bottomed wells at 15-500 cells per ml
and DNA synthesis was found to be related to cell density. Growth in round-bottomed
wells was independent of cell numbers, though physical separation of cells using latex
beads abrogated this effect (Reilly et al 1989). Other studies showed most AML patient
blasts required exogenous colony-stimulating factors to promote and sustain growth.
At least 106 blast cells per ml were required for optimal growth, but this effect could in
part, be substituted by a portion of irradiated blasts or isolated membranes (Nara
et.al.1985). Blast cell conditioned medium from crowded cells was able to enhance the
growth of cells more than conditioned medium from non-crowded cells. This
presumably arises from the adhesion-dependent autocrine GM-CSF release. Prior
culture of blasts in round-bottomed flasks to enhance cell-cell contact for 72 hours
gave rise to more colonies than flat bottomed culture alone. Cell-cell contact was
capable of stimulating blast cell growth which was decreased by physical separation
using latex beads whereas mitomycin c treated blasts increased blast cell growth (Reilly
et.al. 1989b).
In the study outlined in this thesis 77 AML samples were processed in the blast cell
colony assay (BCCA). Of these 18/77 (23.4%) showed partial or complete
autonomous growth (Figure lid). This is much less than the 70% patients described
by Russell's group (Reilly et.al. 1989a; Hunter et.al.1993; Russell et.al.1995) but is
similar to the findings of others who described autonomous growth only in aminority
of AML patients (Cheng et.al. 1988; Young et.al. 1988; Metcalf, 1986). When all
variables were taken into consideration autonomous growth was found to be the single
most important indicator of complete remission (CR) and disease free survival (DFS)
(Hunter et.al.1993). The 5 year survival of non-growers was 54.2% as compared to
11.3% survival for autonomous growers. Group 1 & 2 patients had a complete
remission rate of 94% as compared to 57% for patients in group 3 & 4 . It was not
possible to follow up the course of the disease in patients studied in this thesis since
clinical information was not made available on these patients.
As intimated earlier cells which demonstrate autonomous growth in the blast cell
colony assay have elevated levels of bcl-2 possibly related to growth-factor mediated
tyrosine kinase signalling mechanisms, and may also lack functional retinoblastoma
protein (Olsson et.al. 1996). The mean MESF bcl-2 per cell in all AML cases was 11-
74 xl03 molecules per cell (MESF), the patients in this thesis had a mean of 56 with
range of 11-306 x 103 MESF. Group 1 & 2 patients were found to have low levels of
bcl-2 (19.3 x 103 +/_ 2.4 molecules per cell). Group 3 & 4 patient blasts on the other
hand expressed 40.9 x 103 +/- 3.6 molecules per cell. In those patients where it was
effective an anti GM-CSF antibody was able to down-regulate bcl-2 from 51.4 +/- 8.9
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x 103 to 38.5 +/- 7.4 x 103 molecules per cell. This was not however associated with
induction of apoptosis but did lead to an increased sensitivity to cytotoxic drugs
(Lotem et.al. 1993). Conversely G-CSF which is used to ameliorate chemotherapy-
induced myelosuppression may enhance tumour cell proliferation and has been
described to enhance the survival of leukaemic cells in response to the cytotoxic effects
of adnamycin and etoposide (Kondo et.al. 1994).
Of the patients studied a variable response was seen to an anti-GM-CSF neutralising
antibody present at 5ug/ml (sufficient to neutralise more than 250IU/ml GM-CSF).
Only 3/18 patients showed any demonstrable reduction in tumour cell growth (Figure
lid). A further 8 peripheral-blood progenitor cell harvests from patients
demonstrating autonomous growth of blast cells at presentation revealed no
autonomous growth in this assay. This could be related to the low density of blast cells
in these harvests and and the probability that only one in a hundred cells is likely to be
a leukaemic CFU cell. However this pattern of colony inhibition is consistent with the
poor level of autonomous cell growth seen in these patients. There was no funding
available to perform a CD34 positive immuno-magnetic selection on these samples to
see if the sensitivity could be increased. It was not clear which, if any, of the colony-
stimulating factors, these blast cells were dependent upon for growth since there was
occasional colony formation similar to early CFU-GM formation in samples cultured in
the presence of conditioned medium. Indeed many group 4 patients' cells show a poor
response to the inhibitory effects of neutralising antibodies leading some researchers to
suppose that these may in fact be truncated receptors acting purely in an intracellular
environment.
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(Figure lid). Peripheral blood and bone marrow samples from AML patients were
grown in the blast cell colony assay to look for autonomous growth. 18/77 Patient
showed some degree of growth and were treated with a neutralising anti-GM-CSF
antibody or bcl-2 or control antisense to purge leukaemic colony-initiating cells.
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Antisense bcl-2
Because of the limited availibility of AML samples which demonstrated autonomous
growth attention was concentrated on the development of the therapeutic potential of
bcl-2 protein modulation. The suitability of bcl-2 as a potential therapeutic target
remains promising however, since as indicated, patients with high levels of
autonomouus growth and elevated levels of bcl-2 present with a poorer disease
prognosis. Strategies such as therapeutic manipulation with monoclonal antibodies to
growth factors and their receptors have a limited clinical role because of their poor
discrimination between normal and tumour cells and the potential to initiate an anti-
antibody response. Therefore other tactics have been adopted in AML including
differentiation of blast cells.
ATRA or recombinant colony-stimulating factors may differentiate blast cells or recruit
blasts into cycle to make them more responsive to S-phase specific drugs or to induce
terminal differentiation of blasts. Other pharmaceutical agents may perform similar
functions. For example the promyelocytic leukaemia cell line HL-60 can be
differentiated using 1.2% DMSO, plus PMA (lOng/ml) every 72 hours. This induces
differentiation to monocyte like cells with a concomitant reduction in bcl-2 protein
expression. These differentiated HL-60 cells which have much reduced bcl-2 were
found to be in G1 phase. PMA-induced monocyte-macrophage differentiation also
causes a rapid reduction in bcl-2 and strong up-regulation of the adhesion molecule
CD1 lb which is a component of the complement C3 receptor, and also has binding
domains for heparin, fibrinogen and ICAM-1 (Delia et.al. 1992). CD1 lb expression is
up-regulated on HL-60 with PMA treatment (90% positive cells at 2 days), DMSO on
its own however only gave 16% positive cells. All trans retinoic acid (ATRA) is used
therapeutically in patients with APML (M3) which differentiates the leukaemic clone
and increases sensitivity of HL-60 cells to cytosine arabinoside. This was associated
with down-regulation of bcl-2 protein expression. K562 erythroleukaemia cells
similarly treated with luM ATRA for 24 hours also down regulate bcl-2 but without
any evidence of apoptosis induction (Fenaux et.al. 1996). The half-life of bcl-2 protein
in control cells was 20 hours, in the presence of ATRA it fell to 12 hours and was
increased in the presence of hydrocortisone to 43 hours. Hydrocortisone has a
protective effect on cytosine arabinoside and daunorubicin-treated cells but the
mechanism is unclear (Smets et.al. 1994). Cytosine arabinoside and daunorubicin are
more effective if the bcl-2 level in blasts is first down regulated by ATRA. Blasts are
more sensitive to cytosine arabinoside in the presence of G-CSF and less in the
presence of GM-CSF. This may be due to the up-regulation of bcl-2 by GM-CSF but
an increase in cell cycling induced by G-CSF. Bcl-2 expression in blasts was greater in
the presence of GM-CSF or G-CSF plus GM-CSF than G-CSF alone, ATRA
however down regulated bcl-2 (Hu et.al. 1996).
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Because of widespread interest in its efficacy in haematological and other malignancies
an antisense to bcl-2 messenger RNA was used to achieve direct therapeutic
manipulation of bcl-2 protein levels in AML blast cells in this thesis. This was with a
view to either inducing blast cell differentiation or increasing cell sensitivity to standard
chemotherapeutic agents independent of their mechanism of action. Induction of
apoptosis is not limited to highly proliferative cells (Hickman et.al.1994). It was felt
that should bcl-2 be sufficiently down-regulated then the resistance of blast cells to
therapy might be tipped towards cell death rather than survival caused by elevated bcl-2
levels.
Antisense uptake in normal peripheral blood cells
In order to achieve baseline values and characterise the binding and uptake kinetics of
antisense molecules into haematopoietic cells normal peripheral blood was used as a
control system. Antisense phosphodiester (native DNA backbone) and
phosphorothioate (where one of the acid phosphate group oxygens is replaced by
sulphur) molecules were synthesised with and without a 5'-FAM (fluorescein addition
monomer) or 5'-biotin detected by labelled streptavidin. The labels were used to
monitor the concentration and kinetics of uptake by flow cytometry and to monitor
cellular compartmentalisation of antisense by UV microscopy.
Calibration of antisense uptake
In order to quantify the fluorescence signal associated with cells a calibration system
was established. This utilised polycarboxylate spheres with a reactive carboxylate
group. These beads were coupled to an 5'-amine labelled cDNA molecule
complementary to antisense sequences using EDC coupling reagent (Peirce, UK)
according to the manufacturers protocol. Saturating amounts of antisense species were
hybridised to the complementary sequence (Biotinylated and FAM-conjugated
antisense molecules).
The fluorescent signal associated with saturating amounts of FAM-labelled antisense or
biotinylated antisense (detected by streptavidin-PE) hybridised to the complemetary
sequence (conjugated to beads) was determined by flow cytometry. Therefore the
fluorescence intensity of both the FAM and biotinylated antisense molecules could be
directly related to each other through hybridisation to an equivalent amount of cDNA.
The FAM-labelled probe was to be used to measure total cellular association (intra- and
extracellular) with antisense DNA and the biotinylated probe used to detect only the
extracellular component of the antisense association. This could be achieved because
the detecting molecule streptavidin is impermeable to cell membranes therefore only the
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accessible extracellular component could be detected. Thus the difference in DNA
content (total FAM-extracellular Biotin) should relate to the intracellular concentration
of antisense uptake.
Hybridisation efficiencies between all antisense species to the label used were
measured on aliquots of each labelled species which were denatured at 95°C for 5
minutes to dissociate beads from DNA before being spun to remove the spheres. The
concentration of oligonucleotide in the supernatant was then measured. The mean
concentration of oligonucleotide (+ standard deviation) in each supernatant was found
to be 30.5 ± 0.8 for FAM-, and 29.8 ± l.lng per 103 spheres for biotin-labelled
antisense respectively. Therefore, it was concluded that there was no difference in
hybridisation efficiency. This calibration allowed the determination of correction
factors which could then be applied to the fluorescence values to calculate antisense
concentrations. For FAM-labelled antisense, the equivalent amount of streptavidin-
labelled biotinylated antisense in PE (Fl-2) units was given by the green fluorescence
(FL-1) value multiplied by 4.61 and the equivalent of biotinylated antisense in FAM
(FL-1) units was given by the red fluorescence (FL-2) value multiplied by 0.216.
Cellular uptake
Having determined calibration settings for antisense values, cells of normal peripheral
blood and KGl-a (acute myeloid leukaemia cell line) were studied in a dose and time
dependent fashion to determine baseline values for normal and leukaemic cell types.
Whole blood, from which red cells had been lysed, were studied in triplicate to
determine uptake in granulocytic cell types (neutrophils and eosinophils), lymphocytes
and monocytes. Lymphocytes, density-gradient purified followed by adherent and
phagocytic-cell depleted, and continuously growing AML cell cultures were also
studied.
Naked antisense DNA was incubated with cells for 0, 30, 60, 120 or 240 minutes in
the presence of 0, 0.1, 1.0, 10uM antisense-FAM or antisense-biotin in serum free-
medium (QBSF-51 Sigma, UK). Cells were washed in PBS, if neccessary surface-
labelled with PE-labelled CD19 (B cells); CD3, CD4 or CDS (T cells) washed again
and 40|xl propidium iodide solution added to assess cellular viability and cells analysed
by flow cytometry. Cells were identified as follows, lymphocytes were of small to
intermediate size with little granularity, monocytes were larger and more granular,
neutrophils were of intermediate size but with a greater granularity than lymphocytes,
and finally eosinophils (where present) were small and extremely granular (Figure
13). Lymphocytes were further classified into T and B cells on the basis of surface
immunophenotype as described above.
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The levels, and kinetics of antisense uptake varied considerably between normal
peripheral blood cell types with granulocytic and monocytic cells having far greater
antisense association than lymphocytic cells. Monocytes took up most antisense,
neutrophils intermediate levels, and lymphocytes the least. Monocytes and neutrophils
both showed high levels of extracellular binding at the earliest time point, which then
decreased over time in culture, while their intracellular levels steadily increased.
Lymphocytes showed much lower levels of cell surface binding, which remained
constant throughout the culture period with intracellular concentrations for all but the
lowest dose used, had reached maximum levels by 1 hour in culture, KGl-a cells
retained lowest levels of antisense association at all time points and doses (Figs. 14,
15, 16, 17). Within the lymphocyte population CD19+ B cells were found to have
the highest levels of antisense association. There were no differences found in the
levels of antisense uptake between CD4 and CD8 positive T cells (Figure 18a).
KGl-a cells and normal and leukaemic CD34+ cells had levels similar to lymphocytes
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(Figure 13). Bi-variate flow-cytometric dot-plot demonstrating the distinctive light
scatter characteristics of normal peripheral-blood white cells.
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Extracellular association of antisense with cells
In all cell populations extracellular uptake was found to be dose-dependent and non-
saturating within the range of doses (0.1 to IOjaM) studied. The highest levels of
extracellular association were detected at earlier time points (<lhr), with decreases
observed over time.
Cellular uptake of antisense into cells
In all cell populations intracellular uptake of antisense was dose and time-dependent,
and was not saturated at concentrations of antisense up to lOuM for 4 hours. By 4
hours intracellular concentrations of antisense had reached levels equivalent to the
extracellular concentrations achieved within the first hour.
Lymphocytes
At 0. l^iM there was no apparent elevation of extracellular antisense levels during the 4
hour incubation period. Similarly very little change in the intracellular levels was seen
until 2 hours after addition of the drug. The intra and extracellular levels were similar at
this time point however by 4 hours there was a three-fold increase of intracellular over
extracelluar levels indicating a possible active uptake at this time point (Figures 14a,
16a, 16d).
With 1 .OnM drug extracelluar levels at 30 minutes were similar to those seen with
0. l^M, however these levels had trebled by 60 minutes but dropped by 4 hours
incubation. This is not reflected in intracelluar levels which at 30 minutes started with
six-fold more antisense in intra over extracellular levels which then dropped to a two¬
fold elevation by 2 hours but then recovered to a maximum of four times extracelluar
levels at 4 hours (Figures 14b, 16b, 16d).
The KVM antisense dose saw a marked elevation in extracelluar levels (twenty times
more than 0. l^M values), a level which remained fairly constant over the 4 hour
incubation period. This was not paralleled in intracellular levels which were similar to
the 0. ljiM values at 30 minutes but rose steadily to plateau at four times the 30 minute










(Figure 14a). Showing the extracellular association of a 0.1 jaM dose of biotinylated
antisense in normal peripheral blood cell types.
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EXTRACELLULAR BIOTINYLATED ANTISENSE





(Figure 14b). Showing the extracellular association of a l.OjiM dose of biotinylated
antisense in normal peripheral blood cell types.
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EXTRACELLULAR BIOTINYLATED ANTISENSE





(Figure 14c). Showing the extracellular association of a 10(xM dose of biotinylated
antisense in normal peripheral blood cell types.
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EXTRACELLULAR LEVELS OF

























(Figure 15). Showing the extracellular association of all doses (0. 1-IOjaM) of
biotinylated antisense in KGl-a (AML) cells.
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Monocytes
Monocytes showed the greatest levels of extracellular antisense association. At 0. luM
antisense monocytes had a higher association of drug than either lymphocytes (20x
values) or neutrophils (1.5x values) within the first half-hour of incubation. Similar
levels were found inside as outside the cells indicating equilibnum and suggesting this
might be passive diffusion at this time point. Extracellular levels remained constant
over the first 90 minutes when the levels dropped by half at 2 hours and to one third 30
minute values by 4 hours. However intracellular levels rose consistently throughout
the period of incubation until by 4 hours there was nine times as much inside as
outside the cells. Furthermore there was one hundred times more than inside
lymphocytes and two times more than inside neutrophils at the same time point
(Figures 14a, 16a, 16e).
Using l.OuM drug demonstrated that at 30 minutes there was again an equal amount of
antisense inside as outside the cells. Again extracellular levels dropped, such that by 4
hours there was one quarter as much outside cells as at the 30 minute values. There
was however a fourteen-fold increase in the amount of drug inside the cells at this time
point. Intracellular values interestingly had remained constant until 2 hours when the
levels started to incrementally rise (Figures 14b, 16b, 16e).
At lOuM antisense there was a three-fold increase in extracellular levels over the 1,0uM
values by 30 minutes. This level remained constant over the first 2 hours until 4 hours
when levels fell by a factor of seven over the 30 minute values. Intracellular values
showed a doubling over the first 60 minutes, remained constant over the next 60
minutes and doubled again by 4 hours. By this time there was twelve times as much
antisense inside the cells as outside (similar values to 0.1 and l.OuM). Intracellular
values at this time point were tenfold more than lymphocytes and two times more than
neutrophils at the same drug concentration (Figures 14c, 16c, 16e).
Neutrophils
With 0. luM drug by 30 minutes incubation antisense levels in neutrophils were
approximately twenty-fold more than in lymphocytes with equal amounts of drug
found inside neutrophils as associated with membranes. However with increasing time
there was an incremental decrease in extracellular levels of antisense to levels one
quarter the thirty minute values. However intracellular values had doubled in the first 2
hours at which time levels plateaued at two times the extracellular levels and ten-fold
more than lymphocytes and half the monocytic level (Figures 14a, 16a, 16f).
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CELLULAR UPTAKE OF FAM-LABELLED ANTISENSE
(0.1 nM) IN PERIPHERAL BLOOD CELLS
(Figure 16a). The intracellular compartmentalisation of a 0. l^M dose of FAM-
labelled antisense in normal peripheral blood cell types.
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CELLULAR UPTAKE OF FAM-LABELLED ANTISENSE























(Figure 16b). The intracellular compartmentalisation of a l.OpM dose of FAM-
labelled antisense in normal peripheral blood cell types.
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CELLULAR UPTAKE OF FAM-LABELLED ANTISENSE
(10 nM) IN PERIPHERAL BLOOD CELLS





(Figure 16c). The intracellular compartmentalisation of a 10(xM dose of FAM-
labelled antisense in normal peripheral blood cell types.
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At thirty minutes after addition of l.OjiM antisense extracellular levels were double that
of 0. l^M antisense values. These levels had effectively doubled by 60 minutes but
rapidly decreased such that 4 hour values were one quarter of the 90 minute levels.
Intracelluar levels meanwhile remained constant over the first 60 minutes and were
similar to extracellular levels. However by 2 hours five times as much signal was
associated inside as outside the cell the levels of which had increased to fourteen times
the extraceduar values at 4 hours (Figures 14b, 16b, 16f).
IOhM antisense gave extracellular 30 minute levels which were two times those of
intracellular compartments. Levels remained consistent until 90 minutes incubation but
dropped by 50% by 2 hours, and then remained constant until the end of the study at 4
hours. Intracellular levels rose incrementally over the four hour period and were
similar to extracellular levels until 2 hours when a two-fold increase was seen, which
then rose to three times extracelluar levels by four hours. At this time point levels were
half of monocyte values and five times those of lymphocytes (Figures 14c, 16c,
16f).
KGl-a (AML) cells
KGl-a cells treated with 0.1(^M antisense had extra and intracellular levels of drug
similar to lymphocytes at 30 minutes. There was no change in the extracellular level
which remained low over the 5 hour incubation. Intracellular levels remained
consistent until 3 hours when there was approximately two times as much inside as
outside cells with levels again similar to lymphocytes (Figures 15, 16g, 17).
1.0|4Vl antisense treated cells had extracellular levels more than two times greater than
0. l|xM antisense levels at 30 minutes. These levels again remained constant during the
study. Intracellular levels rose slowly such that by 5 hours there was twice as much
inside cells as found at 30 minutes, however intra and extracellular levels were similar
indicating that passive diffusion may account for most of the uptake. Again levels were
found to be similar to those of lymphocytes (Figures 15, 16g, 17).
10nM antisense levels on the surface of cells was found to be fifteen times more than
that found with 0. l^M drug at 30 minutes. This level remained constant over the 5
hour incubation period, however there was a small decrease found at 30 minutes with
an increase found at 5 hours. Intracellular levels remained low however at between one
fifth to one half of levels found on the cell surface. These levels were lower even than
levels found in lymphocytes (one seventh) with a similar extracellular value. This may
represent relatively poor cellular uptake or an efficient system for removal of drug in
these cells (Figures 15, 16g, 17).
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(Figure 16d). The intra and extracellular compartmentalisation of antisense in normal
lymphocytes.
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(Figure 16e). Intra and extracellular compartmentalisation of antisense in monocytes.
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(Figure 16f). Intra and extracellular association of antisense in neutrophils.
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INTRA & EXTRA-CELLULAR ANTISENSE









































ANTISENSE-FAM IN KGl-a CELLS
(Figure 17). The intracellular compartmentalisation of all (0. l-10(iM) doses of FAM-
labelled antisense in KGl-a (AML) cells.
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ANTISENSE UPTAKE IN LYMPHOCYTE SUB-TYPES
400
luM, lhr luM, 5hr 5uM, lhr
DOSE AND TIME
5uM, 5hr
(Figure 18). The intracellular compartmentalisation of a 1 and 5[xM dose of FAM-
labelled antisense in normal peripheral blood lymphocyte sub-types. CD19+ B cells are
seen to take up lOx more than all types ofT cells.
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All cells
Antisense association with peripheral blood leucocytes was rapid with a fluorescent
signal associated with in monocytes by 30 minutes. There is a dip in the extracellular
concentration of oligo in myeloid cells which is not reflected in a change in intracellular
concentration. This may relate to receptor-ligand internalisation or down-regulation.
Levels of antisense uptake are greatest in myeloid cells with the following ranking:
monocytes > neutrophils > B cells > T cells (CD4 and CD8 cells equivalent) (Figure
18).
Efflux of antisense
Once inside lymphocytes, antisense exited very slowly. No significant efflux was
detected up to 18 hours after antisense removal from culture. In light of the long-term
stability of antisense within cells, it seems clear that a bolus, or short pulse,
administration of the oligonucleotide should be capable of achieving effective
intracellular concentrations without many of the concomitant side effects (Figure 19).
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(Figure 19). Antisense efflux from lymphocytes was negligible over an 18 hour
period following loading with either 1.0 or lO^iM antisense-FAM.
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Antisense quenching
As described above the initial study aim was to use FAM-labelled antisense to quantify
total antisense association and biotinylated oligo (detected by streptavidin) to measure
the extracellular component. However the arithmetic did not seem to justify that this
assumption could be correct. There was an anomaly in the amounts of DNA detected
and frequently the biotin signal was equivalent to or greater than that from FAM. Thus
it appeared that something was in fact quenching the signal from this dye. An
investigation of fluorescence quenching agents was therefore sought. The effects of
known quenching agents on fluorescent signals was monitored for similarity to that
seen with the FAM label.
Trypan blue, crystal violet and tannic acid are agents known to effectively quench
fluorescence signals by absorbing the emitted fluorescence light. 0.05% trypan blue
was shown to quench the stable membrane dye PKH-26 but not intracellular ethidium
bromide, tannic acid was shown to quench FITC-labelled yeast (Giaimis et.al. 1994;
van Amersfoot et.al. 1994). This results from a phenomenon known as fluorescence
resonance energy transfer where the emission wavelength of the first dye is absorbed
as the excitation wavelength of a second dye which results in a quenching of
fluorescence. Therefore the effects of these agents on green and red fluorescence from
beads (Calibrite™ Becton Dickinson, Oxford, UK) or viable cells stained with
monoclonal antibody was determined. Trypan blue (2mg/ml) from two sources (BDH
and Sigma, UK) was studied as they had previously been described as possessing
differing quenching abilities, crystal violet (2mg/ml) (BDH, UK) or Tannic acid at 1
and 10 % were added to 50ul Calibrite™ Beads and incubated for 5 minutes at room
temperature and the beads' residual fluorescence measured by flow cytometry . There
was a marked and obvious quenching of both the Fl-1 and Fl-2 signals when the beads
were quenched with both forms of the trypan blue with Sigma Trypan blue being
slightly more effective in FL1 and BDH Trypan blue on Fl-2. However overall the
green fluorescence was more effectively quenched than the red. Crystal violet and 1%
tannic acid were able to effectively quench the signal in both FL-1 and 2, however
10% tannic acid caused severe flocculation of the beads without any quenching. The
action of propidium iodide (40^1 of a 0.025% solution) was similarly measured in the
assay since this and the streptavidin-PE were the only differences between the biotin
and FAM labelled cells. However PI had no effect on the fluorescence of the beads
(Figure 20). Similarly the effects of these agents on monoclonal antibody stained
peripheral blood mononuclear cells revealed a similar pattern. Cells were stained with
either CD38-FITC, CD45-FITC, CD45-PE or CD3-PE and the fluorescence measured
after 5 minutes at room temperature. Again quenching with trypan blue was seen
though not as dramatic as with the calibration beads nor did the effectiveness appear to
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be constant between different antibodies with differing binding sites. This may result
from the differences in the initial intensity of staining and may also be related to the F:P
ratio with more heavily labelled probes being more effectively quenched due to the
proximity of flourophores eg. CD45-FITC versus CD45-PE (Figure 21). Crystal
violet and tannic acid at both concentrations were found to destroy normal cellular
morphology and so were rejected as unsuitable for further use.
An attempt therefore was made to look at the potential for quenching agents on the
fluorescent signal both on FAM-labelled DNA-conjugated beads or on leukaemic cells
treated with 5^M antisense for 24 hours. This time trypan blue was similarly found to
be an effective agent at quenching the fluorescence signal though the effect was
minimal at this time point.
Similarly PI was monitored for its effectiveness since a previous study using ethidium
bromide (Fattorossi et.al.1989; Vogel et.al.1994) had been shown to effectively
quench the F1TC signal from labelled Candida albicans. There was an obvious marked
reduction in the fluorescent signal from both beads and cells which was wholly
surprising given the lack of quenching seen with antibody-labelled beads or cells
(Figure 22). When monitored by fluorimetry the data was confirmed, both trypan
blue and propidium iodide were able to quench the signal from FAM labelled antisense
DNA. Thus the initial discrepancy between the FAM and biotin labelled antisense
uptake had been revealed. The propidium iodide initially used as a viability stain had
effectively quenched the extracellular fluorescence revealing only the intracellular
compartment to be visualised both by flow cytometry and fluorescent microscopy.
Though this appeared to be a time-dependent phenomenon it merely reflected changes
in the cellular partitioning of antisense with time such that with increasing time there
was more intracellular fluorescence and therefore the portion quenched by PI became
reduced.
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(Figure 20). Trypan blue, crystal violet and 10% tannic acid are all effective at










(Figure 21). The effects of quenching agents on antibody staining. Trypan blue has a
variable effect, crystal violet and tannic acid though effective destroy cell morphology.
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QUENCHING OF FAM BY
PROPIDIUM IODIDE
(Figure 22). Propidium iodide is able to quench the signal from FAM-labelled
antisense linked to beads or cells. Beads were quenched to their background levels
whereas cells had residual signal from intracellular antisense.
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It was therefore possible to compare the intracellular concentration of a single dose
(1 jxM at 4 hours) of antisense in differing cell types to obtain a direct comparison of
uptake. Monocytes were found to have the highest levels with neutrophils taking up
similar but slightly lower levels. CD 19 positive B cells and CD34 positive AML patient
blasts took up similar levels of antisense with similar to but slightly greater than normal
CD34 positive cells. T cells took up least amounts of antisense with no apparent
differences between CD3, 4, and 8 positive cells (Figure 23).
Enhancers of antisense uptake
Having now been satisfied that there was antisense uptake into these cells confocal
microscopy revealed that the majority of antisense appeared to be sequestered in
cytoplasmic vesicles (Figure 24) which is in agreement with other authors findings
(Bergan et.al. 1996). In control cells treated with antisense the oligo is sequestered to
the cytoplasmic vesicles. However following electroporation the oligo localised
directly to the nucleus and non-vesicular cytoplasmic structures within the cytoplasm.
No effect of c-myc oligos were seen without electroporation. This method allowed up
to 7 times more signal inside cells following electroporation than those incubated with
naked DNA (Bergan et.al. 1996).
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INTRACELLULAR LEVELS OF
l.OpM ANTISENSE AT 4 HOURS
10000 -r
(Figure 23). A single dose (l.OjiM) of antisense for 4 hours reveals a decreasing
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EFFECTS OF AGENTS ON UPTAKE OF
ANTISENSE IN KGl-a CELLS
(Figure 25). The effects of agents on antisense uptake into cells. DMSO may
improve cytoplasmic delivery and together with SSB may reduce potential secondary
structure formation. The CD18 antibody may interfere with integrin/Mac-1-mediated
antisense cellular intemalisation.
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In K562 (an erythroleukaemia cell line) cells an increase in transfection efficiency
could be achieved using transferrin-conjugated antisense (Bergan et.al.1996; Cotten
et.al. 1990). Rapidly dividing cells and cells synthesising haem (neoplastic or
haematopoietic) require elevated iron and a 20 hour incubation with desferrioxamine
(50[iM) was able to increase the transferrin receptor four fold. This related to a 5-15
fold increase in DNA tranfection when performed in the presence of KXVM
chloroquine (4 hours) (Schultz et.al.1997). The antisense is sequestered in cytoplasmic
vesicles and chloroquine acts to increase lysosomal pH, causing them to rupture and
release contents into the cytoplasm thus improving the bioavalibility of the drug.
However this type of method is costly, cumbersome and time consuming so a simpler
more direct approach was sought.
DMSO (10%), an agent commonly used for bacterial transformation of DNA, was co-
incubated with antisense molecules to see whether transfection efficiency could be
improved. Similarly sterile ammonium chloride (100nM) was also used to see if this
weak base could be used to increase lysosomal pH and thus cause rupture of vacuoles
and release antisense into the cytoplasm. However in both these approaches no
increase in antisense was seen but an increase in cytotoxicity was apparent (Figure
25).
Liposomal transfection using Lipofectin™ was attempted again to increase the
availibility of antisense to cytoplasmic targets. A solution of antisense in serum-free
medium was added to a solution of Lipofectin™ in serum-free medium and incubated
for 15 minutes at 37°C. Cells were incubated in the presence of the liposomal-
antisense complex for 4 hours at 37°C, 5% CO2. Cells were then washed twice in
serum-free medium, surface stained with fluorescent antibody when required, and
analysed. However the results again were variable with either poor transfection or high
levels of cytotoxicity. Also microscopy revealed poor fusion of the liposomal complex
to many of the cells.
Streptolysin O was used as an agent for reversible permeabilisation of cell membranes
(Spiller et.al.1995). An optimal dose and time of incubation was sought to deliver
antisense molecules directly to cytoplasmic and nuclear targets. In the presence of the
flourescent vital stains, propidium iodide and fluorescein di-acetate, non-permeabilised
viable cells should be green only; permeabilised non-viable cells red only and
permeabilised viable cells should have a red nucleus with green cytoplasm. However
using this combination of propidium iodide and fluorescein di-acetate solution it was
difficult to adjust the compensation settings on the flow cytometer to allow
discrimination of the red and green signals. It also proved to be an unreliable technique
in that frequently there would be no permeabilisation at all, then under identical
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conditions there would be massive cytotoxicity. These methods were therefore
abandoned in favour of the simpler, though less effective, direct incubation system.
Biologic effects of bcl-2 antisense
Having established that the bcl-2 antisense did not overlap with any other known
protein sequence GenBank search (Appendix 1) and that antisense was available to
an intracellular compartment its biologic effects on leukaemic colony formation and
effects on bcl-2 protein expression were studied. Cells were incubated in the presence
of 5uM antisense molecules to look for specific and non-specific effects of antisense
molecules. Other authors have described the effective use of antisense in haematologic
malignancy with an emphasis on purging of leukaemic cells from autologous bone
marrow and leukapheresis products, c-myc (Bergan et.al.1996), Interleukin-lp
converting enzyme (Stosic-Grujicic et.al. 1995) and bcl-2 (Campos et.al. 1994) have all
been described as potential therapeutic targets in AML.
Antisense effects on proliferation
Therefore of the 77 AML samples studied for colony formation those 18 patients who
demonstrated any degree of autologous growth were further selected and treated with
either 5^M antisense bcl-2, control nonsense antisense or an anti-GM-CSF antibody to
look for cytostatic or cytotoxic effects. No patients showed any demonstrable
reduction in colony growth with either of the antisense species at day 3 or 7 post-
incubation. Of patients treated with an anti GM-CSF antibody 5 out of 18 (28%)
patients showed a partial reduction in the number of colonies formed though none
showed complete abrogation of growth (Figure 1 Id).
The effects of antisense on the ability ofKGl-a cells to form colonies in vitro was
studied using 1(VM antisense. No effects on colony formation were found (Figure
26). Similarly the effects of antisense species were monitored for anti-proliferative
effects using an MTT dye reduction assay. Briefly 105 KGl-a cells were incubated for
hours with 1 and 5uM antisense bcl-2 (phosphorothioate and phosphodiester forms),
nonsense bcl-2, and control antisense with a limited reduction in cell growth seen with
all species excepting the bcl-2 phosphorothioate antisense (Figure 27). These
antisense effects are most probably non-specific toxic polyanionic effects which have
been described by other authors (Stein, 1995).
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ANTISENSE EFFECTS ON COLONY FORMATION
150
(Figure 26). Limited effects of antisense were seen on the ability of KGl-a cells to



























Effects on bcl-2 expression
The effects of antisense species on bcl-2 protein expression were quantified on the
KGl-a (acute myeloid leukaemia) cell line using the quantitative flow cytometric
analysis descnbed before. Similarly carcinoma cell lines EJ, MGHU, SD, CF-PAK
were measured for the effects of antisense on bcl-2 expression (Figure 28). Briefly
cells (106/ml) were incubated in the presence of various antisense moieties for 1-7 days
and the cells harvested, washed, permeabilised and stained for bcl-2 and DNA content.
It was expected that there might not be gross induction of apoptosis but that there
might be limited down-regulation of bcl-2 content wich in turn might lead to limited
differentiation of these cells since more mature myeloid cells have been shown to be
associated with a lower bcl-2 content (Porwit-McDonald et.al. 1995). There was no
obvious reduction in bcl-2 content except a small reduction in total bcl-2 content seen
occasionally with KGl-a cells which did not reflect any development of apoptosis,
similar to findings by other authors (Keith et.al. 1995).
Antisense effects in the presence of cytotoxic agents
Given the poor effects of bcl-2 antisense on cellular viability on its own, the
synergistic effects of antisense in the presence of known cytotoxic agents was studied.
Cytosine arabinoside (Ara C) was chosen since it is of therapeutic clinical use in the
treatment of leukaemias, particularly in relapsed and resistant forms. It uses the
equilibrative nucleoside transporter (up to 24,000 receptors per AML cell) to enter cells
before conversion to the active triphosphate Ara CTP and has its effect on rapidly
proliferating tumours (Wiley, 1997). Actinomycin D (ActD) another potentially useful
clinical agent (although now surpassed by more effective agents) is known to
intercalate into DNA backbones and prevent de novo mRNA translation.
Cycloheximide (CHX) is widely used as a research tool for its ability to prevent de
novo protein synthesis. It was hoped that CHX might mimic or interfere with
antisense-specific effects on mRNA inhibition because of its similarity of action. ActD
and CHX are not thought to be cell-cycle specific drugs whereas AraC is S-phase
specific. In some cell types apoptosis is not dependent on protein synthesis but in
others it can be blocked by Cycloheximide or Actinomycin D (Arends et.al. 1991).
Others have found there was no correlation between the metabolic activity of AML
blasts compared with their proliferative capacity (Elgie et.al. 1996). The less active cells
however appeared to be more sensitive to 6-thioguanine and more active cells to
cytosine arabinoside. These agents however have all been described to induce
apoptosis in many cell systems and are kown to induce apoptosis in KGl-a cells (AC
unpublished data).
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(Figure 28). Flow cytometric histograms demonstrating the effects of bcl-2 antisense
on bcl-2 protein expression in tumour cell lines. A small reduction in bcl-2 expression




ANTISENSE ON CYTOTOXIC AGENTS
150
(Figure 29a). No potentiating effects of antisense were seen in the presence of
Cycloheximide or Actinomycin D. However antisense bcl-2 phosphorothioate
ameliorated the cytotoxic effects ofActinomycin D.
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Following determination of an approximate LD50 for each of these drugs (ActD 4|iM,
CHX 50nM, AraC luM) using the MTT viability assay cells were incubated in the
presence and absence of 5[iM antisense bcl-2 (phosphorothioate and phosphodiester),
control antisenses (biotinylated control and unlabelled nonsense (scattered) sequence)
in the presence and absence of drug (Figure 29).
106 cells were incubated in the presence or absence of various antisense moieties for 1-
7 days and the cells harvested, washed, permeabilised and stained for total bcl-2 and
DNA content. A parallel sample was harvested and stained with Annexin V-FITC and
propidium iodide to measure the functional effectiveness at inducing apoptosis. All
conditions were measured by flow cytometry and evidence of apoptosis confirmed by
microscopy.
An MTT cell proliferation assay of duplicate samples of the above conditions in the
presence and absence of antisense revealed there to be no obvious synergy of effects
on cell proliferation at 7 days post incubation (2 day antisense alone followed by 5
days antisense + drug) (Kitada et.al. 1994). However there appeared to be an
interesting anomaly in that antisense bcl-2 phosphorothioate appeared to abrogate the
cytotoxic effects of Actinomycin D (Figures 29a and d). This effect was not seen
with the same DNA sequence antisense bcl-2 phosphodiester.
The cells were therefore studied by flow cytometry in a time-dependent fashion to see
if the pattern could be replicated. Inhibitors of cell proliferation (eg. dibutyryl cAMP,
azide, amsacrine, mitomycin C, cycloheximide all of which reduce tritiated thymidine
(3H)-uptake have ben shown to to affect MTT and in some cases increase the signal.
MTT has been shown to be more closely linked to glycolysis and drugs which affect
glucose transport (Berridge et.al. 1996). However it is clear that this is not the case in
this study and all data was confirmed by flow cytometric detection of bcl-2 content and
apoptosis induction by the Annexin assay.
Flow cytometry revealed similar patterns of bcl-2 expression as expected from the
MTT assay viability results. As previously described, apoptotic cells display a
characteristic bi-phasic bcl-2 expression with the lower expression representing
apoptotic cells and the higher peak representing viable cells (Figure 30). Therefore an
increase in the percentage cells in the apoptotic lower bcl-2 content peak was used as a
measure of the functional effectiveness of the antisense.
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Cells treated in the absence of cytotoxic drugs there was a similar response to all
antisense species. There was no obvious difference from untreated control cells except
at six days when there seemed to be a marked elevation in bcl-2 levels with all
antisense compared with the control (Figure 29a and b). The reason for this is
unclear but may represent a non-specific toxicity because of nutrient loss and natural
pH reduction or a reduced pH caused by the acid DNA rather than any true antisense-
mediated effect.
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EFFECTS OF ANTISENSE ALONE ON
APOPTOSIS INDUCTION
TIME (DAYS)
-□ CTRL + NO ANTISENSE
~0— CTRL + BIOTINYLATEED CONTROL
-O CTRL + PHOSPHODIESTER BCL-2
-A CTRL + PHOSPHOROTHIOATE BCL-'
ID CTRL + SCATTERED
(Figure 29b). KGl-a cells treated in the presence of antisense and absence of
cytotoxic agents show no induction of apoptosis.
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SYNERGISTIC EFFECTS OF ANTISENSE AND
CYCLOHEXIMIDE ON APOPTOSIS INDUCTION
TIME (DAYS)
CHX + NO ANTISENSE
CHX + BIOTINYLATED CONTROL
CHX + PHOSPHODIESTER BCL-2
CHX + PHOSPHOROTHIOATE BCL-:
CHX + SCATTERED
(Figure 29c). KGl-a cells treated in the presence of antisense and Cycloheximide
show no potentiation in the induction of apoptosis.
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In cells treated with Cycloheximide there did not appear to be any synergistic effect of
antiscnsc on apoptotic low bcl-2 cell populations (Figure 29b). It appeared therefore
that apoptosis in these cells is not dependent on de novo protein synthesis. It is more
likely that a protein phosphorylation-dephosphorylation signal forms the major
apoptotic stimulus in these cells. Cycloheximide may also affect changes in the relative
half-lives of essential proteins required for viability such as bcl-2. An increase in the
relative concentration of a pro-apoptotic member of the bcl-2 family may therefore
induce apoptosis.
Cells treated with Actinomycin D showed a similarly high level of apoptosis in control
cells. At early time points there appeared to be some protective effects of antisense on
cellular viability with all antisense species though this effect was abrogated by day 5
post culture. It is unclear through what mechanism this may be acting, potentially the
antisense might block entry of Actinomycin D to the cells at early time points an effect
which is overcome as intracelluar levels of ActD rise over time (Figure 29c) and
levels of phosphodiester antisense molecules decrease. However in cells treated with a
combination of Actinomycin D and antisense bcl-2 phosphorothioate the cytoprotective
effect is most apparent with only a fraction of cells undergoing apoptosis under these
conditions. ActD is known to readily enter cells and to bind to double stranded DNA at
2 coincident G-C pairing regions. This might be a possible explanation for the
cytoprotective effects of antisense bcl-2 phosphorothioate. To address this possibility
samples of antisense were electrophoresed on an 18% polyacrylamide gel to look for
differences in migration patterns (Figure 32). This revealed that the antisense bcl-2
phosphorothioate did in fact have a different migration pattern to that of the native bcl-2
phosphodiester moiety. This might be related to secondary structure formation such
that several of the antisense molecules might homodimerise. In certain species this
would give rise to double stranded DNA molecules containing the prerequisite
Actinomycin D binding sites. Each antisense dimer would then have the capacity for
binding two molecules of ActD (Figure 31) effectively abrogating its cytotoxic
action. Polyacrylamide gel electrophoresis revealed a difference in migration pattern
between the bcl-2 antisense species. The phosphodiester moiety migrated further than
the phosphorothioate species indicating there were differences in structure between the
two molecules (Figure 32). Whether this structural difference is sufficient to account
for the differing actions in the presence of Actinomycin D is unclear.
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SYNERGISTIC EFFECTS OF ANTISENSE AND
ACTINOMYCIN D ON APOPTOSIS INDUCTION
TIME (DAYS)
ACT D + NO ANTISENSE
ACT D + BIOTINYLATED CONTROL
ACT D + PHOSPHODIESTER BCI^2
ACT D + PHOSPHOROTHIOATE BCL-2
ACT D + SCATTERED
(Figure 29d). KGl-a cells treated in the presence of antisense and Actinomycin D
show no potentiation in induction of apoptosis. However 5^M bcl-2 antisense
phosphorothioate is able to suppress the induction of apoptosis in these cells.
125
SYNERGISTIC EFFECTS OF ANTISENSE AND
CYTOSINE ARABINOSIDE ON APOPTOSIS INDUCTION
TIMEPAYS)
-□ ARA C + NO ANTISENSE
■ o ARA C + BIOTINYLATED CONTROL
-O— ARA C + PHOSPHODIESTER BCL-2
-A ARA C +PHOSPHOROTHIOATE BCL-2
-IP ARA C + SCATTERED
(Figure 29e). KGl-a cells treated in the presence of antisense and cytosine
arabinoside show a small potentiation in induction of apoptosis with all antisense
species. However 5wM bcl-2 antisense phosphorothioate is able to the increase the
induction of apoptosis in these cells 50% more than cells with no antisense.
126
Normal
Forward Scatter BCL-2 FITC
Apoptotic
(Figure 30). These flow cytometric dot plots and histograms graphically demonstrate
the reduced bcl-2 content of apoptotic cells. This represents a log reduction in bcl-2
content between viable and apoptotic cells. This feature was found in all cells studied
though it is unclear whether the low bcl-2 content is an initiating event or a secondary
event in apoptosis induction.
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Potential antisense secondary structure formation
Bcl-2 antisense sequence: A) Partial Annealing
5 ' -TCTCCCAGCGTGCGCCAT- 3'
I I I I
3 ' - TACCGCGTGCGACCCTCT - 5 *








3' - TCCGGCTCGCACTCACGT - 5 '
OR
5' - TGCACTCACGCTCGGCCT - 3 '
I I I I
3' -TCCGGCTCGCACTCACGT- 5'
Control antisense sequence has no obvious secondary structure formation.
5 ' - CTCTCGCACCCATCTCTCTCCTTCT - 3 '
(Figure 31)
This antisense-Actinomycin complex may be sequestered into cytoplasmic vesicles and
reduce the bioavailbility of Actinomycin D. E.coli single-stranded DNA binding
protein was used at a molar ratio of 0.7 ssDNA to SSB (Bleiberg et.al. 1981) in an
attempt to reduce this effect but was not found to be effective at increasing antisense
uptake in KGl-a cells (Figure 25).
Cells treated with cytosine arabinoside showed a small but discernible synergistic
effect with all antisense molecules studied with the greatest effect seen with antisense
bcl-2 (Figure 29d). It is known that cytosine arabinoside can cause cell membrane
fragility (White et.al.1987; Rathmell et.al.1986). AraC may therefore disrupt the
membrane barrier and allow antisense access to the cytoplasmic mRNA target whereas
normally it is sequestered in vesicles. This might allow for specific hybridisation to
target sequences and thus exert a true antisense-mediated effect.
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There may also be possible non-specific antisense-mediated effects such as non¬
specific protein binding and antisense sequestration to the nucleus (Leonetti et.al.1991)
where again effects on histones, transcription factors may all exert non-specific anti¬
proliferative effects (Stein, 1995).
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(Figure 32). This polyacrylamide gel (20%) demonstrates the different migration
patterns between bcl-2 phosphodiester (lanes 1+2) and bcl-2 phosphorothioate (lanes
3+4) antisenses. Nonsense (scattered) antisense (lanes 5+6) and biotinylated control
antisense are also shown.
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Mac-1 - an Antisense Receptor ?
A previous study by (Neckers, 1993) have described a putative antisense receptor to be
an 80kDa cell membrane protein, recent publications however have suggested that
antisense uptake may be associated with the CD1 lb-CD18 (Mac-1) integrin. This
molecule is a receptor for many ligands including complement C3, ICAM-1, and
fibrinogen (Diamond et.al. 1995). Mac-1 contains a number of binding sites including a
divalent cation-dependent-adhesion-site and heparin-binding sites. CD1 lb has
relatively limited lineage-restricted expression and is normaly found on neutrophils,
monocytes and some NK cells. In their resting states there are differences in the levels
of expression with monocytes having greater levels than neutrophils which in turn
have higher levels than NK cells. Basal levels may be up or down-regulated by various
cytokines or pharmacologic agents.
Peripheral blood
Therefore normal peripheral blood CD11 b levels were characterised in samples
analysed by flow cytometry using a PE labelled CD1 lb monoclonal antibody (Leu-15a
Becton Dickinson, Oxford UK). CD1 lb levels in normal peripheral blood were
determined and were found to be similar (in levels of expression) to the patterns of
antisense uptake found in these cells. (Figure 33a and b). It therefore appeared as
though antisense uptake might be dependent on some characteristc of the Mac-1
molecule. The most likely epitope was likely to be a heparin-binding site since
antisense molecules are highly charged acidic molecules (Bleiberg et.al. 1981).
Antisense DNA backbones are heavily negatively charged because of the acid
phosphate groups and are therefore attracted to non-specific positively charged sites.
Antisense phosphorothioate molecules also structurally resemble natural heparins in
their degree of linearity and sulphation.
KGl-a cells
Similarly KGl-a cells were stained with anti-CD 1 lb antibody and approximately 10%
of the cells were found to express this marker but were otherwise phenotypically
normal. KGl-a cells had a typical immunophenotype of CD34, 7, 71, 45, 95 positive,
CD. 19, 41a negative, with varable amounts of CD33 and 38. They were also known
to express the following adhesion moecules CD 54, 31, 58, 49d, 49c 1 la, 44, 36.(Dr
M. Turner personal communication). The levels of uptake of 5uM antisense-FAM were
studied at 5 and 10 hours in the CD1 lb positive and negative fractions ofKGl-a cells
simultaneously (Figure 34). It was found that higher levels of antisense were found
in CD1 lb positive cells at 5 and 10 hours and somewhat lower levels found in CD1 lb
negative KGl-a cells. By 10 hours the extracellular levels in CD1 lb positive and
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negative eells had risen to levels found inside the eell indicating equilibrium had been
reached in both eases although at differing intensities. This may be due to differing
levels of similar equilibrative transport systems.
The expression of CD1 lb was determined in conjunction with levels of 5iiM antisense
uptake in CD1 lb positive KGl-a cells and it was found that there was an inverse
relationship between the two. As antisense levels increased the cellular CD1 lb content
decreased at a similar rate indicating that the antisense was triggering a down-
regulation of CD1 lb expression in these cells (Figure 35). This can be most readily
explained by antisense binding to CD1 lb and being internalised prior to antisense
compartmentalisation into cytoplasmic vesicles. These vesicles are a feature of many
receptor-mediated ligand internalisation processes such as that described for transferrin
(Cotten et.al. 1990; Zenke et.al. 1990; Wagner et.al. 1990) and are readily apparent
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(Figure 33a). This figure shows the similarity between patterns of cellular antisense
association and the CD1 lb expression on cell types of normal peripheral blood.
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RELATIONSHIP BETWEEN CDllb
EXPRESSION AND ANTISENSE UPTAKE
(Figure 33b)
(Figure 33a and b). These figures demonstrate the similarity between patterns of
cellular antisense association and the CD1 lb expression on cell types of normal
peripheral blood.
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ANTISENSE LEVELS IN CDIIb POSITIVE
AND NEGATIVE KGl-a CELLS
(Figure 34). This figure demonstrates that within a single cell line (KGl-a) those
cells which express the adhesion molecule CD1 lb have a greater antisense association
than those which do not, with almost a doubling of the concentration inside the cell at
10 hours.
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Inhibition of antisense uptake
The evidence that CD lib was a possible antisense receptor suggested that a hepann-
binding site was the most likely epitope. To address this possibility 5^M antisense was
co-incubated with increasing doses (0-100 IU/ml) of low-molecular weight heparin
(Pump-Hep, Leo Laboratories, UK). The fluorescent antisense signal was measured in
CD1 lb positive and negative KGl-a cells. There was an obvious inhibitory effect of
heparin on antisense uptake in both cells (Figure 36). However the rate of inhibition
appeared greater in CD1 lb positive (slope -32) than CD1 lb negative (slope -12) cells.
The effects of polyanions were studied in KGl-a cells (Figure 37a) and compared to
agents which are known to affect CD1 lb and or bcl-2 expression in HL-60
promyelocytic leukaemia cells were studied (Figures 37b,c). DMSO and retinoic
acid are known to drive HL-60 towards neutrophilic cells with a concomitant reduction
in bcl-2 content and up-regulation of CD1 lb. PMA, a phorbol ester, is known to drive
these cells towards monocyte-like cells but with lesser effects on CD1 lb expression.
The polyanionic effects of heparin and antisense were thus compared for effects on
CD1 lb and bcl-2 content. Heparin and control antisense showed similar effects in
down regulating CD1 lb expression in KGl-a cells. Levels were reduced to
approximately 60% of control cells in the presence of 100 IU/ml heparin or 5uM
control antisense indicating a likely polyanionic effect. In HL-60 cells DMSO heparin,
and bcl-2 antisense increased the percentage of CD11 positive cells whereas PMA
showed a slight reduction. The intensity of CD1 lb expression was down-regulated by
PMA, DMSO and retinoic acid and to a lesser extent with heparin and bcl-2 antisense.
However the control antisense had a marked elevation of CD1 lb intensity indicating a




UPTAKE AND CDlib EXPRESSION IN
KGl-a CELLS
TIME (HOURS)
O CDllb expression y = -6.696x + 288.561 t = 0.903
■0 Antisense-FAM uptake y= 11.882x + 52.960 \ = 0.993
(Figure 35). Showing the inverse relationship between antisense uptake and CD1 lb
expression. As antisense is taken up into cells the CD1 lb expression drops,
suggesting a receptor-mediated internalisation or competition for epitopes.
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INHIBITORY EFFECTS OF HEPARIN ON ANTISENSE UPTAKE Or
CDllb POSITIVE AND CDllb NEGATIVE KG1-A CELLS
HEPARIN DOSE (IU/ML)
-□ CDllb positive y= -32.920LOG(x) + 538.960
-# CDllb negative y= -12.610LOG(x) + 307.130
(Figure 36). This graph shows the differential inhibition of heparin on antisense
uptake into CD1 lb positive and negative KGl-a cells.
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Bcl-2 expression appeared to be less affected by any of the treatments with only a
slight reduction in intensity seen with any of the treatments.
Similarly because of the many ligands for Mac-1, including fibrinogen, the uptake of
antisense in the presence and absence of serum was monitored. KGl-a cells were
incubated with 5|xM antisense in QBSF-51 serum-free medium for 5 hours in the
presence and absence of 10% foetal calf serum (Figure 38). Levels of antisense were
greater in serum-free medium indicating the presence of an inhibitory component of
serum. This is unlikely to be caused by fibrinogen because it is removed during
preparation of the serum, it may however be due to complement components (known
to bind Mac-1) or non-specific binding components of serum such as albumin or alpha
2-macroglobulin which are known to bind small molecules.
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CDllb EXPRESSION IN KGl-a CELLS
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(Figure 37a). This graph shows the similarity of effects of the polyanionic molecules
heparin (100 IU/ml) and control antisense (5|xM) on the reduction of CD1 lb
expression in KGl-a cells.
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EFFECTS OF AGENTS ON CDllb
EXPRESSION IN HL-60 CELLS
(Figure 37b). The effects of PMA, DMSO, Retinoic acid, heparin and antisense
were studied for their ability to induce changes in the patterns of CD1 lb expression in
the HL-60 promyelocytic leukaemia cell line. DMSO, heparin and antisense bcl-2
increase the number of CDllb positive cells, which is likely to represent a
differentiation towards a neutrophilic lineage.
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EFFECTS OF AGENTS ON CDllb




















(Figure 37c). The effects of a number of agents were studied for their ability to
induce changes in CDllb and bcl-2 expression in HL-60 cells. PMA, DMSO, Retinoic
acid are known to be capable of inducing differentiation in these cells and the effects




(Figure 38). This flow cytometric histogram graphically demonstrates the inhibitory
effects of serum on the uptake of 5|xM antisense into KGl-a cells. Cells were incubated




In summary this thesis set out to look at bcl-2 protein levels in normal and AML cells
and relate these levels to colony growth in AML blast cells. Antisense was used in an
attempt to reduce bcl-2 protein levels and increase the sensitivity ofAML cells to
chemotherapy to improve the prognosis for these patients.
This study found there was no overall elevation of bcl-2 level above normal cell types
though individual patients had abnormally high levels. This was borne out by the poor
ability of blast cells from these AML patients to form colonies in vitro. It was not
possible however to monitor these patients' subsequent clinical progress.
Studies on the uptake of fluorescent antisense molecules described a discrete cellular
partitioning with a high level of extracellular association and intracellular vacuolar
location. This cellular association appeared to be linked with the (32 integrin Mac-1
(CDllb-CD18) expression on cell membranes. Higher levels of antisense uptake were
found in cells expressing CD1 lb and could be inhibited with polyanionic molecules
such as heparin.
This offers a potential in vivo therapeutic targetting mechanism of antisense molecules
to cells which express this integrin (neutrophils, monocytes, NK cell and some AML
blast cells). CD 1 lb-expressing AML blast cells have similarly been associated with a
poorer disease prognosis and may benefit most from this type of antisense approach.
Targetting of antisense molecules to peripheral blood cells may therefore also present a
viable therapeutic option. Neutrophils are easily targetted with a short bolus of high
concentration drug. Because of elevated levels of CD1 lb on neutrophils and their short
life-span non-specific effects on other cell types could be minimsed. In the lung excess
eosinophils are thought to be involved in the pathology of inflammatory lung disease.
Antisense to pro-inflammatory mediators such as IL-5 could be administered as an
aerosol and eosinophils targetted through CD1 lb expression.
Similarly with monocytes levels of CD1 lb could be up-regulated by systemic
administration of TNF-cc (unlikely because of toxic systemic effects) or GM-CSF thus
increasing the therapeutic index of the drug (Ohsaka et.al. 1997). This last option is of
considerable interest in AML since those leukaemias which express CD1 lb are
associated with a poor complete remission response and these patients are also
associated with elevated levels of bcl-2.
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One could therefore envisage therapeutic administration of growth factors (namely
GM-CSF) to a) alleviate the neutropenia associated with chemotherapy, b) mobilise
blast cells into cycle and increase their sensitivity to S-phase specific chemotherapy and
c) upregulate levels of CD 1 lb to allow more effective targetting of antisense bcl-2 to
resistant tumour cells.
Further studies should confirm that antisense can exit from these vacuoles using
lysosmotropic agents and is similarly effective at reducing the capacity of AML blast
cells at surviving toxic insults. Furthermore alternative targets other than bcl-2 may be




Bcl-2 protein has been definitively located by electron microscopy to the outer
mitochondrial, and the cytoplasmic side of nuclear and endoplasmic reticulum
membranes and is intimately involved in the regulation of permeability pore transition
and is found in many cell types (Yang et.al.1996). The t(14;18) chromosomal
translocations which gives rise to elevated bcl-2 levels in lymphoma are often also
found in normal healthy individuals' tonsils, or in peripheral blood. Also lymphomas
without the chromosomal translocation similarly have elevated bcl-2 levels. Thus bcl-2
elevation through translocation is not sufficient for tumourigenesis. Elevated long-term
expression of bcl-2 and suppression of apoptosis may allow accumulation of further
DNA damage, perhaps as a result of the chemotherapy used to treat the original
disease. Similarly loss of bcl-2 protein in breast cancer is correlated with a poorer
prognosis (Yang et.al. 1996). Bcl-2 expressing cells enter into GO upon growth factor
removal. A rise in p53 (due to DNA damage) causes a transient arrest in G1 (to repair
DNA). This is facilitated by p53-induced p21 which in excess inhibits cyclin-cdk
complexes which normally drive cellular progression through G1 and S phases (Cory,
1995). Bcl-2 is able to inhibit this p53-mediated apoptosis in some cell lines (Nunez
et.al. 1994), thus bcl-2 is intimately linked to cellular homeostasis as described above.
Antisense bcl-2
Bcl-2 is expressed in normal haematopoietic cells including bone-marrow blasts
promyelocytes and also malignant AML and CML blasts. Up to 70% ofAML blasts
have been shown to have autonomous growth and express increased bcl-2 which is
linked to a poorer response to chemotherapy (Campos et.al. 1993; Lowenberg
et.al. 1993). Therefore bcl-2 would appear to be an important therapeutic target
especially in the more aggressive forms ofAML. Downregulation of bcl-2 by
pharmacologic methods should provide a single, reliable method applicable to most or
all forms of refractory or resistant AML.
The exquisite theoretical specificity of antisense DNA should allow precise inhibition
of single tumour-specific proteins. This type of technology has been shown in many
cell free and in vitro systems to provide the specificity required but is limited at present
by kack of an efficient specific in vivo delivery system (Zamecknik et.al. 1986; Spiller
et.al.1995; Leonetti et.al. 1991; Fisher et.al. 1993b). However many studies on primary
clinical material have provided amore optimistic therapeutic potential. The study
monitoring group 3 and 4 patients (those with partial or complete autonomous growth)
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found that group 3 had a better (50% ) response rate to antisense whereas group 4
patients had only 14% response. Patient samples and HL-60 cells required a dose of
5uM antisense for 3 days before any effects on bcl-2 were observed, presumably
because of vacuolar partitioning (Keith et.al. 1995). Antisense treatment on its own
failed to indude apoptosis but increased the sensitivity to cytosine arabinoside,
similarly in a previous study this group were able to reduce GM-CSF production with
antibody treatment but this did not induce apoptosis either.
Bcl-2 is found to be expressed in normal myeloid and cell lines (such as KGl-a,
K562, HL-60) and in the mantle zone of lymph nodes and in peripheral blood T and B
cells (Campos et.al.1994; Porwit-McDonald et.al. 1995). The highest levels were
found in growth-factor independent cell lines. This is similar to the data found in this
thesis with highest levels found in KGl-a cells. No effect of antisense was seen until
day 11 using 25-50hM antisense, with only a 30% cell survival using 50^M drug.
Again two peaks of bcl-2 expression were seen on flow cytometry indicating the lower
bcl-2 content of the apoptotic cell population (Figure 30). Whether the reduction in
bcl-2 is secondary to the initiating apoptotic signal, or whether reduced bcl-2 is part of
the apoptotic signalling process is however unclear. The effectiveness of a 4ug/'ml dose
of cytosine arabinoside was shown to be more effective in the presence of antisense
than sense or control molecules. According to this paper the highest intracellular
antisense phosphorothioate content is achieved after 4-5 days which accounts for the
delay in its functional effectiveness(Campos et.al.1994).
Chemotherapeutic agents induce apoptosis in highly-replicative target cells. Apoptosis
is not cell cycle specific but the action of the drugs is. As well as increasing the
sensitivity to these drugs antisense bcl-2 has been shown to accelerate death in pre-B
cell leukaemias, T-ALL, NHL and AML. The normal half-life of that of bcl-2 mRNA
approximately 3 hours whereas bcl-2 protein is more than 10 hours, but this may be
altered by molecules such as bag-1, bax, bcl-x, mcl-1 (Reed, 1996).
Liposomal transfection of 75-300nm antisense or an inducible plasmid containing bcl-2
antisense, gave a reduction of bcl-2 mRNA within one day in SUDHL-4 t( 14; 18)
lymphoma cells, protein levels however took about 3 days to show an effect (Kitada
et.al. 1994). Antisense had little or no effect on growth in the first three days and
antisense-mediated reductions in bcl-2 protein levels (as in other cells) does not
accelerate cell death unless the cells are deprived of growth factors or there is another
pro-apoptotic stimulus. Cells treated for two days with antisense then exposed to
cytotoxic drugs showed approximately an 80% increase in cytotoxicity over that seen
with antisense treated cells alone or than control oligos plus drug. Antisense bcl-2
increased sensitivity of cells to cytosine arabinoside and methotrexate but effects on
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bel-2 protein reduction in the absence of cytotoxic drug had no effects on proliferation
or survival. However the addition of 10-7M cytosine arabinoside to cells transfected
with a metallothionein-driven bcl-2 anlisense-containing plasmid inhibited growth. In
those containing the plasmid, but not induced by heavy metals no decrease in cellular
survival were seen (Kitada et.al. 1994).
Other targets for antisense in AML
Other potential targets for antisense therapy in AML include antisense to c-myb (a
transcription factor important in haematopoietic development) which has been shown
to inhibit AML cell growth in K562 erythroleukaemia (M6) cells (Gewirtz, 1992),
KG la (MO-MI) cells but especially HL-60 (M3) cells. Antisense-treated HL-60 cells
appeared to be arrested in G1 or at the Gl-S boundary. Inhibitory effects of c-myb
antisense were found to be greater in leukaemic than haematopoietic progenitors and
CFU-L could be reduced by 75-80% (Gewirtz, 1992). Antisense to c-myc in HL-60
cells causes cells to undergo terminal differentiation though some continue to
proliferate (Kirkland, 1994). HL-60 APML cells contains high levels of bcl-2 which
decreases dramatically during differentiation induced by PMA and other agents. PMA
causes HL-60 to stop proliferating and differentiate into macrophage-like cells then die.
PMA (lOng/ml) induces differentiation into monocytic cells and up-regulates CD lib
and down-regulates bcl-2 (Blagosklonny et.al. 1996) though the bcl-2 protein down-
regulation is not required for differentiation. The half-life of bcl-2 protein in HL-60
cells is approximately 20 hours but can be as much as 2 times this in drug-resistant
forms (Blagosklonny et.al.1996). Normal granulocytes were found to be bcl-xl
negative, while monocytes and macrophages were found to be positive. Treating HL-
60 cells with l^M retinoic acid differentiates towards granulocytes (bcl-xl negative)
whilst treating with PMA differentiates cells towards the macrophage and monocyte
lineage (bcl-xl positive). In both treatment regimens bcl-2 levels drop (Sanz et.al. 1997)
as the cells differentiate.
An antisense phosphorothioate to IL-lp converting enzyme (ICE) at 10-75uM was
found to inhibit proliferation of peripheral blood and bone marrow leukaemic cells and
inhibited leukaemic colony (CFU-L) formation. IL-1 has been shown to be important
in initiating paracrine and autocrine colony growth (Stosic-Grujicic et.al. 1995) which
is also associated with high GM-CSF secretion and high bcl-2 levels. The Wilms
Tumour (WT) gene product is found to be expressed in all of 96 patients with AML or
CML and is another potential targe for antisense therapy in AML. There were no
effects of aWT antisense on normal CFU-GM but leukaemic colonies were inhibited
by antisense. A WT cDNA to the antisense sequence (driven by a CMV promoter)
abrogated antisense efects as determined by flow cytometry (Yamagami et.al. 1996)
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thus definitively demonstrating an antisense-speeifie inhibition.
Antisense Uptake
The objeetive of this thesis was therefore to determine the characteristics of uptake of
antisense molecules into AML and normal blood cells in vitro with a view to
developing an efficient.purging or systemic therapy to destroy leukaemic AML cells
based on antisense to bcl-2 protein. This included determination of cellular localisation,
dose-concentration relationships and delivery dynamics of unmodified antisense
phosphorothioate molecules. The data described a consistent dose and time-dependent
uptake of antisense into peripheral blood leucocytes, and that this uptake is made up of
an extracellular and intracellular compartment, which are both dose-dependent. There
appears to be an association of antisense to cell-surface heparin-binding sites including
CD1 f b which is in agreement with other authors findings (Bleiberg et.al. 1981;
Harenberg et.al. 1995; Benimetskaya et.al. 1997).
Phosphorothioate antisense oligos have been shown to localise in the acidic
intracellular compartment in HL-60 cells. 80% of internalised phosphorothioate resided
in a cellular compartment with a turnover time of 2-5 hours. Uptake of oligos plateau at
3-6 hours (Tonkinson et.al. 1994) and at 4°C 90% of the oligo associated with cells is
localised on the membrane. However at 37°C the intracellular concentration rose and
plateaued at 1-2 hours in serum-free medium. This uptake of antisense oligos was
found to be taken up in a sequence independent manner (Neckers, 1993).
U937 cells (a diffuse histiocytic lymphoma cell line with monocyte-macrophage
characterisics) were treated with c-myc antisense by electroporation which appeared to
cause rapid cell death (presumably through an antisense effect). This treatment
appeared to have little effect on normal hematopoietic cells. Electroporation causes
transient pore formation in membranes, and with optimisation can get 100%
transfection and suppression of c-myc and decreased cell viability. In control cells plus
antisense the oligo is sequestred to the cytoplasmic vesicles. However with
electroporation the oligo localises to the nucleus and non-vesicular cytoplasmic
structures in cytoplasm. No effect of c-myc oligos were seen without electroporation.
This method allows up to a 7-fold increase in signal inside cells following
electroporation (Bergan et.al. 1996).
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Non-specific (polyanionic effects) of antisense
Many so-called sequence-dependent antisense-specific effects of phosphorothioate
oligodeoxynucleotides can potentially be explained by the non-specific targetting of
phosphorothioates to cell adhesion molecules. Here they may act as agonists or
antagonists of natural ligands depending on a) antisense sequence or b) the target cell
phenotype.
This study and others (Zhao et.al. 1996), have shown preferential uptake of
polyanionic molecules such as heparins, or antisense phosphorothioate molecules to
myeloid cells. Heparin (a linear, sulphated, negatively charged polysaccharide) binding
is found to be higher in human granulocytes (264-2458 fluorescence units-FU) than in
monocytes (10-80 FU) and lymphocytes (5-31FU). It has been described as
possessing anti-inflammatory, anti-metastatic and anti-atherosclerotic properties
(Bleiberg et.al. 1981).
In the study described in this thesis antisense binding shows a clear delineation of
myeloid > B cells > T cells (CD4=CD8). The following decreasing levels of uptake:
peripheral blood CD33 > CD22 > CD8 = CD4: bone marrow CD15 > CD20 > CD7
(Zhao et.al. 1996). Similarly in acute myeloid leukaemia CD34+ leukemic blasts were
able to take up more antisense than normal CD34+ cells, an effect potentiated by IL-3
and SCF. Normal CD34+ bone marrow cells have a relatively low uptake unless
stimulated by IL-3 and IL-6. Similarly heparin (0.1-lOO^.g/ml) was able to inhibit the
growth of U-937 leukaemic cell proliferation and is also able to induce terminal
differentiation (Volpi et.al. 1994) in these cells. This effect is related to charge density,
particularly the degree of N-sulphation (of glucosamine) which is also required for
heparin binding to the complement C3Receptor (CD1 lb-CD18) (Diamond et.al. 1995).
It seems likely that the higher levels of intracellular uptake of antisense into monocytes
and neutrophils are a direct consequence of higher levels of extracellular binding to
these cells. Higher membrane associated antisense on monocytes and neutrophils may
represent higher levels of DNA-binding proteins. This may be related to the levels of
CD1 lb and other, similar heparin-binding proteins on the cell surface. Extracellular
levels of antisense on monocytes and neutrophils were found to decrease over time.
Therefore it is reasonable to consider that this decrease may represent a down-
regulation of these binding proteins or receptors despite the continued presence of the
oligonucleotide. This may occur either as a consequence of DNA binding and
subsequent internalisation, or changes in affinity or cell phenotype during culture
which is known to occur when CD1 lb is activated.
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Phagocytic cells such as monocytes and neutrophils poscss storage pools of |52
integnns (notably Mac-1) in peroxidase-negative granules and are able to increase
levels up to ten fold in response to pro-inflammatory mediators (Smyth et.al.1993).
Heparin is also able to up-regulate the degree of CD1 lb expression, an effect which
mimics TNF-a, G-CSF, arachidonic acid, or IL-8 treated neutrophils (Diamond
et.al.1995; Ohsakaet.al.1997). Heparin binds both Mac-1 (CDlib-CD 18) and CD45
(Coombe et.al. 1994) and blocks their binding to stroma, an effect which is dependent
on the degree of heparin sulphation. However only certain isoforms of CD45 (the 180
kDa lacking the three terminal exons) are able to bind glycosaminoglycans. CD45 is
able to regulate myeloid cell proliferation in association with IL-3 and GM-CSF.
Fibrinogen, a homodimeric 340kDa glycoprotein, which is a natural ligand for Mac-1
binds the RGDS (Arg-Gly-Asp-Ser) sequence, which is also recognised by
fibronectin, vitronectin, von Willebrand factor, the tat (transactivation) protein of HIV-
1 and other molecules (Levesque et.al. 1991). Fibrinogen binds other extracellular-
matrix components and also proteases of the coagulation cascade. It also promotes
adhesion and motility to endothelial cells through the vitronectin receptor. Fibrinogen
interacts with activated complement receptors CR3 (am(52) and CR4 (ax(52) on
monocytes, macrophages and neutrophils. Fibrinogen has also been found to be
mitogenic for human hematopoietic progenitors and increases CFU-GM formation in
Dexter-type long-term bone-marrow cultures. Fibrinogen is able to enhance the
mitogenic effect of IL-3 on CD34+ progenitors in CFU-GEMM assay, an effect which
is not inhibited by RGD peptides (Levesque et.al. 1991). CD34 is expressed on
hematopoietic progenitors, high endothelial venules (HEV), vascular endothelium and
some fibroblasts. It is a mucin-like sialoprotein which contains a large number of O-
linked and N-linked glycosylation sites. It may play a role in haematopoietic progenitor
cell adhesion to bone marrow stroma through L-selectin binding (Carlos et.al. 1994).
Therefore it is likely that antisense molecules may act as partial agonists or antagonsists
for heparin or fibrinogen-type interactions depending on the individual cell type and
antisense sequence. Agonists of the fibrinogen receptor (aiib(53) increase its binding
properties and cause poly-phosphoinositide hydrolysis and release of diacylglycerol
and IP3 (inositol triphosphate) which activate protein kinase C (Smyth et.al.1993).
Phorbol esters such as phorbol myristyl-acetate (PMA) are able to differentiate HL-60
promyelocytic leukaemia cells also cause an increase in (53 subunit phosphorylation.
Agonists which promote (52 integrin activation cause sub-unit phosphorylation,
increase intracellular Ca2+ and stimulate protein kinase C activity (Smyth et.al. 1993).
Loading neutrophils with thiophosphate (a non-hydrolysable phosphate) enhances am
(32 activity and prevents deactivation. Agonists of am (52 regulate neutrophil
phospholipases and stimulate phospholipase A2. Agonists however, which elevate
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cAMP or lower intra-cellular Ca2+ however promote inaetivation of (52 integrins, high
cAMP levels can also inhibit smooth muscle growth (Indolfi et.al.1996).
Pro-inflammatory mediators promote the binding of neutrophils and monocytes to
fibrinogen, factor X, C3bi, by activating (52 integrins Mac-1 (am (52) and pl50,95.
Activation of (52 integrins peak within 5-10 mins of stimulation and decreases within 30
minutes. This mimics the findings described above with antisense binding to
monocytes and neutrophils. Mac-1 activation results in a rapid increase in avidity
followed by recruitment of further receptors from the cytoplasmic granule store
(Zimmerman et.al. 1992). Surface expression of Mac-1 can be increased by a variety of
agonists including calcium ionophores, phorbol esters, IMetLeuPhe, GM-CSF, C5a,
TNF-a, LTB4. Mac-1 ligands include ICAM-1, fibrinogen, factor X, complement
C3bi.
Neutrophil adhesion depends on CD1 lb-CD 18 and CD1 la-CD 18 interactions with
endothelium and anti-CD18 antibodies can inhibit neutrophil migration to the lungs.
Stimuli which up-regulate Mac-1 also down-regulate L-selectin (Carlos et.al. 1994), (52
integrins are therefore important in neutrophil, monocyte and lymphocyte
transmigration across enothelium. P and L selectins also bind heparin, sulphatides and
sulphated polysaccharides. CD34, a ligand for L-selectin present on high endothelial
venules (HEV) in murine peripheral lymphoid tissue and hematopoietic progenitor cells
(Carlos et.al. 1994) might therefore also be inhibited by antisense phosphorothioate
molecules. Platelet aggregating factor (PAF), synthesised by endothelial cells in
response to thrombin, histamine or LTB4 (Zimmerman et.al. 1992) binds to its receptor
on neutrophils and up-regulates CDllb-CD18 expression.
There are many other potential non-specific immunomodulatory properties of antisense
molecules. Phosphorothioates bind CD4 in a length-dependent manner, and will also
bind to basic FGF, acid FGF, VEGF, PDGF (Stein, 1995). Phosphorothioate
antisense to c-myb used to prevent re-stenosis following angioplasty appear to mediate
their effect through inhibition of heparin-binding growth factors (Wang et.al. 1997).
Phosphorothioate antisense molecules have also been shown to bind bFGF receptors
with a high affinity (Benimetskaya et.al. 1997). Antibodies which inhibit CD1 lb-CD18
also prevent reperfusion injury (Arnaout, 1993). Phosphorothioates also bind laminin
and prevent adhesion, an effect which is dependent on the presence of the G-quartet
and flanking sequences. CpG is an immunomodulatory sequence, and
phosphorothioates are able to cause an increase in polyclonal immunoglobulin
secretion and expression of class I and II MHC (Stein, 1995).
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High levels of dGMP and dAMP from breakdown of oligodeoxynuclcotides can have
varied and pronounced effects on haemopoietic tissue (Milligan et.al. 1994). Short
sequences within oligodeoxynucleotides may have antiproliferative effects, therefore
scrambled or sense sequences by design will not have these effects eg. the G-4
sequence (so-called G-quartet) has antiproliferative effects. Heparins also have anti¬
proliferative effects (as does dextran sulphate (Volpi et.al. 1994; Morahan et.al. 1972;
Regelson, 1968). Oligodeoxynucleotides can act as protein kinase c inhibitors and a
phosphorothioate homopolymer of dC-28 has been shown to inhibit HIV infection of
CD4+ cells (Milligan et.al.1994). Some of these non-specific effects may be however
reduced by using low (l-5uM) concentrations of oligodeoxynucleotides and short (15-
17 bases) sequences (Stein, 1995).
In B cell lymphoma where results of a recent antisense bcl-2 clinical trial have shown
promising results (Webb et.al. 1997) data might be explained by antisense effects on
polyclonal B cell activation through binding CR2 (CD21) leading to apoptosis of B
cells. This is supported by findings from others who showed a progressive antisense
uptake in more mature B cells, where the order of uptake was pre B> pro B> pre-pro
B cells > Thy 1+ cells (Zhao et.al. 1996; Zhao et.al. 1994). Dextran sulphate had a
similar cellular localisation to phosphorothioate antisense, again demonstrating a non¬
specific uptake mechanism for polyanions.
Given the association of antisense phosphorothioate molecules with CD1 lb and their
subsequent internalisation into the endosomal compartment, strategies involving
lysosomal disruption have been attempted. Monesin has been shown to disrupt
endosomal pH by reduceing the acid pH and the pH-dependent quenching of FITC.
lOO^M chloroquine reduces ligand delivery to lysosomes during transfection and it
was found to be able to increase the efficiency of delivery of DNA into liver cells
(Erbacher et.al. 1996). However ammonium chloride, spermine, methylamine (all of
which similarly affect lysosomal pH) had no effect. Chloroquine accumulates in these
vesicles and can reach levels of 9mM in cells (lOOgM, 4hrs) radically elevating
lysosomal pH.
Other methods of enhancing DNA transfection have similarly been attempted to
enhance the bio-availibility of antisense: cyclodextrins (Zhao et.al. 1995); liposome
encapsulation (Farhood et.al.1994); cholesterol conjugation (Zhao et.al. 1995); poly-L-
lysine conjugates (Zhao et.al. 1995; Wagner et.al. 1990); Streptolysin O reversible cell
permeabilisation was demonstrated to achieve up to a 100 fold increase in delivery of
DNA to the nucleus (Spiller et.al. 1995). All of these strategies whilst interesting
research tools still have some way to go before being adopted as routine therapeutic
strategies.
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Yet other studies have eoneentrated on baekbone modifications to enhance stability.
Chimeric molecules ofmethylphosphonate-phosphodiester antisense analogues have
been shown to have a higher selectivity. Phosphorothioates may target RNAse-H
activity against partial complementary sequences of cDNA-RNA. Using chimeric
methylphosphonate-phosphodiester antisense the ranking of efficiency on ability to
inhibit ber-abl mRNA is methylphosphonate-phosphodiester > phosphodiester
>=phosphorothioate > methylphosphonate-phosphorothioate (Giles et.al.1995).
Adding a 5'-propyne group increases the affinity of antisense for target sequences
(Tonkinson et.al.f994) and retains RNAse-H activity, while reducing the size and
using tandem oligodeoxynucleotides eg. 2 x 7mers to the target sequence may allow
synergistic action, and also help reduce non-specific or polyanionic effects caused by
longer sequences (Woolf, 1996).
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Other targets in AML
In the treatment of acute leukaemia the primary target for therapy has been the highly
replicative leukaemic blast cell. Mostly these cells are sensitive to S-phase specific
drugs and conventional chemotherapy has achieved largely succesful treatment of these
cells. However, as previously described there is frequent disease relapse in AML. This
may be due to the presence of persistant residual, slowly-replicative, leukaemic "stem
cells" which are insensitive to S-phase specific drugs (Terpstraet.al.1997). These are
the cells which are most likely to give rise to drug-resistant daughter cells and to
contribute to disease relapse. This presents a far more difficult target for therapy since
these cells are to all intents very similar to normal haematopoietic stem cells. It is these
cells however which must be identified and then targetted to provide a long-term
treatment option for patients with refractory or resistant disease.
The recent study described by (Terpstra et.al. 1996) has found the CD34 negative
fraction ofAML cells contained both immature and mature cobblestone-area forming
cells (CAFC) and produced high numbers of CFU-AML in long-term in vitro bone-
marrow cultures (LT-BMC). The CD34 positive fraction however only produced
small numbers of CFU-AML, mature CAFC, early cobblestone-forming areas
(equivalent to haematopoietic progenitors) and late cobblestone-forming areas
(equivalent to stem cell progeny). For engraftment into SCID (severe combined
immunodeficiency) mice required 7.5 x 106 cells for engraftment at day 35, however
transplantation of 106 cells took between 55-106 days for engraftment. The CFU-AML
were mostly recovered in the CD34 negative fraction, whereas few were recovered in
the CD34+ fraction. Early cobblestone forming areas were found in the CD34 negative
fraction and late cobblestone areas in both CD34 positive and negative populations.
Late CAFC in humans are normally CD34+, Rhodamine 123 dul1, HLA-DR+l°w. Both
CD34+ and CD34 negative cells were able to repopulate SCID mice. Bonnet and Dick
(1997) however found that SCID long-term-initiating-culture cells were exclusively
CD34+38- cells similar to the normal SCID repopulating cells.
This therefore gave rise to two possible theories for leukaemic development. In the
first model the leukaemic process blocks normal development and the subsequent
degree of target cell commitment influences the stage of the leukaemic blasts. The
second model suggests that mutations arise in more primitive cells and the blast cell
heterogeneity results from variability in the ability to differentiate. This theory predicts
little variability in the phenotype of leukaemic stem cells from different patients.
Most AML blasts have limited proliferative capacity and therefore must be constantly
replenished by a limited number ofmore primitive cells. Only 10-20% of CD34+ cells
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proliferate in vitro to give rise to eolonies and approximately one cell in 2 x 105 cells is
able to repopulate SCID mice (Bonnet et.al. 1997). CFU-L treated with 5-FU from
AML patients were transplanted into SCID mice and were able to re-establish the
original AML classification in the mice (Terpstra et.al. 1997) again indicating the
leukaemia-initiating cells were quiescent during therapy. These CFU-AML could be
replated to form secondary colonies and is consistent with AML being a progemtor cell
disease. Therefore it is the levels of these slowly dividing CFU-L which probably
contributes to the level of disease resistance to S-phase-specific chemotherapy and
subsequent relapse.
Other markers, such as the myeloid progenitor-specific galactose-binding residue
found on approximately 8% of CD34+ cells (Pipia et.al. 1997), or Rhodamine dull
cells, in combination with CD38 or CD34 staining may be required to discriminate
leukaemic from normal haematopoietic progenitor cells. CD34 positive selection of
cells for autologous transplantation in AML may therefore contribute to disease relapse
in patients with CD34 positive AML progenitors whereas CD34 depletion would
obviously remove normal progenitors. CD34 positive selection in combination with
CD15 depletion has been shown to provide a reliable reduction in leukaemic
progenitors (Rubin et.al. 1994) without depleting normal progenitors.
However until reliable data confirming the presence or absence of a particular cell
marker becomes available to identify leukaemic progenitors purging of bone marrow
and leukapheresis products will remain ineffective and controversial in the clinical
setting. Similarly given that studies have demonstrated only a contribution to disease
relapse from transplanted leukaemic cells, albeit at a very low level (Rill et.al. 1994;
Brenner et.al. 1993), it therefore remains that the most likely source of tumour cell
contamination, and hence disease relapse, arises from resistant and presumably non-
cycling leukaemic progenitors present in the bone marrow and peripheral circulation of
the patient themselves.
Treatment to destroy leukaemic progenitors in AML is unlikely to be completely
effective given the low proliferative index of these cells (Terpstra et.al. 1997). Long-
term remission may be achieved if the transplanted tumour load is sufficiently low to
allow an effective haematopoietic recovery (Dwenger et.al. 1996). However, if as
indicated above, only a percentage of leukaemic cells are capable of re-establishing the
original disease (Bonnet et.al. 1997) then it is likely only a small contnbution to relapse
can arise from the transplanted tumour cells. A more effective form of cytotoxic
therapy must therefore be found to eradicate these slowly proliferating cells. Either
cells must be mobilised into cycle using growth-factors or cycle-independent cytotoxic
agents must be chosen. Therefore at present the only treatment to effect a cure lies with
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allogeneic transplantation with a limited graft-versus-host (and therefore graft-versus-
leukaemia) response to destroy residual tumour cells.
Cell cycle control in AML
The amounts of growth factor required for maintenance of cellular viability are much
lower than are required for proliferation or for functional cellular activation, and if
progenitors are not in cycle, then appropriate CSFmay be able to induce S-phase in a
number of hours (Nicola, 1989). The decision to exit a self-renewing proliferative
pathway and enter the differentiation-commitment pathway appears to occur in the G1
phase of the cell cycle. Constitutively activated growth-factor genes eg. GM-CSF do
not cause leukaemic transformation on their own but may be a secondary effect in
leukaemic development (Lang et.al. 1990). Differentiation and proliferation may be
therefore uncoupled in leukaemia Growth factor receptors may contain separate
intracytoplasmic domains for each function and the coupling of growth and
transcription factors may control proliferation, differentiation and survival of myeloid
cells. Cell cycle regulation has an important role in this coupling. Duration of G1
influences differentiation, with strong proliferative signals from some cytokines
shortening G1 and suppressing differentiation (Olsson et.al. 1996).
Hypophosphorylation of the retinoblastoma protein for example is also associated with
differentiation. Similarly down-regulation of cdk4 levels (whose primary substrate is
the retinoblastoma protein) induces differentiation into granulocytes. Overexpression
of cyclin D2 shortens G1 and decreases differentiation. DNA damage detected by p53
induces p21waf and inhibits CDK which arrests cells in G1 for DNA repair or
apoptosis. Autonomously growing AML blasts have been shown to lack the
retinoblastoma protein (Olsson et.al. 1996).
The initial phase of G1 is strictly dependent on mitogenic stimuli, however as cells
progress through the restriction (R) point there is a much reduced dependence on
growth factors. Control of the restriction point allows cells to withdraw into
quiescence (GO), repair DNA or differentiate. D-type cyclins seem to be the R point
proteins, with the retinoblastoma protein (Rb) as the major negative regulator and
cyclin dependent kinases as additional components (cdk4 and cdk6 and their inhibitors
cki). Rb sequestrates transcription factors required for progress through S phase and is
regulated by phosphorylation (which inactivates its repression of cycle). Neutralisation
of cyclin DO by antibody prevents phosphorylation of Rb in vivo and arrests cycling
cells in late Gl(Strauss et.al. 1995).
Overexpression of D-type cyclins has been shown to shorten G1 and reduces the
requirement for exogenous growth factors and can prevent terminal differentiation.
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Exit from cell cycle can facilitate terminal differentiation whereas tumour cells abandon
control mechanisms and remain in cycle without maturing. This is obviously a feature
of many myeloid leukaemias and remains to be investigated. Cyclin DO (coded on
chromosome 1 lq 13), and cyclin-dependent kinases (cdk) and eki counterparts are
commonly de-regulated in other cancers (Strauss et.al. 1995). These D-type cyclins act
as growth factor sensors and their expression depends on extracellular cues rather than
cell-cycle status. Mitogen withdrawal leads to cessation of D-type cyclin synthesis and
cells rapidly exit cycle. Inhibitors of cdk4 and cdk 6 block cyclin D dependent kinases
and cause G1 arrest ie. cells do not enter S phase. In cells without retinoblastoma
protein (in many cases ofAML) these inhibitors do not cause G1 arrest.
Retinoblastoma regulates the E2F transcription factor family by sequestering them
when Rb is hypophosphorylated whereas phosphorylation releases these transcription
factors and allows transcription. Inactivation of Rb reduces cellular requirement for
mitogens. When cells enter S-phase cyclin E and E2F are inactivated. Cyclin DO is
overexpressed in many cancers, though pl6ink4a loss may mimic this DO
overexpression. p53 mediates the CDK inhibition of p21cipi and is partially
responsible for G1 arrest, though loss of retinoblastoma can bypass p53 mediated G1
arrest. Most proto-oncogenes mimic persistent mitogenic stimuli whose pathways
converge to mediate cellular passage through G1 (Sherr, 1996).
Thereforemanipulation of cyclin activity may be an alternative target in leukaemic
therapy whether through antisense mechanisms or secondary messenger stimulation.
Growth factors, in addition to regulating cyclin activity also regulate bcl-2 levels.
Perhaps a convergent pathway also exists which allows simultaneous cessation of cell
cycling whilst reducing the levels of bcl-2 which are required to survive this period of
quiescence. It may be that the findings outlined in this thesis the findings that antisense
bcl-2 in combination with chemotherapeutic agents is more effective than cytosine
arabinoside on its own the mitogenic capacity is disrupted through p53 or
retinoblastoma-mediated mechanisms whilst antisense bcl-2 reduces the cell's capacity
for survival in the absence of regulatory signals such as cyclins which may help
explain why antisense on its own has little effect. In cells treated with antisense alone
there is no pro-apoptotic stimulus to provide activation of cytochrome c or AIF release
from the mitochondria therefore reduction in bcl-2 protein levels should be expected to
return to normal after removal of the antisense.
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Therapy
Autocrine stimulation alone is not sufficient for leukaemic development butmay
considerably enhance the proliferative capacity of these cells. For example most
myelomonocytic leukaemias express receptors for GM-CSF, however growth factors
and their receptors may also interact in an intracellular compartment and not be
detectable on the cell surface. It may be the differentiated, non-proliferative progeny of
these cells which secrete growth factors causing stimulation of the blast cells (Lang
et.al. 1990).
Treatment of AML with recombinant growth factors to increase the percentage of
cycling S-phase blasts as an addition to chemotherapy is a potiential treatment option
but will probably require considerable monitoring of blast behaviour in vitro on a
patient-to-patient basis. GM-CSF treatment in vivo in 96% AML patients has been
shown to increase the percentage of leukaemic blasts in S-phase, and there is a clonal
expansion of blasts with the greatest increase in myeloblasts was seen in AML M6
patients (Baer et.al. 1996). G-CSF receptors have been shown to be present in up to
97% of AML patients and treatment with G-CSF caused terminal differentiation of
some leukaemic cells into neutrophils in vitro (Bernstein, 1993). Administration of G-
CSF after chemotherapy has not been shown to have a higher incidence of resistant
disease or relapse (Baer et.al. 1996). However normal CFU-GM are also sensitive to
cytosine arabinoside at 10-6M (the clinical plasma levels are approximately 1(>5M) an
effect which is sensitised by the administration of G+GM-CSF or IL-3. Cytosine
arabinoside at 108M in the presence of stem cell factor (SCF) plus G and GM-CSF
destroyed blast cell progenitors by recruiting more blasts into S-phase (Smith
et.al. 1996).
Differentiation therapy
There is also the potential for differentiation of leukaemic blasts either by growth
factors or pharmaceutical methods. HL-60 cells treated with lOng/ml phorbol myristate
acetate (PMA) for 2 days causes cytostasis and differentiation measured by up-
regulation of CD1 lb and CD14 expression, implicating protein kinase c signalling
pathways in monocytic differentiation. Bcl-2 mRNA was rapidly down-regulated by
this treatment while bax and bcl-xl mRNA were not altered. Bcl-2 mRNA down
regulation was seen only in the parental cell and not in the adriamycin-resistant form
even though both forms were able to differentiate. This suggests that bcl-2 protein
down-regulation is not required for differentiation. Bcl-2 protein half-life was also
increased in the drug-resistant form (Blagosklonny et.al. 1996). Similarly U937 cells
have low levels of bcl-2 but when transfected with a plasmid containing bcl-2 they
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increased their resistance to cytosine arabinosidc by 3 logs (Suresh et.al. 1996).
Arsenic trioxide is an effective component of some traditional Chinese herbal treatment
for APML even in patients resistant to ATRA. ATRA treatment causes bcl-2 protein
and mRNA are down-regulated and apoptosis occurs independent of retinoic acid. HL-
60 cells however were unaffected by arsenic treatment nor were U937 cells. Arsenic is
thought to interfere with phosphorylation-dephosphorylation reactions by replacing
phosphate groups and is also able to bind sulphydryl (-SH) groups (Chen et.al. 1996)
and presumably modifies the phosphorylation status of important proteins required for
induction of apoptosis.
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Thus this data serves to support the hyopothesis that antisense-mediated effects in
areas as diverse as cancer therapy, immune-modulation, and pro-inflammatory disease
will require explicit controls in order to exclude the possibility of non-antisense,
sequence-specific effects. Intracellular calcium, phospholipase A2, protein kinase C,
polyanionic and integrin-mediated effects effects will all have to be controlled for and
excluded in order to justify some of the more extravagant claims on behalf of antisense
molecules. The temptation to see simple cause-and-effect relationships is real but may
obscure some of the more interesting effects mediated by antisense molecules. Future
studies could test this by pre-incubating cells in the absence and presence of unlabelled
antisense, prior to the addition of the labelled molecule or an unlabelled ligand for
specific receptors.
This information might also prove clinically useful, since one could envisage pre-
treatment of patients with a short-lived non-therapeutic oligonucleotide to reduce non¬
specific plasma clearance, extracellular binding, and subsequent sequestration, of
therapeutic oligonucleotide to sites other than the target. This may also be achieved
with saturation with synthetic heparin analogues which have no therapeutic effect
(Harenberg et.al.1995; Diamond et.al.1995; Bleiberg et.al.1981). It must also be noted
that all experiments perfomed in the present study were conducted using isolated cells.
However, in the clinical situation, there may be a variety of factors, such as plasma
protein binding, which may reduce the bio-availability of antisense to the cells as
already seen in the much reduced levels of antisense uptake in the presence of serum.
Thus the therapeutic plasma levels required may be far in excess of those studied here.
There is however a positive outcome from this study in that cells which express
CD lib have higher levels of antisense than those which do not. Fortuitously AML
cells with CD1 lb expression (a recently described novel sub-set ofAML) which have
a poorer complete remission response (Paietta et.al 1998) are more likely to internalise
antisense phosphorothioate molecules. These cells are more likely to have elevated bcl-
2 expression and grow autonomously and are therefore more difficult to treat with
standard chemotherapy. Antisense bcl-2 (or other targets as described above) may
therefore tip the balance of survival in these cells, when treated with standard
chemotherapy, towards apoptosis. This may be envisaged in either a purging setting or
in the elimination of residual disease where more dramatic effects are likely to be seen
where the potential for CFU-AML to contaminate autologous transplants is reduced at
the outset. It is likely to be more successful, that rather than looking for (then
removing from) the proverbial needle in the haystack, to ensure that it never gets there
in the first place.
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